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ABSTRACT OF DISSERTATION 
 
 
 
 
PEPTIDE-FUNCTIONALIZED MAGNETIC NANOPARTICLES FOR CANCER 
THERAPY APPLICATIONS 
 
 Lung cancer is one of the leading causes of cancer deaths in the United States. 
Radiation and chemotherapy are conventional treatments, but they result in serious side 
effects and the probability of tumor recurrence remains high. Therefore, there is an 
increasing need to enhance the efficacy of conventional treatments. Magnetic nanoparticles 
have been previously studied for a variety of applications such as magnetic resonance 
imaging contrast agents, anemia treatment, magnetic cell sorting and magnetically 
mediated hyperthermia (MMH). In this work, dextran coated iron oxide nanoparticles were 
developed and functionalized with peptides to target the nanoparticles to either the 
extracellular matrix (ECM) of tumor tissue or to localize the nanoparticles in subcellular 
regions after cell uptake.  
The magnetic nanoparticles were utilized for a variety of applications. First, heating 
properties of the nanoparticles were utilized to administer hyperthermia treatments 
combined with chemotherapy. The nanoparticles were functionalized with peptides to 
target fibrinogen in the ECM and extensively characterized for their physicochemical 
properties, and MMH combined with chemotherapy was able to enhance the toxicity of 
chemotherapy.  
The second application of the nanoparticles was magnetically mediated energy 
delivery. This treatment does not result in a bulk temperature rise upon actuation of the 
nanoparticles by an alternating magnetic field (AMF) but rather results in intracellular 
damage via friction from Brownian rotation or nanoscale heating effects from Neél 
relaxations. The nanoparticles were functionalized with a cell penetrating peptide to 
facilitate cell uptake and lysosomal escape. The intracellular effects of the internalized 
nanoparticles alone and with activation by an AMF were evaluated.  
Iron concentrations in vivo are highly regulated as excess iron can catalyze the 
formation of the hydroxyl radical through Fenton chemistry. Although often a concern of 
using iron oxide nanoparticles for therapeutic applications, these inherent toxicities were 
harnessed and utilized to enhance radiation therapy. Therefore, the third application of 
magnetic nanoparticles was their ability to catalyze reactive oxygen species formation and 
increase efficacy of radiation. Overall, iron oxide nanoparticles have a variety of cancer 
therapy applications and are a promising class of materials for increasing efficacy and 
reducing the side effects of conventional cancer treatments.  
KEYWORDS: iron oxide nanoparticles, peptides, magnetically mediated hyperthermia, 
magnetically mediated energy delivery, reactive oxygen species  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                     
                                                             
                               __Anastasia Kruse Hauser                         o    
Student’s Signature 
        
 _March 23, 2016___________________                                          
Date
PEPTIDE-FUNCTIONALIZED MAGNETIC NANOPARTICLES FOR CANCER 
THERAPY APPLICATIONS 
 
 
 
By 
 
Anastasia Kruse Hauser 
 
 
 
 
 
 
 
 
 
 
 
        
                                           
 
 
      Dr. J. Zach Hilt                        o 
                                                                                        Co-Director of Dissertation 
                       
         Dr. Kimberly W Anderson___o 
                                                                                        Co-Director of Dissertation 
   
                                                                                      Dr. Thomas Dziubla                o 
                                                                                         Director of Graduate Studies   
                                                                                          
                                                                                         __________________________ 
                                                                           
                                                                                       
                                                                               
 
iii 
 
ACKNOWLEDGEMENTS 
There are several people who have made this dissertation possible through their support and 
encouragement during my time at the University of Kentucky. First, I would like to sincerely thank 
my advisors, Dr. J. Zach Hilt and Dr. Kimberly W. Anderson. Their guidance throughout this 
process has proved invaluable and I would not be where I am today without them. A huge thank 
you to Dr. Hilt for reaching out and inviting me to participate in undergraduate research and to Dr. 
Anderson for suggesting I apply to the REU program. Without that undergraduate research 
experience I would have not considered graduate school. During my time working with both Dr. 
Hilt and Dr. Anderson, I have learned the importance of character, integrity, and professionalism 
as well as how to be an effective mentor.  
I would also like to thank Dr. Thomas Dziubla, a committee member and mentor, for his help 
troubleshooting and brainstorming new ideas. Additionally, I would like to thank him for the 
support he has given the Materials and Chemical Engineering (MACE) Graduate Student 
Association. Dr. Ronald McGarry has also played a vital role in my dissertation and graduate 
education. I am grateful for the time he has been able to spare from the clinic to provide a unique 
perspective to this project. Dr. Bradley Anderson, the outside examiner, has also had a large 
influence on my education at UK, both during my undergraduate studies in the Biopharmaceutical 
track and in graduate school through the Cancer and Nanotechnology Training Center (CNTC). Dr. 
Anderson has always pushed me to be a better scientist and I greatly appreciate all of his advice 
over the years.  
This research has been funded and supported by several agencies and grants, and without this 
funding the work presented here would not have been possible. These include the National Science 
Foundation Graduate Research Fellowship Program, National Science Foundation Integrative 
Graduate Education and Research Traineeship, and the National Institute of Health Cancer and 
 
iv 
 
Nanotechnology Training Center. The P.E.O. Scholar Award, while not directly funding the 
research, helped provide financial support during my graduate education.  
I would like to extend a thank you to all of my fellow graduate students, past and present: Dr. 
Samantha Meenach, Dr. Nathanael Stocke, Dr. Daniel Schlipf, Dr. Andrew Lakes, Kaitlyn Wooten, 
Jacob Lilly, Jennifer Fischer, Rachel Essex, Angela Gutierrez, Shuo Tang, Trang Ma, and Dr. Rohit 
Bhandari. Specifically, I would like to thank Dr. Robert Wydra for all of his help and for being a 
great mentor during my undergraduate research experience. And to Carolyn Jordan, thanks for 
always being up for coffee breaks and willing to listen. I have also had the pleasure of working 
with several exceptional undergraduates: Kendall (Huddleston) Murphy, Michelle Pressley, Alex 
Tsoras, Sarah Patterson, Jonathan Coburn, Ronita Mathias, and Emily Daley. Mentoring 
undergraduates was one of my favorite parts of graduate school and I thank you for all of your hard 
work! 
Lastly, I would like to thank my family and friends for their love and encouragement. Thank 
you to one of my best friends, Tess Simon, for forcing me to eat a “real meal” once a week and for 
always being there to listen and give advice. A very special thank you to my parents for always 
believing in me and instilling in me the importance of faith and family. Even though I will not be 
what you consider to be a “real doctor”, I hope to contribute to making the world a better place for 
your grandchildren. Thank you to my brother, John, and sister, Alyssa, for always being able to 
make me laugh (even if it’s at my own expense). Most importantly, I would like to thank my 
husband, Paul, for his continual love and encouragement, even while living 149 miles apart. Thank 
you for pushing me to pursue my dreams even if it made things a bit more difficult. Amidst all the 
technical knowledge I have gained in graduate school, I have also learned that distance truly does 
make the heart grow fonder.  
 
 
v 
 
Table of Contents 
 
ACKNOWLEDGEMENTS ............................................................................................................ iii 
Table of Contents ............................................................................................................................. v 
List of Tables .................................................................................................................................. ix 
List of Figures .................................................................................................................................. x 
Chapter 1 Introduction ..................................................................................................................... 1 
1.1 Objectives ........................................................................................................................ 3 
Chapter 2 Active targeting strategies of iron oxide magnetic nanoparticles.................................... 5 
2.1 Introduction ............................................................................................................................ 5 
2.2 Active Targeting .................................................................................................................... 8 
2.2.1 Antibodies ..................................................................................................................... 10 
2.2.2 Aptamers ....................................................................................................................... 14 
2.2.3 Peptides ......................................................................................................................... 17 
2.2.4 Small Molecules ............................................................................................................ 25 
2.3 Conclusions and Future Perspectives ................................................................................... 31 
Chapter 3 Magnetic nanoparticles and nanocomposites for remote controlled therapies .............. 33 
3.1 Introduction .......................................................................................................................... 33 
3.2 Remote controlled energy release ........................................................................................ 36 
3.2.1 Thermal therapy ............................................................................................................ 36 
3.2.2 Nanoscale Energy Delivery .......................................................................................... 42 
3.3 Combination therapy ............................................................................................................ 47 
3.4 Conclusions .......................................................................................................................... 53 
Chapter 4 Synthesis and characterization of CREKA-conjugated iron oxide nanoparticles for 
hyperthermia applications .............................................................................................................. 55 
4.0 Abstract ................................................................................................................................ 55 
4.1 Introduction .......................................................................................................................... 56 
4.2 Materials and Methods ......................................................................................................... 59 
4.2.1 Materials ....................................................................................................................... 59 
4.2.2 Crosslinked dextran coated iron oxide nanoparticle synthesis ..................................... 60 
4.2.3 CREKA conjugation of iron oxide nanoparticles ......................................................... 60 
4.2.4 Particle characterization ................................................................................................ 62 
4.2.5 Cytotoxicity analysis of particle systems ...................................................................... 64 
4.2.6 CREKA and CREKA IONP binding affinity to fibrinogen clots ................................. 64 
 
vi 
 
4.2.7 In vitro magnetically mediated hyperthermia and cisplatin combined treatment ......... 65 
4.2.8 Statistical analysis ......................................................................................................... 66 
4.3 Results and Discussion ........................................................................................................ 66 
4.3.1 Particle characterization ................................................................................................ 66 
4.3.2 Remote controlled heating of iron oxide magnetic nanoparticles via AMF ................. 69 
4.3.3 Cytotoxicity analysis of particles .................................................................................. 70 
4.3.4 Fibrinogen binding affinity ........................................................................................... 71 
4.3.5 Magnetically-mediated hyperthermia ........................................................................... 72 
4.4 Conclusion ........................................................................................................................... 76 
Chapter 5 The effects of synthesis method on the physical and chemical properties of dextran 
coated iron oxide nanoparticles ..................................................................................................... 78 
5.0 Abstract ................................................................................................................................ 78 
5.1 Introduction .......................................................................................................................... 79 
5.2 Materials and Methods ......................................................................................................... 83 
5.2.1 Materials ....................................................................................................................... 83 
5.2.2 Dextran coated iron oxide nanoparticle synthesis via two-step method ....................... 84 
5.2.3 Dextran coated iron oxide nanoparticle synthesis via semi-two-step method .............. 84 
5.2.4 Dextran coated iron oxide nanoparticle synthesis via simultaneous semi-two-step 
method ................................................................................................................................... 85 
5.2.5 Dextran coated iron oxide nanoparticle synthesis via one-step method ....................... 85 
5.2.6 Epichlorohydrin crosslinking of dextran coated iron oxide nanoparticles .................... 85 
5.2.7 Particle characterization ................................................................................................ 86 
5.3 Results and Discussion ........................................................................................................ 88 
5.4 Conclusions .......................................................................................................................... 99 
Chapter 6 Peptide conjugated magnetic nanoparticles for magnetically mediated energy delivery
 ..................................................................................................................................................... 101 
6.0 Abstract .............................................................................................................................. 101 
6.1 Introduction ........................................................................................................................ 102 
6.2 Materials and Methods ....................................................................................................... 107 
6.2.1 Materials ..................................................................................................................... 107 
6.2.2 Synthesis of uncoated iron oxide nanoparticles .......................................................... 107 
6.2.3 Synthesis of dextran coated iron oxide nanoparticles (Fe3O4 + Dx) ........................... 108 
6.2.4 Epichlorohydrin (ECH) crosslinking of dextran coated iron oxide nanoparticles (Fe3O4 
+ Dx-ECH) ........................................................................................................................... 108 
6.2.5 Amine functionalization of crosslinked dextran coated iron oxide nanoparticles (Fe3O4 
+ Dx-ECH-Amine)............................................................................................................... 108 
 
vii 
 
6.2.6 TAT peptide conjugation to iron oxide nanoparticles (Fe3O4 + TAT)........................ 109 
6.2.7 Iron concentration assay ............................................................................................. 109 
6.2.8 Iron oxide nanoparticle characterization ..................................................................... 109 
6.2.9 Cell Culture ................................................................................................................. 110 
6.2.10 Iron oxide nanoparticle uptake .................................................................................. 110 
6.2.11 Reactive Oxygen Species (ROS) Generation ............................................................ 111 
6.2.12 Acridine orange lysosomal permeabilization experiments ....................................... 111 
6.2.13 Mitochondrial membrane depolarization studies (JC-1) ........................................... 112 
6.2.14 Caspase 3/7 apoptosis studies ................................................................................... 112 
6.2.15 Viability studies ........................................................................................................ 112 
6.3 Results and Discussion ...................................................................................................... 113 
6.3.1 Iron oxide nanoparticle characterization ..................................................................... 113 
6.3.2 Cellular uptake of iron oxide nanoparticles ................................................................ 116 
6.3.3 Intracellular reactive oxygen species formation ......................................................... 117 
6.4 Conclusions ........................................................................................................................ 125 
Chapter 7 Targeted iron oxide nanoparticles for the enhancement of radiation therapy ............. 127 
7.0 Abstract .............................................................................................................................. 127 
7.1 Introduction ........................................................................................................................ 128 
7.2 Materials and Methods ....................................................................................................... 133 
7.2.1 Materials ..................................................................................................................... 133 
7.2.2 Synthesis of uncoated iron oxide nanoparticles (uncoated Fe3O4).............................. 133 
7.2.3 Synthesis of dextran coated iron oxide nanoparticles (Fe3O4 + Dx) ........................... 134 
7.2.4 Epichlorohydrin (ECH) crosslinking of dextran coated iron oxide nanoparticles (Fe3O4 
+ Dx-ECH) ........................................................................................................................... 134 
7.2.5 Amine functionalization of crosslinked dextran coated iron oxide nanoparticles (Fe3O4 
+ Dx-ECH-Amine)............................................................................................................... 134 
7.2.6 TAT peptide conjugation to iron oxide nanoparticles (Fe3O4 + TAT)........................ 135 
7.2.7 Iron Concentration Assay............................................................................................ 135 
7.2.8 Cell Culture ................................................................................................................. 135 
7.2.9 Transmission electron microscopy .............................................................................. 135 
7.2.10 Acridine orange lysosomal permeabilization experiments ....................................... 136 
7.2.11 Mitochondrial stress test ........................................................................................... 136 
7.2.12 Reactive Oxygen Species (ROS) Generation ............................................................ 138 
7.2.13 Viability studies ........................................................................................................ 138 
7.3 Results and Discussion ...................................................................................................... 138 
 
viii 
 
7.4 Conclusions ........................................................................................................................ 149 
Chapter 8 Conclusions ................................................................................................................. 151 
8.1 Significant Findings ........................................................................................................... 152 
Appendix A Combination treatment of multi-cellular tumor spheroids ...................................... 154 
A. 1 Introduction ...................................................................................................................... 154 
A.2 Materials and Methods ...................................................................................................... 158 
A.2.1 Materials..................................................................................................................... 158 
A.2.2 Cell culture ................................................................................................................. 159 
A.2.3 MCTS formation ........................................................................................................ 159 
A.2.4 MCTS dissociation ..................................................................................................... 160 
A.2.5 Acid phosphatase assay .............................................................................................. 160 
A.2.6 Resazurin assay .......................................................................................................... 160 
A.2.7 Calcein AM/Ethidium homodimer-1 (live/dead) assay ............................................. 161 
A.2.8 Assay validation studies ............................................................................................. 161 
A.2.9 Incubator-induced hyperthermia with CDDP ............................................................ 162 
A.2.10 Incubator induced hyperthermia with radiation ....................................................... 163 
A.3 Results and discussion ...................................................................................................... 163 
A.3.1 MCTS assay validation .............................................................................................. 163 
A.3.2 Cisplatin combined with hyperthermia on MCTS ..................................................... 168 
A.3.3 Radiation combined with hyperthermia on MCTS .................................................... 169 
A.4 Conclusions ....................................................................................................................... 173 
References .................................................................................................................................... 175 
Vita............................................................................................................................................... 202 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
List of Tables 
 
Table 4.1 Nanoparticle systems synthesized and characterized, their size as analyzed via DLS, and 
SAR values from AMF heating. Size of Fe3O4+Dx-ECH-Amine-CREKA via DLS could not be 
completed due to the fluorescent tag but minimal difference from the other systems is expected.
 ....................................................................................................................................................... 67 
Table 4.2 Bound-to-free fluorescence for each system to fibrin clots represented by average ± 
standard error (n = 4). The * indicates a significant difference from the FITC-IONP bound-to-free 
fluorescence ratio (p<0.05). ........................................................................................................... 72 
Table 4.3 Magnetically mediated hyperthermia treatments and controls. ..................................... 73 
Table 5.1 Size analysis via dynamic light scattering of iron oxide nanoparticles synthesized by the 
various methods represented by average ± standard deviation (three independent batches and three 
samples from each batch). .............................................................................................................. 89 
Table 5.2 Dextran weight percentage via thermogravimetric analysis of iron oxide nanoparticles 
synthesized by the various methods (n=3). .................................................................................... 91 
Table 5.3 Iron oxide crystal size estimated using XRD spectra and the Scherrer equation and TEM 
images of iron oxide nanoparticles synthesized by the various methods (mean ± st. dev. n=3 for 
XRD and n=150 for TEM). ............................................................................................................ 97 
Table 5.4 Specific absorption rates (W/g) of iron oxide nanoparticles (3 mg/mL Fe3O4) heating in 
an alternating magnetic field (58 kA/m, 292 kHz) of iron oxide nanoparticles synthesized by the 
various methods (n=3). .................................................................................................................. 99 
Table 6.1. Iron oxide nanoparticle size from dynamic light scattering in DI water and cell culture 
media and zeta potential represented as average ± standard deviation (n=3). ............................. 115 
Table 7.1 Equations developed by Babincova et al. for analysis of combinational treatments. .. 148 
Table 7.2 Calculations to analyze the effects of combined Fe3O4 + TAT nanoparticles and radiation 
treatments. Values represent viability average ± standard error (n=12) on days 3, 5 and 7 post 
treatment. * (p<0.05) and ** (p<0.01) indicate a significant difference from the [Fe3O4 + 
TAT]x[Radiation]/100 group on the same day. ........................................................................... 149 
 
 
 
 
 
 
 
 
 
 
x 
 
List of Figures 
Figure 2.1 Targeting methods for magnetic nanoparticles include A) passive targeting and B) active 
targeting. Active targeting includes targeting the i) extracellular matrix, ii) cell surface receptors 
and/or iii) utilizing cell penetrating peptides to target specific intracellular organelles. ................. 7 
Figure 3.1 This section highlights the uses of MNPs for controlled release therapies. A) Thermal 
therapy can be remotely controlled for i) local applications or ii) nanoscale heating applications. B) 
Thermal therapy is often administered in combination with a secondary treatment such as i) a 
therapeutic or ii) radiation. ............................................................................................................. 36 
Figure 4.1 Iron oxide nanoparticle synthesis process for the (a) dextran coating, (b) epichlorohydrin 
crosslinking, (c) amine conjugation, and (d) conjugation with an AMAS linker, connecting the 
FAM-labeled CREKA to the primary amine. ................................................................................ 62 
Figure 4.2 TEM images of (a) dextran coated iron oxide nanoparticles (Fe3O4+Dx) and (b) dextran-
epichlorohydrin crosslinked iron oxide nanoparticles (Fe3O4+Dx-ECH). ..................................... 66 
Figure 4.3 Normalized absorbance (at 540 nm) of the iron oxide nanoparticle systems in (a) PBS 
and (b) DMEM with 10% v/v FBS over 12 hours using UV-visible spectroscopy. ...................... 68 
Figure 4.4 Normalized mass loss of each nanoparticle system in the synthesis process via TGA. 69 
Figure 4.5 Heating profiles of each nanoparticle system in the synthesis process (5 mg/mL Fe3O4) 
in the presence of an alternating magnetic field at 58 kA/m and 292 kHz (n = 3). The gray box 
indicates the target hyperthermia range. ........................................................................................ 70 
Figure 4.6 Normalized viability of each nanoparticle system in the synthesis process on A549 lung 
cancer cells after (a) 24 hours of exposure and (b) 48 hours of exposure.  Error bars represent 
standard error (n = 4) and * indicates a significant difference (p < 0.05) using a 1-way ANOVA 
test. ................................................................................................................................................. 71 
Figure 4.7 Relative viability of A549 lung cancer cells 48 hours post magnetically mediated 
hyperthermia treatment. Error bars represent standard error (n = 12) and ** indicates a significant 
difference (p < 0.01).  Representative images of A549 cells stained with calcein AM after 48 hours 
for: (a) Control, (b) IONP, (c)MMH, (d) CDDP, (e) CDDP+IONP, and (f) CDDP+MMH. ........ 75 
Figure 4.8 Relative viability of A549 lung cancer cells 72 hours post magnetically mediated 
hyperthermia treatment. Error bars represent standard error with n = 12 and ** indicates a 
significant difference (p < 0.01).  Representative images of A549 cells stained with calcein AM 
after 72 hours for: (a) Control, (b) IONP, (c) MMH, (d) CDDP, (e) CDDP+IONP, and (f) 
CDDP+MMH. ................................................................................................................................ 76 
Figure 5.1 Schematic of iron oxide nanoparticle synthesis methods. The co-precipitation reaction 
for each of the methods is completed at 85 °C for one hour after the addition of the reducing agent 
(ammonium hydroxide). ................................................................................................................ 83 
Figure 5.2 FTIR spectra of dextran coated iron oxide nanoparticles synthesized by the various 
methods. ......................................................................................................................................... 91 
Figure 5.3 Mass loss and d%/dT with increasing temperature of dextran coated and epichlorohydrin 
crosslinked iron oxide nanoparticles synthesized via the (a) two-step method, (b) semi-two-step 
method, (c) simultaneous semi-two-step method, (d) one-step method with 5 grams dextran, and 
(e) one-step method with 1 gram dextran. ..................................................................................... 92 
 
xi 
 
Figure 5.4 Stability of dextran coated and epichlorohydrin crosslinked iron oxide nanoparticles 
synthesized via the (a) two-step method, (b) semi-two-step method, (c) simultaneous semi-two-step 
method, (d) one-step method with 5 grams dextran, and (e) one-step method with 1 gram dextran 
in PBS over 12 hours analyzed by UV-visible spectroscopy (λ=540). .......................................... 93 
Figure 5.5 XRD patters of dextran coated iron oxide nanoparticles synthesized via the (a) two-step 
method, (b) semi-two-step method, (c) simultaneous semi-two-step method, (d) one-step method 
with 5 grams dextran, (e) one-step method with 1 gram dextran and (f) dextran only. ................. 96 
Figure 5.6 TEM images of dextran coated iron oxide nanoparticles synthesized via the (a) two-step 
method, (b) semi-two-step method, (c) simultaneous semi-two-step method, (d) one-step method 
with 5 grams dextran, and (e) one-step method with 1 gram dextran. ........................................... 97 
Figure 6.1 TAT-conjugated iron oxide nanoparticles are internalized by cancer cells and 
permeabilize endosomal/lysosomal membranes due to the positive charge of the peptide. Upon 
exposure to an AMF, the nanoparticles generate the hydroxyl radical via Fenton chemistry, friction 
from Brownian rotaion and nanoscale heat effects by Neél relaxation........................................ 106 
Figure 6.2. Iron oxide nanoparticle synthesis and functionalization of the TAT peptide. ........... 115 
Figure 6.3 Nanoparticle characterization. a. FTIR spectra of amine functionalized and TAT 
conjugated iron oxide nanoparticles. b. TEM images of dextran coated iron oxide nanoparticles to 
confirm Fe3O4 crystalline structure. c. X-ray diffraction pattern of dextran coated iron oxide 
nanoparticles. ............................................................................................................................... 116 
Figure 6.4 Uptake of Fe3O4 nanoparticles into a.) A549 and b.) H358 lung cancer cells. Error bars 
represent standard error (n=3) and significant differences are indicated by * (p<0.05) and ** 
(p<0.01) via a one-way ANOVA. ................................................................................................ 117 
Figure 6.5 Normalized carboxy-DCF fluorescence of a.) A549 and b.) H358 lung cancer cells after 
treatment with Fe3O4 nanoparticles with and without 30 minutes or 1 hour AMF exposure. Error 
bars represent standard error (n=3) and significant difference is indicated by * (p<0.05) via a two-
way ANOVA. .............................................................................................................................. 119 
Figure 6.6 Average fluorescence of A549 and H358 cells after 2 hours of exposure to 50 µM 
carboxy-DCF. Error bars represent standard error (n=5) and * indicates a significant difference 
(p<0.05) via a t-test. ..................................................................................................................... 120 
Figure 6.7 Relative acridine orange (AO) fluorescence of a.) A549 and b.) H358 lung cancer cells 
after treatment with Fe3O4 nanoparticles with and without 1 hour AMF exposure. Error bars 
represent standard error (n=3) and significant difference from the control is indicated by * (p<0.05) 
via a two-way ANOVA. .............................................................................................................. 121 
Figure 6.8 Percentage of a.) A549 and b.) H358 cells with depolarized mitochondrial membranes 
as indicated by a decrease in the ratio between FL3/FL1 (JC1 ratio). Error bars represent standard 
error (n=3) and * indicates a significant difference (p<0.05) compared to the control as determined 
via a two-way ANOVA. .............................................................................................................. 122 
Figure 6.9 Percentage apoptosis of a.) A549 and b.) H358 lung cancer cells 12 and 24 hours after 
treatment with Fe3O4 nanoparticles with and without 1 hour AMF. Error bars represent standard 
error (n=3) and significant difference from the control is indicated by * (p<0.05) via a two-way 
ANOVA. ...................................................................................................................................... 124 
 
xii 
 
Figure 6.10 Relative viability of a.) A549 and b.) H358 lung cancer cells 48 hours after treatment 
with Fe3O4 nanoparticles with and without 1 hour AMF. Error bars represent standard error (n=3) 
and significant difference from the control is indicated by * (p<0.05) via a two-way ANOVA. 125 
Figure 7.1 TAT-conjugated iron oxide nanoparticles are internalized into the cell, followed by 
lysosomal membrane permeabilization. This results in release of proteolytic enzymes as well as the 
nanoparticles into the cytoplasm where they can interact with organelles such as the nucleus and 
mitochondria and catalyze the formation of the hydroxyl radical. .............................................. 132 
Figure 7.2 Bioenergetic profile of control A549 cells over time. Error bars represent standard error 
(n=12)........................................................................................................................................... 137 
Figure 7.3 Internalization of Uncoated or TAT-conjugated iron oxide nanoparticles by A549 lung 
carcinoma, with and without radiation treatment. Scale bars represent 200 nm. ......................... 139 
Figure 7.4 Normalized acridine orange (AO) fluorescence of A549 lung carcinoma after 2 hour 
treatment with Fe3O4 nanoparticle systems with and without radiation. Error bars represent standard 
error (n=3) and ** indicates a significant difference from the control (p<0.01) via a two-way 
ANOVA. ...................................................................................................................................... 141 
Figure 7.5 Basal oxygen consumption rates of A549 lung carcinoma cells after Fe3O4 nanoparticle 
treatment with and without radiation. Error bars represent standard error (n=12). * indicates a 
significant difference between the no radiation and radiation treatments within a nanoparticle 
system (p<0.05), † indicates a significant difference compared to the control without radiation 
(p<0.05) and ‡ indicates a significant difference from the control with radiation (p<0.05), via a 
two-way ANOVA with an interaction term. ................................................................................ 143 
Figure 7.6 Maximal oxygen consumption rates of A549 lung carcinoma cells after Fe3O4 
nanoparticle treatment with and without radiation. Error bars represent standard error (n=12). * 
indicates a significant difference between the no radiation and radiation treatments within a 
nanoparticle system (p<0.05), † indicates a significant difference compared to the control without 
radiation (p<0.05) and ‡ indicates a significant difference from the control with radiation (p<0.05), 
via a two-way ANOVA with an interaction term. ....................................................................... 144 
Figure 7.7 Oxygen consumption rate vs. extracellular acidification rate of A549 lung carcinoma 
after exposure to Fe3O4 nanoparticle systems with and without radiation and FCCP stimulation. 
Error bars represent standard error (n=12) and ** indicates a significant difference in both OCR 
and ECAR from no-radiation Fe3O4 nanoparticle. ..................................................................... 145 
Figure 7.8 Relative carboxy-DCF fluorescence in A549 lung carcinoma following 24 hour 
treatment with Fe3O4 nanoparticle systems with and without 5 Gy radiation treatment. Error bars 
represent standard error (n=12) and * indicates a significant difference compared to radiation alone 
and † indicates a significant difference compared to 500 µg/mL uncoated and 500 µg/mL amine 
functionalized Fe3O4 nanoparticles. ............................................................................................. 146 
Figure 7.9 Relative viability of A549 lung carcinoma 3, 5 or 7 days following a) uncoated b) Dx-
ECH c) amine functionalized or d) TAT-conjugated Fe3O4 nanoparticle treatment with and without 
5 Gy radiation. Error bars represent standard error (n=12) and * indicates a significant difference 
(p<0.05) via a one-way ANOVA. ................................................................................................ 148 
 
1 
 
Chapter 1 Introduction 
 
Cancer is the second leading cause of death in the Unites States. Survival rates of lung cancer 
are especially low with the 1- and 5-year relative survival rates at 44% and 17%, respectively. 
These low survival rates are partially due to more than half (57%) of patients not being diagnosed 
until the cancer has progressed to an advanced stage. In addition, current treatments (e.g., 
chemotherapy and radiation) result in severe side-effects. Therefore, there is a clear need to 
improve current cancer therapies in order to prolong survival and reduce the toxic side-effects of 
treatments.  
Treatment of lung cancer via hyperthermia, the heating of tissue to 42-45 °C, in conjunction 
with radiation and chemotherapy has resulted in synergistic effects in regard to efficacy of the 
conventional treatment and has the potential to decrease the prevalence of toxic side effects (Genet, 
Fujii et al. 2013). Current hyperthermia methods include whole body and regional hyperthermia. 
Whole body hyperthermia is relatively invasive and results in greater toxic side-effects than 
regional hyperthermia, but both have several disadvantages, including the burning of healthy tissue, 
limited penetration of heat into the body, under-dosage of heat, and complications such as increased 
heart rate and increased cardiac output (Zwischenberger, Vertrees et al. 2004, Issels 2008, Kumar 
and Mohammad 2011). Magnetically-mediated hyperthermia (MMH), the heating of tissue using 
heat generated by magnetic nanoparticles in the presence of an alternating magnetic field (AMF), 
shows great promise in overcoming the limitations of current hyperthermia treatments due to the 
ability of nanoparticles to deliver heat directly to the tumor site. Iron oxide nanoparticles are a class 
of magnetic nanoparticles which have been previously studied due to their inherent 
biocompatibility, magnetic properties, and lack of protein adsorption after proper coating (Laurent, 
Dutz et al. 2011). Iron oxide nanoparticles have the ability to passively and/or actively target tumors 
and, upon activation by an external alternating magnetic field, generate heat via multiple possible 
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loss mechanisms: hysteresis, Néel paramagnetic switching, and friction from Brownian rotation 
(Dennis, Jackson et al. 2009).  
One of the main limitations to MMH is the difficulty in achieving a high magnetic nanoparticle 
concentration within tumor tissue following intravenous injection of the nanoparticles. Properly 
masking the nanoparticles with a biocompatible coating to improve stability, biocompatibility, and 
circulation time has been used to improved tumor concentrations via passive targeting and 
utilization of the enhanced permeation and retention (EPR) effect (Veiseh, Gunn et al. 2010, Wu, 
Wu et al. 2015). Additionally, functionalizing the nanoparticle surface with active targeting ligands 
has been shown to improve tumor targeting and retention of the magnetic nanoparticles 
(Turcheniuk, Tarasevych et al. 2013, Singh and Sahoo 2014, Hola, Markova et al. 2015).  
Despite extensive research, MMH treatment has yet to make its clinical debut. A recent focus 
for magnetic nanoparticle research has been in magnetically mediated energy delivery (MagMED). 
In this approach, cells internalize magnetic nanoparticles and when exposed to an AMF, the 
nanoparticles locally delivery energy in the form of local heat dissipation, mechanical effects, 
and/or surface reactivity without a measurable temperature rise (Kozissnik, Bohorquez et al. 2013). 
MagMED treatment has been shown to elicit cellular responses such as lysosomal permeabilization, 
increased mitochondrial reactive oxygen species (ROS) generation, opening of ion channels, and 
apoptosis (Domenech, Marrero-Berrios et al. 2013, Sanchez, Diab et al. 2014, Connord, Clerc et 
al. 2015).  
The main focus of magnetic nanoparticles in biomedical research has been their ability to 
deliver energy to increase the regional temperature in response to an AMF, but recent focus has 
shifted to understanding the mechanisms of MagMED toxicity, such as the generation of ROS. Iron 
oxide nanoparticles can catalyze the Haber-Weiss reaction through Fenton chemistry, producing 
the highly reactive hydroxyl radical. Cancer cells are more susceptible to oxidative insults 
compared to normal cells due to fast cell proliferation and metabolism so additional ROS stress 
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induced by exogenous agents can overwhelm the relatively low antioxidant capacity and disrupt 
the redox homeostasis inside cancer cells leading to selective tumor cell toxicity (Huang, Chen et 
al. 2013).  
This dissertation provides an investigation into applications of peptide-functionalized iron 
oxide magnetic nanoparticles for cancer therapy. Peptides were chosen as the targeting ligands for 
the studies completed as part of this dissertation, and chapter 2 reviews various targeting modalities 
utilized to effectively target magnetic nanoparticles to tumor tissues. Chapter 3 then reviews 
magnetic nanoparticles for remote controlled therapies such as thermal therapy, nanoscale energy 
delivery, and combinational therapies.  
1.1 Objectives   
 
The overall objective of this dissertation was to develop peptide-functionalized iron oxide 
magnetic nanoparticles for cancer therapy applications such as magnetically mediated 
hyperthermia, magnetically mediated energy delivery, and reactive oxygen species generation in 
order to enhance the efficacy of conventional cancer treatments.  The overall objective was 
accomplished through the following four projects: 
1. Synthesis and characterization of CREKA-conjugated iron oxide nanoparticles for 
hyperthermia treatment of cancer 
2. Effect of synthesis method on the physical and chemical properties of dextran-coated iron oxide 
nanoparticles 
3. Peptide conjugated magnetic nanoparticles for magnetically mediated energy delivery to A549 
lung carcinoma and H358 bronchi alveolar 
4. Peptide conjugated iron oxide nanoparticles for the enhancement of radiation therapy 
Chapter 4, entitled “Synthesis and characterization of CREKA-conjugated iron oxide 
nanoparticles for hyperthermia treatment of cancer” presents a peptide-conjugated iron oxide 
magnetic nanoparticle system for targeted magnetically mediated hyperthermia treatment in 
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combination with chemotherapy. This chapter analyzes the physicochemical characteristics of the 
nanoparticle system and provides a proof-of-concept study with magnetically mediated 
hyperthermia and cisplatin, a common chemotherapeutic. Although iron oxide nanoparticle 
synthesis has been extensively studied, researchers are continually searching for methods to 
improve size, stability, and heating capabilities of the nanoparticles. The iron oxide nanoparticles 
developed in chapter 4 had optimal size and stability but low heating capabilities compared to other 
systems in literature.  Chapter 5 entitled “Effect of synthesis method on the physical and chemical 
properties of dextran-coated iron oxide nanoparticles” aimed to improve the properties of dextran-
coated iron oxide nanoparticles synthesized by the co-precipitation method. This chapter also 
solidified the process by which dextran-coated iron oxide nanoparticles are synthesized in our lab.  
Chapter 6, “Peptide conjugated magnetic nanoparticles for magnetically mediated energy 
delivery to A549 lung carcinoma and H358 bronchi alveolar”, utilizes iron oxide nanoparticles 
conjugated to a cell penetrating peptide in the presence of an AMF to elicit intracellular changes 
through MagMED. The physicochemical properties of the nanoparticle system are characterized 
and a variety of assays are completed in hopes of improving our understanding of the intracellular 
effects of this treatment.  Chapter 7, “Peptide conjugated iron oxide nanoparticles for the 
enhancement of radiation therapy” utilizes the iron oxide nanoparticles developed in chapter 6 to 
catalyze intracellular ROS generation and permeabilize lysosomal structures which sensitizes the 
cancer cells to subsequent radiation treatment. Finally, chapter 8 reports the conclusions of this 
dissertation and potential future directions for peptide-functionalized iron oxide nanoparticles.  
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Chapter 2 Active targeting strategies of iron oxide magnetic nanoparticles 
2.1 Introduction 
Magnetic nanoparticles have been utilized in a variety of biological applications due to their 
flexible design and low toxicity, including contrast agents in magnetic resonance imaging (MRI), 
magnetic separation, magnetically mediated hyperthermia (MMH), and magnetically mediated 
energy delivery (MagMED). Although a multitude of magnetic nanoparticles exist, iron oxide is a 
class of magnetic nanoparticles that has received particular interest due to ease of preparation, ease 
of modification, and superparamagnetic properties. Maghemite (Fe2O3) and magnetite (Fe3O4) iron 
oxide crystals usually fall below the superparamagnetic size threshold of approximately 15 nm, 
making them the most common form of iron oxide studied for biological applications (Tucek, 
Zboril et al. 2006, Pankhurst, Thanh et al. 2009, Laurent, Dutz et al. 2011). In addition, iron oxide 
nanoparticles are biocompatible at low doses and biodegradable, which increases their potential for 
biological applications.  
Coating of magnetic nanoparticles with a biocompatible compound is required prior to 
biological use. The magnetic nanoparticle coating can serve to decrease nanoparticle aggregation 
by suppressing particle-particle interactions, prevent degradation of the core iron oxide in 
biological environments, and provide functional groups for conjugation of targeting agents, drugs, 
or other biological compounds (Gupta and Gupta 2005). Coating the magnetic nanoparticles can 
also mask the nanoparticles from recognition by the immune system, prolonging circulation time 
and ultimately leading to increased uptake.  
There are a wide variety of organic and inorganic coatings for magnetic nanoparticles that 
protect and stabilize the nanoparticles for biological use. There are several recent reviews that 
examine these coatings and their applications (Gupta, Naregalkar et al. 2007, Veiseh, Gunn et al. 
2010, Xie, Liu et al. 2011, Jiang, Win et al. 2013, Jin, Lin et al. 2014, Chu, Yu et al. 2015, Wu, Wu 
et al. 2015). Organic coating materials include small molecules, surfactants, polymers, and 
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biomolecules. Magnetic nanoparticles coated with these materials are commonly used for MRI, 
drug targeting, and magnetic separation. Citric acid and silanes are examples of small molecules 
which can be used to synthesize water-soluble iron oxide nanoparticles directly (Wydra, Kruse et 
al. 2013) and to functionalize compounds to bare iron oxide nanoparticles. Small molecules allow 
the magnetic nanoparticles to retain their saturation magnetization values after coating due to the 
low mass fraction of the total particle (Wu, Wu et al. 2015). Polymers are a class of organic coatings 
that pose several advantages over small molecules such as multifunctional groups and ability to 
provide more colloidal stability (Pierrat, Zins et al. 2007). Several polymers, both natural and 
synthetic, have been studied for functionalizing magnetic nanoparticles. Dextran is widely used 
due to its biocompatibility and stability following crosslinking, but other polymers commonly 
studied include poly (ethylene glycol), chitosan, poly (D,L-lactide) (PLA), and poly (acrylic acid) 
(Chu, Yu et al. 2015). Biomolecules have continued to gain interest as coating materials for 
magnetic nanoparticles, and a variety of biomolecules have been successfully conjugated to the 
surface of iron oxide nanoparticles including enzymes, antibodies, proteins, and polypeptides 
(Glickson, Lund-Katz et al. 2009, Hajshafiei, Fatahian et al. 2014, Zaloga, Janko et al. 2014, Wu, 
Wu et al. 2015, Xie and Zang 2016).  
Inorganic coatings can also be used to coat magnetic nanoparticles for biological applications, 
and these are also used for improving semiconductor efficiency and information storage. Silica is 
by far the most explored inorganic coating for biological magnetic nanoparticles. Silica coatings 
enhance nanoparticle dispersion by screening the magnetic dipolar attraction between the 
nanoparticles while providing protection from acidic environments (Tarn, Ashley et al. 2013). 
Other inorganic coatings include metals (gold, silver, copper, etc.), metal oxides, and sulfoxides.  
Prolonging circulation time of magnetic nanoparticles by coating with a biocompatible agent 
is often insufficient to accumulate the nanoparticles at a specific tissue site. For example, 
researchers have taken advantage of the underdeveloped, leaky vasculature of cancer tissue to 
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passively target cancer tissue by the enhanced permeation and retention (EPR) effect (Bertrand, 
Wu et al. 2014). As nanoparticles circulate throughout the body, they passively accumulate within 
cancerous tissue and are retained due to the inability of the tissue to properly remove waste.  While 
this method has been shown to increase magnetic nanoparticle concentrations within tumor tissues, 
the concentration is often insufficient to induce a therapeutic effect or significantly influence MRI 
contrast. Therefore, active targeting is regularly utilized to increase magnetic nanoparticle 
concentration within the tissue of interest and more specifically target the tissue based on selective 
recognition as shown in Figure 2.1.  
 
Figure 2.1 Targeting methods for magnetic nanoparticles include A) passive targeting and B) active 
targeting. Active targeting includes targeting the i) extracellular matrix, ii) cell surface receptors 
and/or iii) utilizing cell penetrating peptides to target specific intracellular organelles. 
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2.2 Active Targeting 
Active targeting of magnetic nanoparticles involves functionalizing the nanoparticle surface 
with a specific moiety in order to direct the magnetic nanoparticle towards a specific binding site 
of interest. The targeting method can help detect, characterize, and treat diseases based on 
accumulation and aims to avoid off-target toxicities. This targeting method is often more effective 
than relying solely on passive accumulation. Targeting functionalities for magnetic nanoparticles 
include peptides, antibodies, and small molecules lending to a variety of biological targets such as 
cell surface receptors, enzymes, proteins, and integrins.  
Although there are a variety of methods for conjugating ligands to the surface of magnetic 
nanoparticles, amines or carboxylic acids on the nanoparticle surface are commonly used for further 
functionalization. These primary functional groups are usually present on the nanoparticle surface 
via adsorption of polymers or small molecules (Hola, Markova et al. 2015). Amine functionalized 
nanoparticles are easily modified with ligands containing carboxylic acids through the use of 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxosuccinimide (NHS) 
crosslinking. Ligands with sulfhydryl groups such as those present on peptides and antibodies can 
be functionalized to the surface using heterobifunctional linkers such as N-Succinimidyl 3-[2-
pyridyldithio]-propionate (SPDP) or N-α-maleimidoacet-oxysuccinimide ester (AMAS) 
(McCarthy and Weissleder 2008). However, it has been suggested that ECD/NHS chemistry leads 
to randomly oriented antibodies on the nanoparticle surface which could result in a loss of 
bioactivity of the conjugated antibody. Therefore, a more sophisticated method is to react amine 
groups on the nanoparticle surface with heterobifunctional linkers to introduce maleimide, pyridyl 
disulfide or iodoacetyl groups (Gruettner, Mueller et al. 2013). A comparison of antibody binding 
after magnetic nanoparticle conjugation using EDC/NHS chemistry or maleimide and SPDP based 
reactions demonstrated advantages of the latter. The bioactivity of the antibody was 88% after 
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maleimide and SPDP reactions, and 35% for the EDC/NHS chemistry (Gruettner, Mueller et al. 
2007).  
Nanoparticles with carboxylic acid functionalized surfaces can also be modified with targeting 
ligands but through a more tedious reaction which requires activation of the carboxylic acids. 
Amine and carboxylic acid groups on the surface of nanoparticles are also interchangeable as 
reaction of amine groups with succinic anhydride or glutaric anhydride converts the surface to 
carboxylates, whereas the activation of carboxylic acid functionalized particles with EDC and NHS 
followed by reaction with diamine results in amine functionalized nanoparticles.  
There are a wide variety of moieties used to functionalize magnetic nanoparticles for active 
targeting. Determining the appropriate ligand for functionalization depends upon the biological 
target and the ultimate goal. Smaller peptides and nucleic acid based aptamers can be engineered 
to have only one active molecular handle per molecule which ensures consistent linking to the 
nanoparticle surface and no loss of binding activity. Small organic molecules can also be 
engineered to assemble at high densities but may require longer linker molecules to ensure that the 
nanoparticle coating does not obscure the active region (Veiseh, Gunn et al. 2010). Peptides and 
aptamers can also be chemically synthesized and have been shown to be non-immunogenic unlike 
many antibodies and proteins. Relatively bulky proteins and antibodies can be difficult to assemble 
onto a nanoparticle surface due to lack of consistent covalent bonding orientation due to these 
ligands having multiple active functional groups per molecule and non-specific physical 
interactions between the molecule and the nanoparticle. However, due to the ease of conjugation 
and specificity of these molecules they continue to gain interest for nanoparticle targeting. This 
section provides an overview of recent advances in active targeting of magnetic nanoparticles via 
antibody, aptamer, peptide, and small molecule functionalization.  
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2.2.1 Antibodies 
Antibodies are one of the most used biomolecules to provide specificity and bioactivity to 
nanoparticles due to their high specificity and large diversity. It is feasible to obtain or engineer 
specific antibodies against virtually any substance in high amounts so it is possible to find 
antibodies that recognize a large number of antigens ranging from large pathogens (viruses, 
bacteria, etc.) to small molecules (drugs, hormones, bacterial toxins, allergenic peptides, etc.). 
Antibodies have high binding affinities and retain their specificity for target molecules even in 
complex environments or low target concentrations (Montenegro, Grazu et al. 2013). Antibodies 
have continued to gain interest for their cancer targeting abilities due to cancer cells having different 
surface expression than healthy cells however, other applications include cell separation (Bloemen, 
Denis et al. 2015) and targeting of atherosclerotic plaques (Jacobin-Valat, Laroche-Traineau et al. 
2015).  
Anti-human epidermal growth factor receptor 2 (HER/neu) monoclonal antibodies are 
commonly used for breast cancer targeting as about 25% of breast cancer patients show 
overexpression of HER2/neu, making it a target of interest for enhancing drug delivery. There are 
a variety of anti-HER2 moieties that have been studied for nanoparticle targeting. Kanazaki et al. 
synthesized iron oxide nanoparticles conjugated to one of three anti-HER2 moieties: Trastuzumab, 
anti-HER single chain fragment variabile (scFv) and anti-HER2 peptide (Kanazaki, Sano et al. 
2015). Iron oxide nanoparticles conjugated with the anti-Her2 scFv showed higher tumor 
accumulation and tumor-to-background ratios than the other targeting moieties. Recently, Mu et al. 
functionalized PEG coated iron oxide magnetic nanoparticles with the anti-HER2/neu peptide and 
carboxymethylated-B-cyclodextrin to allow hydrophobic loading of paclitaxel (PTX) (Mu, Kievit 
et al. 2015). SK-BR-3 (HER2/neu positive) and MDA MB 231 (HER2/neu negative) cells were 
used for uptake studies and uptake was significantly greater in the SK-BR-3 cells indicating that 
uptake was dependent upon the presence of HER2/neu. Cytotoxicity results showed that the iron 
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oxide nanoparticle system was non-cytotoxic, and PTX treatment was nearly the same for both cell 
lines but the nanoparticle formulation loaded with PTX was more effective on SK-BR-3 cells. In 
vivo targeting of the nanoparticles to a SK-BR-3 xenograft tumor mouse model showed enhanced 
accumulation of the targeted nanoparticles compared to non-targeted. The radiant efficacy ratio 
(tumor/whole body) was increased by 2.5 fold in the targeted system.  
Another recent study which utilized the Herceptin monoclonal antidoby (Trastuzumab) was 
completed by Choi et al. In this study, chitosan conjugated, pluronic-based nano-carriers loaded 
with iron oxide nanoparticles and doxorubicin were developed (Choi, Lee et al. 2015). The Cy5.5 
fluorophore was conjugated to the nanoparticle along with Herceptin monoclonal antibody. 
Cytotoxicity of the multifunctional nanoparticles was greater than DOX alone when tested on SK-
BR-3 cells likely due to the Herceptin antibody. Tumor bearing mice were established by 
subcutaneous inoculation of SK-BR-3 cells into the right rear flank. After injection of the targeted 
or non-targeted nanoparticle systems, the fluorescence intensity was monitored over time. 
Accumulation at the tumor site of the targeted multifunctional NPs increased up to 24 hours post 
injection and although the non-targeted system still accumulated at the tumor site, there was 
significantly greater fluorescence in the mice receiving the targeted system compared to the non-
targeted. Tumor growth suppression was monitored, and as expected, the targeted multifunctional 
nanoparticles (day 20: 885 mm3) showed a stronger tumor suppression than the non-targeted 
nanoparticles (day 20: 1314 mm3), DOX alone (day 20: 2873 mm3), or saline (day 20: 3340 mm3). 
Animal weight was monitored during the experiment to confirm the absence of additional toxicities 
due to the nanoparticle treatment.  
Another common target in breast cancer cells is MUC1. Shanehsazzadeh et al. developed 
dextran crosslinked iron oxide nanoparticles that were conjugated with C595 monoclonal antibody 
to target MUC1 (Shanehsazzadeh, Gruettner et al. 2015). Uptake of the targeted nanoparticles into 
MUC1 positive cells was more than 9 times higher than the uptake into MUC1 negative cells. In 
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vitro MRI signal enhancements in MDA MB 231 and MCF 7 were -75 and -70%, respectively, 
indicating that nanoparticle systems is uptake was sufficient to enhance contrast in MR imaging in 
both cell lines.  
The varying expressions of protein, ligands, and receptors on cancer cell surfaces are what 
allows for selective targeting of nanoparticles. Prostate specific membrane antigen (PSMA) is 
expressed at high levels in prostate cancer cells but minimally in healthy tissue, allowing for 
selective targeting. PSMA contains a unique sequence which mediates internalization and 
endosomal recycling, leading to high intracellular retention. The J591 antibody has high specificity 
for PSMA and was selected by Tse et al. for conjugation to iron oxide nanoparticles to enhance 
MRI contrast of preclinical prostate cancer (Tse, Cowin et al. 2015). Conjugation of J591 to the 
iron oxide nanoparticles did not affect its binding ability to PSMA but rather increased the iron 
concentration in cells positive for PSMA compared to cells lacking PSMA expression. In an in vivo 
study with orthotopic LNCaP-luc tumor bearing mice, intravenous injection of the J591-conjugated 
iron oxide nanoparticles led to significant reduction in MRI intensity compared to non-targeted 
nanoparticles. Prussian blue staining also indicated significant accumulation of iron within the 
tumor when the mice were treated with the targeted nanoparticles. 
Epidermal growth factor receptor (EGFR) is commonly expressed on gliobastoma (GBM) and 
is the target for the recombinant monoclonal antibody cetuximab. Cetuximab is a 152 kDa chimeric 
monoclonal antibody which binds to the extracellular domain of the human EGFR, and has been 
used to treat GBM. Kaluzova et al. conjugated cetuximab to amphiphilic triblock copolymer coated 
iron oxide nanoparticles in order to investigate the therapeutic targeting effect of the cetuximab-
iron oxide nanoparticles against EGFR and EGFRvIII expressing GBM stem-like cells, as these 
cells are responsible for tumor initiation, progression, and re-growth after chemoradiation 
(Kaluzova, Bouras et al. 2015). GBM neurospheres were utilized for testing the nanoparticle system 
as neurospheres are pathologically relevant models that maintain genomic changes of the primary 
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tumor, exhibit stem-like properties, and display the invasive characteristics of GBM. Cetuximab-
iron oxide nanoparticles significantly decreased cell survival in all neurospheres tested, especially 
after 72 hours of treatment. Cetuximab alone had a modest effect and due to non-specific uptake of 
free iron oxide nanoparticles, viability of N08-74 neurospheres was also compromised, but less 
effectively. Mice were implanted with GBM neurspheres and the mice which received the 
cetuximab-iron oxide nanoparticles lived significantly longer (164 days) compared to the control 
(146 days) or the cetuximab only (147 days) groups. In follow-up work, a similar cetuximab 
conjugated iron oxide nanoparticle system was used in combination with fractional radiotherapy to 
increase the radiosensitivity of glioblastoma in a rodent model (Bouras, Kaluzova et al. 2015). 
Primary in vitro work found that exposure of human GBM cells to cetuximab-iron oxide 
nanoparticles for 24 hours followed by fractionated radiation resulted in a significant decrease in 
GBM survival compared to control cells with radiation, cetuximab with radiation, or iron oxide 
nanoparticles with radiation.  Elevated levels of cleaved caspase 3 and apoptosis were found in the 
cetuximab-iron oxide nanoparticle and radiation combined treatment as well. In vivo studies were 
completed with athymic mice inoculated with GBM cells. Mice were treated with cetuximab-iron 
oxide nanoparticles, cetuximab or PBS followed by fractionated radiation and the median survival 
for the three groups was 60, 24, and 15 days, respectively, indicating that the tumor cells were 
sensitized to subsequent radiation treatment by the cetuximab-iron oxide nanoparticles.  
Another growth factor which is of particular interest for targeting cancer is the vascular 
endothelial growth factor (VEGF). Many tumor types have extensive areas of hypoxia and necrosis 
leading to up-regulation of angiogenesis which includes secretion of pro-angiogenic factors such 
as VEGF, making VEGF a promising target for tumor tissue. Abakumov et al. synthesized bovine 
serum albumin (BSA) coated iron oxide nanoparticles that were further functionalized with the 
monoclonal antibody against VEGF (mAb VEGF) (Abakumov, Nukolova et al. 2015).  In vitro 
targeting of the nanoparticles to their receptor was evaluated on C6 glioma cells expressing 
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membrane bound VEGF. The immunofluorescence assay suggested that the targeted nanoparticles 
bound to glioma C6 cells but negative control IgG conjugated nanoparticles did not. Confocal 
imaging showed that the nanoparticles were located within lysosomes following cell uptake. In vivo 
MRI was completed on rats bearing glioma C6 tumors but there was no difference between the MR 
image contrast in rats receiving IgG functionalized or mAb VEGF functionalized nanoparticles five 
minutes and two hours following IV injection. However, after 24 hours, there was significant 
contrast in the targeted group compared to the control indicating that the residence time of the 
nanoparticles at the tumor is increased by functionalizing with mAb VEGF.  
2.2.2 Aptamers 
Aptamers are single stranded oligonucleotides, DNA or RNA, with the ability to bind with high 
affinity and specificity to a broad range of targets such as peptides, proteins, drugs, organic and 
inorganic molecules, or even whole cells and viruses based on their specific binding pockets or the 
target molecule (Delaviz, Gill et al. 2015). Aptamer-based nanoparticle formulations have merits 
comparable to those of natural receptors such as antibodies and enzymes. Aptamers have the ability 
to be amplified by polymerase chain reaction, they are flexible yet fold into well-defined 3D 
structures upon binding to the target, and they can be easily modified or labeled with dyes or 
functional groups (Kim, Raston et al. 2016). Although aptamer technology is still in its infancy 
compared to that for antibodies, interest and applications continue to grow. While aptamers are 
used for nanoparticle targeting to specific tissues for imaging or theranostic applications, recent 
advances in aptamer targeting have focused on detection and separation of target molecules 
(Ilkhani, Sarparast et al. 2015, Zhang, Ma et al. 2015, Sun, Lu et al. 2016, Wang, Qian et al. 2016). 
The opportunity for magnetic separation of a target molecule is afforded by attaching aptamers to 
magnetic nanoparticles. For example, Delaviz et al. developed a method for selectively capturing 
hepatitis C virus (HCV) particles from human plasma samples using aptamer-conjugated magnetic 
nanoparticles (Delaviz, Gill et al. 2015). The aptamer used was specific for binding to E1E2 
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glycoprotein of HCV. In vitro results indicated that after exposure to the aptamer functionalized 
magnetic nanoparticles, the viral load in a solution was significantly reduced. At the highest 
concentration of aptamer-conjugated magnetic nanoparticles used, viral particle removal was more 
than 91%. A similar concept was utilized by Xi et al. who tethered selected aptamers against the 
hepatitis B surface antigen (HBsAg) to the surface of carboxylated magnetic nanoparticles (Xi, 
Huang et al. 2015). After binding of HBsAg to the nanoparticles, they were magnetically decanted 
and treated with a primary and secondary antibody system which catalyzed the chemiluminescence 
of AMPPD, allowing for quantification of the HBsAg concentration. The nanoparticle system 
resulted in a linear relationship between concentration of HBsAg and chemiluminescence intensity 
in the range of 0.1-200 ng/mL using aptamer H01. The detection limit of 0.1 ng/mL was below the 
detection limit of the ELISA assay used in the hospital and this technique is more time efficient 
than ELISA assays. 
Another unique detection method developed by Hu et al. utilized a simple optical aptasensor 
based on gold nanoparticles and magnetic beads for the detection of AGR2 proteins (Hu, Li et al. 
2015). The system is a sandwich-type, where the magnetic beads are functionalized with the anti-
AGR2 aptamer and the gold nanoparticles are functionalized with the partially complementary 
DNA probe of the aptamer. As the concentration of AGR2 increased in solution, the sandwich 
structure disassembled so the magnetic beads bound to the proteins and the gold nanoparticles 
remained in suspension. After separation of the magnetic beads containing the AGR2, the gold 
nanoparticles were detected by a spectrometer to determine the concentration. Analyses of spiked 
human serum samples for AGR2 protein concentration revealed a recovery range of 93.5-103.8%. 
An interesting proof of concept study was completed by Park et al. for the optical detection of 
Salmonella Typhimurium (Park, Jeong et al. 2015). Magnetic nanoparticles were functionalized 
with aptamers that specifically interact with outer membrane proteins on the surface of Salmonella 
Typhimurium. The surface reactivity of the magnetic nanoparticles is reduced via DNA-mediated 
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shielding of catalytic activity. In the presence of hydrogen peroxide, uncoated magnetic 
nanoparticles promote the oxidation of 3,3’,5,5’-tretramethylbenzidine (TMB) (a colorimetric 
substrate) by peroxidase-like activity. The blue-colored product can be detected by the naked eye. 
In the presence of Salmonella Typhimurium the aptamers detach from the nanoparticle surface and 
the nanoparticles can react with the hydrogen peroxide and TMB to generate a blue-colored 
substrate. However, this reaction is limited when the aptamers remain attached to the nanoparticle 
due to lack of Salmonella Typhimurium. This study showed a decrease in colorimetric absorbance 
of TMB following DNA (aptamer) attachment to the nanoparticles and then an increase in 
colorimetric absorbance when Salmonella Typhimurium was added, causing the aptamers to detach 
and expose the nanoparticles. 
As previously mentioned, aptamers have also been conjugated to magnetic nanoparticles for 
imaging and targeted drug delivery applications as they are cheaper than antibodies yet have similar 
binding affinities. Meng et al. developed a multifunctional nanoprobe for contrast enhanced 
bimodal cellular imaging and targeted therapy (Meng, Lu et al. 2015). This mesoporous silica 
nanoparticle based system was loaded with doxorubicin and chlorin e6 and coated with MnO2 sheets 
and aptamer sgc8 for targeting PTK7 expressing cells. In the binding and cell uptake studies, there 
was a significant increase in fluorescence of CEM (positive) cells compared to Ramos (negative) 
cells after treatment with the nanoprobe. A control aptamer sequence was also tested as a targeting 
modality and in both cell lines a weak signal was observed. A second recent study that utilized 
aptamer targeted nanoparticles for drug delivery was completed by Roy et al. The anticancer bio-
drug bovine lactoferin (bLf) was conjugated to iron oxide nanoparticles encapsulated with chitosan 
coated calcium phosphate (Roy, Kanwar et al. 2015). The nanoparticles were targeted with the 
locked nucleic acid (LNA) modified aptamer against the epithelial cell adhesion molecule 
(EpCAM) and nucleolin molecules. The nanoformulation was fed orally to mice injected with triple 
positive (EpCAM, CD133, CD44) sorted colon cancer stem cells in a xenograft cancer stem cell 
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mouse model. Complete regression of the tumor was observed in 70% of mice fed the non-targeted 
nanocomposites, with 30% of the mice showing recurrence after 30 days. Only 10% of the mice 
fed the targeted system showed tumor recurrence indicating a higher survival rate after treatment 
with the targeted nanoparticles.  
2.2.3 Peptides 
Peptides are short, single strand amino acid sequences that target receptors on cell surfaces or 
components of the extracellular matrix of tissues. Peptides can often rival the binding affinity of 
much larger molecules such as antibodies, but due to their smaller size, multiple peptides can be 
functionalized to the surface of a single nanoparticle resulting in nanoparticles that contain multiple 
binding sites. A variety of peptides have been synthesized for specific biological targets, and this 
section reviews the most recent advances in peptide conjugated magnetic nanoparticles. 
2.2.3.1 Targeting the extracellular matrix 
CREKA is a linear, five amino acid peptide, which was found to bind to fibrin(ogen) complexes 
within the extracellular matrix of tumors. Fibrin(ogen) is upregulated within the ECM of tumor 
tissue compared to healthy tissue, making it a potential target for nanoparticle accumulation. In 
2010, Agemy et al. developed a self-amplifying nanoparticle delivery system by conjugating 
CREKA to the surface of iron oxide nanoworms through a Michael addition reaction between the 
thiol on the cysteine in the peptide sequence and the maleimide on the functionalized nanoparticles 
(Agemy, Sugahara et al. 2010). CREKA nanoworms accumulated in the vessels of orthotopic 
22Rv1 human prostate cancer xenograft tumors and caused clotting in them, as evidenced by the 
presence of fibrin(ogen)-containing deposits in the vessel lumens. After methylation of the CREKA 
peptide to increase stability, a 70% reduction in blood flow to the tumor was observed as well as a 
strong reduction in tumor size and extended survival of the animals. Based upon this CREKA-
conjugated nanoworm system, Kruse et al. developed CREKA-conjugated iron oxide nanoparticles 
for magnetically mediated hyperthermia treatment of lung cancer (see Chapter 4) (Kruse, Meenach 
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et al. 2014). CREKA conjugated iron oxide nanoparticles bound to fibrin clots to a greater extent 
than non-functionalized nanoparticles and had sufficient heating capabilities to induce 
hyperthermia conditions upon exposure to an alternating magnetic field (AMF) (292 kHz, 56 
kA/m).  A combination proof of concept study was then completed to prove that magnetically 
mediated hyperthermia can increase the efficacy of a common chemotherapeutic, cisplatin, in A549 
lung carcinoma.  
The CREKA peptide has also been used to target fibrin(ogen) complexes in adhered blood 
clots, or thrombi. Song et al. developed a similar CREKA-conjugated iron oxide nanoparticle 
system, which was also conjugated with fluorescein, as a multimodal imaging agent of 
microthrombi (Song, Huang et al. 2014). The CREKA functionalized nanoparticles tested in vitro 
were shown to bind to fibrin clots to a greater extent than non-targeted nanoparticles. 
Microthrombus was induced in microcirculation of a rat model with acute myocardial ischemia 
reperfusion. CREKA-conjugated iron oxide nanoparticles were found to preferentially accumulate 
within microthrombi and generated a 1.95 fold greater fluorescence ratio as compared to the non-
targeted nanoparticles. CREKA-conjugated iron oxide nanoparticles also resulted in signal loss on 
MR T2 images in vivo whereas no significant change resulted after PBS or non-targeted 
nanoparticle treatment.  
2.2.3.2 Targeting cell surface ligands 
Other peptides have been developed to target specific cell surface ligands that are 
overexpressed on cancer cells but have low or no expression on healthy cells. Chlorotoxin (CTX) 
is a tumor targeting peptide that has been shown to preferentially bind to a variety of cancer cells 
such as prostate, intestinal, sarcomas, and glioblastoma by binding to metalloproteinase-2 (MMP2) 
on the cell surface. Previous work by the Zhang group with chlorotoxin for magnetic nanoparticle 
targeting for MRI (Sun, Du et al. 2010) and siRNA delivery (Veiseh, Kievit et al. 2010) led to the 
development of their multifunctional nanocomposite system (Stephen, Kievit et al. 2014). This 
 
19 
 
multifunctional nanocomposite was developed to deliver O6-benzylguanine (BG) glioblastoma 
multiforme (GBM). BG, an inhibitor of DNA repair by serving as a pseudo-substrate for DNA 
methyltransferase (MGMT), irreversibly inactivates the DNA repair protein. Therefore, when BG 
is combined with a DNA methylating agent, temozolomide (TMZ), resistance of GBM to TMZ is 
reduced. The nanocomposite was comprised of a redox responsive biopolymer shell of PEG and 
chitosan that was conjugated to chlorotoxin and loaded with BG and iron oxide nanoparticles. BG 
is known to induce bone marrow toxicity so while free BG and TMZ significantly reduce white 
blood cell counts and platelet levels indicating toxicity, the BG nanoparticle formulation with TMZ 
resulted in significantly reduced degree of WBC and platelet suppression. Animal survival 
increased from 4 days to 9 days when treated with TMZ combined with the BG nanoparticle 
formulation, compared to TMZ with the unloaded nanocomposite. The magnetic nanoparticles also 
allowed for MR T2 imaging contrast enhancement. Overall, this nanocomposite is promising for 
targeted combination treatment of GBM.  
A peptide recently used for conjugation to magnetic nanoparticles is bombesin (BBN) or its 
human counterpart gastrin releasing peptide (GRP). This peptide has been shown to play an 
important role in cancer growth as gastrin releasing peptide receptors are overexpressed in many 
cancers but have low expression levels in normal tissues. In this study, a bombesin analogue was 
conjugated to dextran coated iron oxide nanoparticles as a new targeting MRI contrast agent for 
breast cancer detection (Jafari, Salouti et al. 2015).  There was no significant decrease in cell 
viability of T47D cells after 24 hours of incubation with bombesin-conjugated iron oxide 
nanoparticles up to a concentration of 30 µg/mL. In addition, no difference in cell viability between 
bombesin targeted and non-targeted nanoparticles was obervered. T47D cell surfaces were highly 
labeled with bombesin-conjugated iron oxide nanoparticles due to specific binding of bombesin to 
the overexpressed GRP receptor on the surface. Non-targeted iron oxide nanoparticles were not 
assoicated with T47D cell surfaces and Bombesin-conjugated iron oxide nanoparticles did not bind 
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to 5637 cells, which do not express GRP. An in vivo proof of concept study for bombesin-
conjugated iron oxide nanoparticles for MR imaging contrast was also completed successfully. 
A more common biological target is the αvβ3 integrin, an adhesion integrin overexpressed on 
the surfaces of endothelial cells of neo-angiogenic vessels involved in the angiogenic process 
(Schleich, Po et al. 2014). Angiogenesis, or the process by which new blood vessels are formed, is 
the ultimate cause of tumor growth and metastasis. Therefore, researchers have continued to utilize 
the αvβ3 integrin as a target for enhanced nanoparticle delivery. The arginine-glycine-aspartic acid 
(RGD) peptide has been shown to preferentially bind to the αvβ3 integrin and has therefore been 
functionalized to a variety of magnetic nanoparticles to improve accumulation at the tumor site and 
enhance MR imaging or drug delivery.  
Several recent studies have shown RGD-functionalized magnetic nanoparticles to enhance the 
negative contrast of T2 MR imaging (Zhang, Jugold et al. 2007, Kumar, Yigit et al. 2010, Xie, Chen 
et al. 2010, Xie, Liu et al. 2011, Yang, Zhuang et al. 2011, Chen, Tao et al. 2012, Jarzyna, Deddens 
et al. 2012, Lin, Dayananda et al. 2012, Rosen, Chan et al. 2012, Zhao, Huang et al. 2012, 
Menichetti, Manzoni et al. 2013, Passemard, Staedler et al. 2013). For example, Melemenidis et al. 
utilized a cyclic variant of RGD (cRGD) conjugated to iron oxide nanoparticles and analyzed 
binding to the αvβ3 integrin. HUVECs were stimulated with S-nitroso-N-acetylpenicillamine 
(SNAP) to upregulate the αvβ3 integrin, and binding of the cRGD-targeted nanoparticles increased 
by 14-fold compared to binding in non-stimulated cells (Melemenidis, Jefferson et al. 2015). 
Additionally, under nanoparticle exposure via flow conditions of 1 dyne/cm2, SNAP stimulated 
HUVECs retained cRGD-targeted nanoparticles 44 times more than non-stimulated cells. 
Intravenous (IV) administration of cRGD iron oxide nanoparticles to mice bearing melanoma or 
colorectal subcutaneous tumors resulted in enhanced negative contrast within the tumor on T2 
weighted images compared to pre-contrast images.  
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Other groups have worked to develop RGD-targeted dual-modality imaging probes. Wang et 
al. also used a cyclic form of RGD conjugated to liposomes encapsulating 2,3-dimercaptosuccinnic 
acid (DMSA) coated iron oxide nanoparticles and CdSe quantum dots into the interior vesicle and 
phospholipid bilayer, respectively (Wang, Li et al. 2015). The average fluorescence of RM-1 cells 
after exposure to targeted liposomes was about 2.5 times stronger than after exposure to non-
targeted liposomes due to interaction of cRGD with the avB3 integrins on the cell surface. An in 
vivo bone metastasis model of prostate cancer was used to examine MR imaging capabilities. Four 
hours after administration of the targeted liposomes there was a relative signal decrease in T2 
indicating accumulation of the magnetic-fluorescent liposomes. Deng et al. developed dual 
modality RGD-targeted magnetic nanoparticles radiolabeled with 125I for SPECT and MR 
imaging (Deng, Zhang et al. 2015). Twenty-four hours post nanoparticle injection, the Bcap37 
tumor-to-contralateral site ratio was 10.61 in SPECT imaging, and a significant signal reduction in 
MR imaging was observed. Xue et al. also combined SPECT and MR imaging modalities into a 
single RGD-targeted nanoparticle system using 99mTc radiolabeling and ultra-small iron oxide 
nanoparticles for MRI contrast. Using free RGD as a competitive binding agent the authors proved 
that accumulation of the nanoparticles at the tumor site was due to RGD binding to the avB3 
integrins, since a decrease in both SPECT and MRI contrast was observed under the competitive 
conditions. 
RGD-targeted magnetic nanoparticles are commonly used for negative contrast enhancement 
in T2 MR imaging. However, recent studies have developed targeted magnetic nanoparticles for T1 
MRI contrast (Luo, Yang et al. 2015) or both T1 and T2 contrast (Xue, Zhang et al. 2015). Luo et 
al. developed RGD-targeted ultra-small iron oxide nanoparticles (<5 nm) for T1 MRI contrast since 
the magnetic moment of the nanoparticles sharply decreases as their size decreases due to reduction 
of their volume magnetic anisotropy and spin disorders on the surface (Luo, Yang et al. 2015). A 
xenografted U87MG tumor model was used to show T1 enhancement via the targeted, ultra-small 
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nanoparticle system. Both targeted and non-targeted nanoparticles increased the signal to noise 
ratio of T1 MR images but the effect over three hours was significantly greater for the RGD targeted 
nanoparticles. 
RGD conjugation to magnetic nanoparticles also provides the opportunity for dual targeting 
for drug delivery: magnetic and active targeting. Lin et al. recently developed RGD-functionalized 
poly[(N-isopropylacrylamide-r-acrylamine)-b-L-lactic acid] (PNAL) coated iron oxide 
nanoparticles loaded with paclitaxel for the treatment of HeLa cells (Lin, Kang et al. 2015). In vitro 
studies confirmed the cytotoxicity enhancement of the nanoparticle system in the presence of a 
magnetic field, which was further enhanced by functionalization with RGD.  In vivo studies 
completed by Schleich et al. with paclitaxel and iron oxide nanoparticle-loaded PEGylated PLGA 
nanoparticles showed that by combining RGD-functionalization to the nanoparticle surface with 
magnetic targeting, survival of CT26 tumor bearing mice was significantly increased to 21.5 days 
from 14.7 or 15 days for active or magnetic targeting, respectively (Schleich, Po et al. 2014). 
Additionally, tumor growth was significantly reduced when the combination targeting modalities 
were compared to either alone.  
A variety of other peptides have been used as specific biological targets but they are not as 
common as some of the previously discussed peptides. The EPPT (Glu-Pro-Pro-Thr) peptide, 
which targets under-glycosilated MUC-1 tumor antigen found on more than 90% of breast cancers, 
has not been used since 2010 for magnetic nanoparticle delivery (Medarova, Rashkovetsky et al. 
2009, Kumar, Medarova et al. 2010). A different magnetic nanoparticle system developed by 
Sungsuwan et al. induced the production of MUC-1 specific antibodies that recognized MUC-1-
positive tumor cells, killing them through complement-mediated cytotoxicity. Rather than being 
functionalized with EPPT as in the previous example, the magnetic nanoparticles were 
functionalized with amphiphilic lipo(glycol)peptides leading to antigen presentation to the immune 
system. Another tumor targeting peptide is WSG (Try-Ser-Gly), which was used to coat iron oxide 
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nanoparticles without the aid of another coating material. The WSG coated nanoparticles more 
easily assembled into cancers compared to non-targeted nanoparticles, indicating the tumor 
targeting properties of WSG (Wei, Yin et al. 2013).  
2.2.3.3 Cell penetrating peptides 
Another peptide category that has been of particular interest recently is that of cell penetrating 
peptides (CPPs). Also known as membrane translocation sequences, Trojan peptides, or protein 
transduction domains, these small, cationic and/or amphipathic peptides have the ability to enter 
cells and mediate uptake of a wide range of macromolecular cargoes (Farkhani, Valizadeh et al. 
2014). The cellular uptake mechanism depends upon the attached cargo as CPPs attached to small 
cargoes can enter the cell via direct translocation whereas large molecules attached to CPPs tend to 
be up taken via micropinocytosis in an energy dependent manner (Ma, Shi et al. 2011). A few 
recent reviews give additional details on the uptake mechanisms of CPPs and their conjugation to 
a wide array of nanoparticle systems (Chou, Ming et al. 2011, Cleal, He et al. 2013, Farkhani, 
Valizadeh et al. 2014, Amin, Joo et al. 2015, Jafari, Dizaj et al. 2015). Thus, this section will focus 
on very recent advances in CPP conjugation to magnetic nanoparticles.  
The first CPP to be discovered was the HIV-1 encoded TAT peptide which mediates interaction 
with anionic motifs on the cell surface in a non-receptor mediated manner (Bolhassani 2011, Koren 
and Torchilin 2012). The TAT peptide carries both a transmembrane and nuclear localizing signal 
within its sequence, making it an even more attractive targeting modality for nuclear delivery. In a 
study by Wang et al., the TAT peptide and FITC fluorophore were functionalized to PEG600-b-
PGA, which was then self-assembled with iron oxide nanoparticles (Wang, Qiao et al. 2012). The 
TAT functionalized nanoparticles quickly entered Caco-2 cells, and the fluorescence following 4 
hours of incubation was much greater in cells exposed to the targeted nanoparticles compared to 
non-targeted nanoparticles. The targeted magnetic nanoparticles were found to internalize into the 
cells and penetrate the nuclear membrane while the non-targeted control nanoparticles were located 
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at the cell membrane. Another study by Nair et al. focused on the intracellular location and 
trafficking of TAT-conjugated iron oxide nanoparticles using 3D electron tomography (Nair, 
Fukuda et al. 2012). TAT-conjugated PEG coated iron oxide nanoparticles were exposed to human 
glioblastoma, and it was shown that some of the nanoparticles had accumulated in a vacuole then 
moved out into the cytoplasm. In unpublished work by Hauser et al., TAT-conjugated dextran 
coated iron oxide nanoparticles were developed to enhance radiation therapy in A549 lung 
carcinoma (see Chapter 7). Radiation treatment increases mitochondrial formation of hydrogen 
peroxide. The presence of excess iron ions catalyzes the formation of highly reactive hydroxyl 
radicals. Therefore, the more intracellular iron oxide present, the greater the damage by the 
hydroxyl radical.  TAT peptide functionalization to iron oxide nanoparticles increased the 
intracellular iron concentration and increased reactive oxygen species (ROS) formation in the 
presence of radiation compared to radiation alone. The TAT-conjugated nanoparticles were found 
to destabilize lysosomal membranes and interact with the mitochondria, sensitizing the cells to 
radiation treatment. In subsequent work by Hauser et al. the TAT-conjugated dextran coated 
nanoparticles were utilized for magnetically mediated energy delivery (MagMED) (see Chapter 6). 
The nanoparticles were internalized by A549 or H358 lung cancer cells and induced celluar damage 
upon exposure to an AMF. An increase in ROS generation was observed upon exposure to an AMF, 
and a slight increase in cell apoptosis was observed. Although the iron oxide nanoparticles were 
too large to permeate the nuclear membrane, the TAT peptide promoted lysosomal destabilization 
and escape of the nanoparticles into the cytosol, allowing for enhanced effects of the nanoparticles. 
The TAT peptide has also been shown to be toxic due to destabilization of organelle membranes. 
Cavalli et al. conjugated a γ-amino-proline derived peptide to dextran coated iron oxide 
nanoparticles and compared their toxicity with TAT-functionalized nanoparticles (Cavalli, Carbajo 
et al. 2012). While the γ-amino-proline derived peptide conjugated iron oxide nanoparticles 
exhibited lower internalization than the TAT peptide, they were determined to be less toxic and 
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stable towards protease degradation. These nanoparticles were also able to reduce T2 intensity 
without showing HeLa cell cytotoxicity.  
Another magnetic nanoparticle system that utilizes CPPs was developed by Chen et al. They 
utilized a peptide and a polymer to enhance nanoparticle penetration of the blood-brain barrier 
(BBB). PF127, a pluronic polymer that enhances BBB penetration via inhibiting the P-glycoprotein 
efflux pump, and angiopep-2 (ANG), a peptide with high capability for BBB penetration via 
receptor mediated endocytosis, were both conjugated to polyacrylic acid coated iron oxide 
nanoparticles (Chen, Su et al. 2014). The effects of PF127 and ANG were analyzed separately and 
both were found to enhance intracellular concentrations of iron oxide in U87 cells. The combined 
targeting system was analyzed in an ex vivo BBB model and found to increase the amount 
permeated from 4.9 µg/mL for PF127 targeted only to 7.6 µg/mL. The dual targeted nanoparticles 
also had increased transversal relaxation rates (167.54/mM/second) compared to conventional iron 
oxide nanoparticle products.  
2.2.4 Small Molecules 
Small molecules, such as glucose and folic acid, have also gained interest as targeting agents 
of magnetic nanoparticles due to the ability to functionalize the nanoparticle surface with an 
increased number of targeting groups with limited steric constraints (McCarthy and Weissleder 
2008). The more targeting ligands, the more likely there will be a multivalent effect between the 
particle and its target.  
Glucose functionalization to magnetic nanoparticles was recently investigated for targeting 
colon cancer metastasis in the liver due to increased metabolic activity of cancer cells requiring 
excess glucose, leading to a targeting method for glucose functionalized magnetic nanoparticles. 
Wydra et al. functionalized glucose to the surface of citric acid stabilized iron oxide nanoparticles 
via amine-carboxyl coupling of d-glucosamine and citric acid (Wydra, Rychahou et al. 2015). 
Glucose functionalization to the nanoparticle surface increased internalization by CT26 cells 
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compared to citric acid coated or uncoated nanoparticles. Cells with internalized magnetic 
nanoparticles were exposed to an AMF for 30 minutes and the generation of reactive oxygen 
species was analyzed. Although there was a slight increase in ROS generation due to the presence 
of uncoated and glucose coated iron oxide nanoparticles, only the citric acid coated iron oxide 
nanoparticles resulted in significant ROS generation. All the nanoparticle systems combined with 
AMF exposure significantly increased apoptosis in CT26 cells compared to no AMF exposure 
when the percent apoptosis was measured 24 hours post treatment. Therefore, it appears as though 
the increase in ROS generation after exposure of CT26 cells containing internalized magnetic 
nanoparticles to an AMF can trigger apoptotic pathways and result in increased apoptosis compared 
to IONP exposure alone. 
Glucose functionalization of the surface of magnetic nanoparticles to target cancer cells due to 
their enhanced metabolic activity has been studied by other groups as well (Xiong, Zhu et al. 2012, 
Herea, Chiriac et al. 2015).  Maharramov et al. coated iron oxide nanoparticles with 2-deoxy-D-
glucose, which is a glucose analogue in which the hydroxyl group bound to the second carbon is 
replaced by a hydrogen atom (Maharramov, Ramazanov et al. 2014). The goal of using the glucose 
analogue was to target the nanoparticles to the cancer cells due to metabolic needs, but block the 
glycolytic pathway. A proof of concept study on the growth inhibitory effects of 2-deoxy-D-
glucose functionalized magnetic nanoparticles was completed on HCT116, HT29, and RKO 
colorectal cells. Although 2-deoxy-D-glucose was more toxic alone, the nanoparticle formulations 
significantly reduced the viability compared to control cells. Future use for the nanoparticle system 
would include MR imaging. 
Other groups have developed glucose functionalized magnetic nanoparticles for cancer cell 
targeting via the glucose transporter protein (Shan, Hu et al. 2012, Barbaro, Di Bari et al. 2015). 
Barbaro et al. developed a small D-glucose coated iron oxide nanoparticle using metal vapor 
synthesis to target pancreatic cancer cells that express glucose transporter (GLUT-1) in the cell 
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membrane (Barbaro, Di Bari et al. 2015). Glucose coated iron oxide nanoparticles were taken up 
at greater concentrations into BxPC3 cells expressing GLUT-1 compared to polyvinylpyrrolidone 
(PVP) iron oxide nanoparticles. Additionally, pre-treatment with antiGLUT1 reduced cellular 
accumulation of glucose functionalized nanoparticles by 41% but did not affect PVP functionalized 
nanoparticles. 
Folic acid is another small molecule that is of particular interest for tumor targeting of magnetic 
nanoparticles due to its high binding affinity to the folate receptor (FR), low cost, ease of 
conjugation, compatibility with both organic and aqueous solvents, and a lack of immunogenicity 
(Low, Henne et al. 2008). The FR is overexpressed on the surface of several cancers including 
breast, kidney, lung, brain and ovary (Parker, Turk et al. 2005) and due to the limited expression 
of FR on normal tissues, folate may be an appropriate choice for targeting tumor cells in NP based 
cancer therapies. Folate can bind to FR and facilitate the transfer of folate-targeted nanoparticles 
through receptor mediated endocytosis. Folic acid is an essential nutrient needed by all cells for 
biosynthesis of nucleotides and the normal action of some metabolic pathways that mediate uptake 
via a non-destructive endosomal pathway (Parker, Turk et al. 2005, Murthy 2007, Mansoori, 
Brandenburg et al. 2010).   
Bahrami et al. in 2015 reviewed folate conjugated nanoparticles as a therapeutic approach for 
cancer therapy with a section devoted to magnetic nanoparticles (Bahrami, Mohammadnia-Afrouzi 
et al. 2015). For additional information or studies prior to 2015, readers are directed to this review. 
Therefore, this section will summarize recent advances in folate-conjugated magnetic 
nanoparticles. Several investigations have developed strategies to conjugate folate derivatives to 
magnetic nanoparticles and characterize their physicochemical properties (Dolores, Raquel et al. 
2015, Karamipour, Sadjadi et al. 2015, Socaci, Magerusan et al. 2015) while others have proven 
the targeting ability and receptor-mediated endocytosis associated with folate functionalized 
nanoparticles (Li, Yang et al. 2015, Razjouyan, Zolata et al. 2015). FR targeted core-shell magnetic 
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nanoparticles have been of particular interest for thermal therapy (Sadhasivam, Savitha et al. 2015), 
drug delivery (Li, Dong et al. 2015, Tudisco, Cambria et al. 2015) and imaging (Chen, Zheng et al. 
2015, Ma, Liu et al. 2015, Yin, Hong et al. 2015) of cancer. Carbon encapsulated iron oxide 
nanoparticles were surface engineered with PEG-folic acid by Sadhasivam et al. to induce selective 
hyperthermia in FR overexpressed cancer cells (Sadhasivam, Savitha et al. 2015). The nanoparticle 
system was non-toxic to human fibroblasts (low FR expression) both with and without AMF 
exposure as determined by the LDH assay. However, in HeLa cells (high FR expression), 
significant cytotoxicity was induced upon treatment with the targeted nanoparticles and AMF 
compared to the targeted nanoparticles alone. This is a result of enhanced uptake by the HeLa cells 
as non-targeted nanoparticles resulted in a relative iron uptake of 0.105 mg/mL while the targeted 
nanoparticles resulted in a relative iron uptake of 0.316 mg/mL.  
Li et al. encapsulated iron oxide nanoparticles and sorafenib (SRF) into folate-conjugated 
PLGA nanoparticles (Li, Dong et al. 2015). Cell uptake potential of SFR, non-targeted magnetic 
nanoparticles and targeted magnetic nanoparticles were investigated in FR over-expressing 
BEL7402 hepatocellular carcinoma. Uptake was time dependent in all systems, but significantly 
greater for targeted nanoparticles. The 24 hour IC50 values in BEL7402 cells for SRF, non-targeted 
magnetic nanoparticles and targeted magnetic nanoparticles were 2.35 µg/mL, 2.48 µg/mL, and 
0.84 µg/mL respectively, suggesting that folic acid-targeted nanoparticles were more effective at 
inducing cell toxicity.  
Another application of folic acid targeted nanoparticles to enhance the intracellular transport 
of N-methylated drugs was evaluated by Tudisco et al. (Tudisco, Cambria et al. 2015). PEG, folic 
acid, and carboxy-X-rhodamine were conjugated to magnetic nanoparticles along with 
tetraphosphonate cavitand (Tiiii) that has molecular recognition properties towards N-methylated 
guests. The most significant finding of this study was that the nanoparticles were able to facilitate 
intracellular transport of PCZ, an N-methylated molecule, when PCZ and the nanoparticles were 
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introduced to LoVo cells simultaneously. The decrease in cell viability following dual, 
simultaneous treatment compared to PCZ alone indicated that the nanoparticles interact with PCZ, 
and are then internalized via folate receptors. 
As previously mentioned, folate receptor targeted magnetic nanoparticles are often used as 
MRI contrast agents. Ma et al. developed magnetic-lanthanide-doped fluoride nanoparticles which 
were targeted with folic acid to be used as bimodal probes for cellular fluorescence and magnetic 
resonance imaging of HeLa cells overexpressing FR (Ma, Liu et al. 2015). In vitro fluorescence 
imaging after exposure to targeted and non-targeted nanoparticles was evaluated using HeLa cells 
overexpressing FR. HeLa cells treated with folic acid-conjugated nanoparticles displayed a strong 
green fluorescence. In contrast, HeLa cells treated with non-targeted nanoparticles and MCF-7 cells 
(lower FR expression) treated with targeted nanoparticles had a weak fluorescence signal. The 
targeted nanoparticles were also used to increase T2 contrast in HeLa cells in vitro. Yin et al. were 
also interested in magnetic nanoparticles for dual imaging modalities (Yin, Hong et al. 2015). 
Amphiphiles were embedded with oligo(p-phenyleneethynylene) (OPE) via covalent linkages and 
this OPE based structure was further functionalized with folic acid to serve as the targeting ligand. 
These amphiphilic OPE molecules were used to encapsulate fluorescent magnetic nanoparticles so 
the final magnetic nanoparticles could be used for fluorescence and magnetic resonance imaging. 
HeLa cells were incubated with the targeted and non-targeted nanoparticle formulations at different 
concentrations (with and without folic acid) for three hours. A decrease in MRI signal intensity was 
observed as nanoparticle concentration increased.  However, cells incubated with the targeted 
nanoparticles exhibited a greater signal decrease than those incubated with non-targeted 
nanoparticles at concentrations greater than 0.042 mg/mL. The dual imaging capability of this 
nanoparticle system was analyzed in vivo as well. Tumor bearing mice were injected with the 
targeted or non-targeted nanoparticle system. MR imaging four hours after injection indicated a T2 
signal reduction within the tumor compared to pre-injection images for both nanoparticle systems. 
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However, the signal reduction was greater in the targeted nanoparticle groups due to increased 
intra-tumor iron concentration as confirmed by Prussian blue staining. Two-photon optical imaging 
of tumor biopsies showed similar results to the MRI analyses. Tumor slices excised from mice 
treated with targeted nanoparticles showed intense fluorescence with high resolution and 
sensitivity. However, weak fluorescence was observed in tumors of mice that received the non-
targeted nanoparticle formulation.  
While the majority of FR targeted nanoparticles are used for cancer therapy or imaging 
applications, Dai et al. coated superparamagnetic iron oxide nanoparticles with glucose and dextran 
then functionalized the nanoparticles with folic acid due to its specific binding to the recruited and 
activated macrophages of synovium in rheumatoid arthritis (RA) that overexpress folic acid 
receptors. RA was induced in rat paws using Freund’s complete adjuvant injection, and 14 days 
after the injection, degeneration or necrosis in the epithelium as well as infiltration of inflammatory 
cells were observed. Functionalized nanoparticles were injected and the rat ankles were imaged via 
MRI 24 hours later. The folic acid functionalized nanoparticles resulted in significant negative 
contrast enhancement while non-targeted nanoparticles only marginally reduced the signal 
intensity. Another non-cancer application of folate receptor targeted magnetic nanoparticles was 
investigated by Li et al. who developed a small magnetite antiretroviral therapy (SMART) 
nanoparticle platform to assess antiretroviral drug tissue biodistribution and PK using MRI scans 
(Li, Gendelman et al. 2015). Alendronate (ALN), a bisphosphate drug that is clinically used to treat 
osteoporosis, was conjugated to polymers for stable magnetite coating. Folic acid was then 
conjugated to the polymers that were attached to the exterior of magnetite. The nanoparticles were 
detected by MRI and rapid uptake by mononuclear phagocytes (MP) provided a noninvasive 
method of detecting regions of disease-associated infection including virus induced inflammation. 
This platform provided a means to rapidly evaluate the efficiency of targeting strategies for HIV 
reservoirs.  
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  Additionally, a variety of studies have utilized folate-conjugated micelles (Li, Yan et al. 2015) 
or liposomes loaded with magnetic nanoparticles for drug delivery and MR imaging contrast. For 
example, Du et al. synthesized thermosensitive liposomes functionalized with PEG2000 and folic 
acid containing C60-Fe3O4 nanocomposites and docetaxel (Du, Han et al. 2015). This 
multifunctional liposome formulation allowed for combined magnetic and folate receptor targeting 
as well as controlled docetaxel release and thermal ablation via the magnetic nanoparticles in the 
presence of RF. In vitro studies indicated that these multifunctional liposomes resulted in higher 
inhibition efficiency of MCF-7 (FR positive) cells than docetaxel alone suggesting that the delivery 
system was able to deliver more drug into the cells. Cellular uptake was analyzed by adding FITC 
to the multifunctional liposomes, and the uptake of the magnetic liposomes was greater than the 
nanoparticles with docetaxel having no folate targeting or liposome structure. Upon radio frequency 
exposure, the C60 component of the liposome generated heat, destabilizing the liposome structure 
and releasing docetaxel. In vivo studies indicated that dual targeting (FR and magnetic) and RF 
exposure significantly reduced tumor growth compared to control groups. 
2.3 Conclusions and Future Perspectives  
Active targeting of magnetic nanoparticles has significantly improved nanoparticle specificity 
and accumulation compared to passive targeting and utilization of the enhanced permeation and 
retention effect. Conjugation of ligands to the surface of magnetic nanoparticles has afforded the 
opportunity to target specific entities within a tissue, whether it be a component of the extracellular 
matrix, cell surface receptors, or organelles. Active targeting of magnetic nanoparticles has been 
repeatedly shown to improve nanoparticle uptake into tissues and cells, making magnetically 
mediated hyperthermia more effective and increasing MRI contrast.  As discussed in this review, a 
variety of targeting ligands can be conjugated to the surface of magnetic nanoparticles. Antibodies, 
aptamers, peptides, and small molecules have all proven to be effective targeting agents for 
magnetic nanoparticles, but choosing the appropriate targeting ligand is dependent upon the target 
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and application of the nanoparticle system. Although antibodies are very specific targeting 
moieties, they are expensive. Aptamers have increased in popularity as an alternative to antibodies 
in that the specificity is retained, and their synthesis is less expensive than antibody production. 
Peptides can be synthesized for a variety of targets with binding specificity rivaling that of larger 
molecules such as antibodies. They are relatively inexpensive to synthesize and, due to their smaller 
size, nanoparticles can be functionalized with multiple peptides per particle to increase the binding 
opportunities. Small molecules have also gained interest as targeting agents as their size allows for 
multiple molecules per particle and lower steric constraints than other targeting ligands.  
Although significant improvements in active targeting of magnetic nanoparticles both in vitro 
and in vivo have been realized, there are still shortcomings that should be addressed in order to 
continue to advance. First, in attempt to translate targeted nanoparticle systems into the clinic and 
receive FDA approval, a single nanoparticle formulation with the ability to be functionalized with 
a variety of targeting ligands should be established. This would allow for a versatile system that 
could be easily altered for different targets and applications. Secondly, subcellular targeting is a 
relatively new focus in magnetic nanoparticle targeting but poses interesting opportunities. 
Lysosome sequestration is the normal fate of magnetic nanoparticles taken up by cells through 
endocytosis leading to degradation and low therapeutic effect. However, if the nanoparticles are 
appropriately functionalized to target subcellular organelles, their potential for therapeutic efficacy 
is drastically increased. Finally, in vivo testing of targeted magnetic nanoparticles should be scaled 
to larger animals in order to improve understanding and translation of the targeted nanoparticles to 
humans.  
 
 
 
 
 
Copyright © Anastasia Kruse Hauser 2016 
 
33 
 
Chapter 3 Magnetic nanoparticles and nanocomposites for remote controlled therapies 
The chapter is taken directly or adapted from work published in Hauser, Wydra, et al. (2015) 
Copyright 2015 Elsevier B.V. Used with permissions from Anastasia K. Hauser, Robert J. Wydra, 
Nathanael A. Stocke, Kimberly W. Anderson and J. Zach Hilt, “Magnetic nanoparticles and 
nanocomposites for remote controlled therapies”, Journal of Controlled Release and Elsevier B.V. 
3.1 Introduction 
Magnetic nanoparticles (MNPs) have been extensively studied for a variety of biological 
applications such as FDA-approved MRI contrast agents (Reimer and Balzer 2003), FDA-approved 
iron deficiency treatment (Auerbach 2008), thermal therapy, and drug delivery. MNPs are often 
coated with or embedded in a polymer or organic matrix in order to: increase colloid stability and 
extend circulation time in biological environments, provide a means for functionalization with 
targeting agents or fluorescent markers, or afford the opportunity for drug loading and conjugation 
(Berry and Curtis 2003, Gupta and Gupta 2005, Duguet, Vasseur et al. 2006, Berry 2009, Shubayev, 
Pisanic et al. 2009, Frimpong and Hilt 2010, Amstad, Textor et al. 2011, Ho, Sun et al. 2011).  
MNPs are able to convert energy from an alternating magnetic field (AMF) to heat primarily 
through Neel and Brownian relaxations, with Neel relaxation being the internal dipole rotation and 
Brownian referring to the physical rotation of the nanoparticle. The heat generated by the MNPs in 
the presence of an AMF can be utilized for a variety of therapies, including controlled release of a 
drug, local thermal therapy, magnetically mediated energy delivery (MagMED), and combinational 
treatments.  Additionally, MNPs respond to static magnetic field gradients and low frequency 
AMFs where the heating effect is negligible or non-existent, allowing for other controlled drug 
delivery strategies, including external guiding/targeting of magnetic nanoparticles and mechanical 
deformations/disruptions for triggered release. 
The unique capability of MNPs and their composites to be remotely controlled has been utilized 
for various applications (Brazel 2009, Liu, Hu et al. 2009, Satarkar, Biswal et al. 2010, Kumar and 
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Mohammad 2011, Bonini, Berti et al. 2013, Li, Huang et al. 2013, Thevenot, Oliveira et al. 2013, 
Jhaveri, Deshpande et al. 2014, Ridi, Bonini et al. 2014, Schleich, Danhier et al. 2015).  When 
applied in drug delivery, the remote control of the MNPs enables for controlled drug delivery 
(temporal and/or spatial). For temporal control, the remote actuation is often based on the AMF 
heating of MNPs to cause a temperature-responsive change in the delivery system release 
properties.  In other cases of temporal control, the remote actuation is based on static or low 
frequency magnetic fields where the mechanical forces induced by the magnetic field result in 
modulation of the release behavior.  For spatial control, the applied magnetic field can remotely 
control the accumulation of a delivery system within the body.  In many cases, enhanced therapeutic 
delivery and associated outcomes have been reported as a result of the remote control over the 
temporal and/or spatial release of a drug. 
Magnetically mediated hyperthermia (MMH) treatment, also referred to as magnetic fluid 
hyperthermia (MFH), is another important application of MNPs.  MMH is the heating of tissue to 
hyperthermia temperatures of approximately 41-45°C by activation of the MNPs in the presence of 
an AMF. This inherently localized heating therapy has been studied extensively for cancer therapy 
both in isolation or combination with a conventional cancer therapy such as chemotherapy or 
radiation (Pankhurst, Connolly et al. 2003, Tartaj, Morales et al. 2003, Mornet, Vasseur et al. 2004, 
Goya, Grazu et al. 2008, Corchero and Villaverde 2009, Pankhurst, Thanh et al. 2009, Kumar and 
Mohammad 2011).  Localized thermal therapy via MMH has been shown to be more effective than 
other forms of hyperthermia delivery. 
MMH has also been shown to enhance the efficacy of traditional cancer therapies such as 
chemotherapy, radiation, surgical resection, and gene therapy. A variety of chemotherapeutics are 
more effective when administered in the hyperthermia range due to increased rate constants of 
alkylation, increased drug uptake, and inhibition of repair of drug-induced lethal or sub-lethal 
damage (Issels 2008). Chemotherapeutics have also been chemically or physically bound to 
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magnetic nanoparticles for controlled drug release upon exposure to an external stimuli such as an 
AMF or change in pH, and upon further exposure to AMF, simultaneous thermal therapy can be 
administered (Gautier, Allard-Vannier et al. , Jhaveri, Deshpande et al. 2014, Rejinold, Jayakumar 
et al. 2015). Additionally, hyperthermia has been shown to increase blood supply to the tumor, 
which increases local oxygen levels.  Since the efficacy of radiation therapy is tied to the formation 
of free radicals more than direct DNA damage, MMH can enhance the effectiveness of radiation 
by increasing free radical formation. Overall, thermal therapy via MNPs is a promising treatment 
method when combined with traditional therapies due to localized tumor heating and sensitization 
of the tumor tissue to additional modalities.  
One of the major translational hurdles of MMH is that a large concentration of nanoparticles is 
required to achieve the necessary increase in temperature in vitro and especially in vivo, and this 
limitation, to date, has limited the application of MMH to direct injection into solid tumors for in 
vivo application (Johannsen, Jordan et al. 2004, Jordan, Scholz et al. 2006).  Therefore, researchers 
have recently focused more on MagMED for nanoscale energy therapy (Kozissnik, Bohorquez et 
al. 2013). This form of therapy utilizing AMF-activated MNPs relies on intracellular effects of 
MNPs and results in a therapeutic effect without a measurable temperature rise, with the exact 
mechanism of toxicity still under investigation. Intracellular concentrations of MNPs can be 
increased by cellular targeting with ligands and antibodies, which has been shown to further 
enhance the effectiveness of MagMED as a treatment modality (Berry and Curtis 2003, Gupta and 
Gupta 2005, Shubayev, Pisanic et al. 2009, Creixell, Bohorquez et al. 2011, Kievit, Stephen et al. 
2012).  Therapeutic approaches based on MagMED have led many researchers to focus on 
determining intracellular targets and understanding intracellular mechanisms. 
This chapter summarizes recent advances in applications of MNPs and magnetic 
nanocomposites for remote controlled thermal therapy, nano-scale energy delivery, and 
combinational therapy (Figure 3.1).    
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Figure 3.1 This section highlights the uses of MNPs for controlled release therapies. A) Thermal 
therapy can be remotely controlled for i) local applications or ii) nanoscale heating applications. B) 
Thermal therapy is often administered in combination with a secondary treatment such as i) a 
therapeutic or ii) radiation.  
3.2 Remote controlled energy release 
3.2.1 Thermal therapy  
Magnetic nanoparticles have been extensively studied for thermal therapy applications due to 
their ability to convert energy from an AMF into thermal energy. This controlled release of thermal 
energy from MNPs can be used for hyperthermia treatment, which is defined as the heating of tissue 
to 41-45°C (Hildebrandt, Wust et al. 2002) and has been shown to be an effective treatment of 
various types of cancer.  Some have suggested that the efficacy of hyperthermia is likely due to 
tumor tissue being more susceptible to heat insults than healthy tissue (Jordan, Scholz et al. 1999, 
Moroz, Jones et al. 2002).  Magnetically mediated hyperthermia (MMH), which is also known as 
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magnetic fluid hyperthermia (MFH), is where MNPs or larger magnetic particles are localized 
within the tumor environment and then exposed to an AMF, resulting in heat generation. For cancer 
therapy, MMH has several advantages over other delivery routes of thermal therapy in that it is 
localized to only the tumor tissue through selectively targeting (e.g., active or passive targeting, 
direct injection, etc.) and provides even temperature distribution throughout the tumor tissue. By 
comparison, regional and whole body hyperthermia are used to heat larger regions such as a limb 
or cavity, or to treat metastatic disease, but often lead to undesirable damage of healthy tissue. 
Beyond delivering thermal energy, MNPs have additional physical properties that make them 
advantageous for thermal delivery such as physical rotation of the nanoparticle in the presence of 
an AMF (Zhang, Kircher et al. 2014), elevated nanoparticle surface temperatures (Polo-Corrales 
and Rinaldi 2012) and nanoscale heating effects (Xu, Karmakar et al. 2010, Creixell, Bohorquez et 
al. 2011). These are all potential explanations to the improvement of MMH over other hyperthermia 
treatments. 
This improvement was demonstrated by Rodriguez-Luccioni et al. when they addressed the 
effects of MMH using MNPs functionalized with carboxymethyl dextran compared to hot water 
hyperthermia (HWH) on MCF-7 and Caco-2 cells (Rodriguez-Luccioni, Latorre-Esteves et al. 
2011).  MMH resulted in a greater decrease in cell viability for both cell lines compared to HWH. 
A thorough review of MMH using iron oxide nanoparticles and the mechanisms of heat dissipation 
was written by Laurent et al. in 2011 (Laurent, Dutz et al. 2011), and others have addressed the 
advances, challenges, promises, and perils of MNPs for hyperthermia applications (Kozissnik, 
Bohorquez et al. 2013, Singh, McMillan et al. 2014). Therefore, this section focuses on recent 
studies that utilize controlled delivery of thermal energy from MNPs and the therapeutic and 
immunotherapeutic effects of the treatment.   
Several research groups have studied the efficacy of magnetically mediated thermal therapy as 
a treatment modality for cancer both in vitro and in vivo (Le, Shinkai et al. 2001, Johannsen, Jordan 
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et al. 2004, Ivkov, DeNardo et al. 2005, Johannsen, Thiesen et al. 2005, Kettering, Winter et al. 
2007, Kallumadil, Tada et al. 2009, Suto, Hirota et al. 2009, Lee, Jang et al. 2011, Bae, Park et al. 
2012, Kut, Zhang et al. 2012, Lartigue, Hugounenq et al. 2012, Mustafa, Zhang et al. 2013, Rivet, 
Yuan et al. 2014, Soni, Tyagi et al. 2014).  Thermoablation is another form of thermal therapy 
induced by raising the bulk solution temperature above 45°C. A recent review highlights the use of 
various nanomaterials, including MNPs, for thermoablative treatment, imaging, and diagnostics 
(Sawdon, Weydemeyer et al. 2014). The temperature at which the thermal therapy is performed 
dictates cellular response, with apoptosis being linked to hyperthermia temperatures and necrosis 
being associated with thermoablation. Both of these thermal therapy treatments can be administered 
via MNPs in the presence of an AMF, but it is important to understand the properties of magnetic 
nanoparticles in cellular environments in order to synthesize magnetic nanoparticle systems with 
the potential for maximum energy delivery. Di Corato et al. analyzed energy delivery by magnetic 
nanoparticles in a cellular environment and compared it to nanoparticles in suspension (Di Corato, 
Espinosa et al. 2014). In all systems, there was a systematic decrease in the heating efficiency for 
nanomaterials associated with tumor cells, which was likely due to inhibition of the Brownian 
relaxation in cellular conditions. The magnitude of this decrease was associated with the type of 
nanoparticle, but in general, it was determined that nanoparticles in the superparamagnetic domain 
are minimally affected by the cellular environment.  
Various superparamagnetic nanoparticle systems have been developed to improve the efficacy 
of thermal therapy as a treatment of cancer. Wydra et al. developed an iron oxide nanoparticle 
system coated with citric acid or poly(ethylene glycol) (400) dimethacrylate (PEG400DMA) via 
atomic transfer radical polymerization (ATRP) (Wydra, Kruse et al. 2013). A549 lung carcinoma 
were exposed to 10 mg/mL Fe3O4 and exposed to an AMF (301 kHz, 27.9 kA/m) for 10 minutes 
resulting in a bulk solution temperature of 55°C in the center of the dish where the magnetic field 
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amplitude was greatest. Minimal cell death occurred in the periphery indicating that temperatures 
in the thermal ablation range were sufficient at inducing cell death, most likely through necrosis.   
Other studies have looked to address the differences between thermal therapies in the 
hyperthermia and thermoablation temperature ranges (Hu, Ma et al. 2011, Wang, Dong et al. 2012). 
In a study completed by Wang et al., the efficacy of high end hyperthermia treatment (47°C) was 
compared to thermoablation treatment at 51°C on subcutaneous MPC-83 tumors in female mice 
(Wang, Dong et al. 2012). Thermal therapy was administered at temperatures of 47 or 51°C for 30 
minutes (300 kHz, 100 G) after the tumors had grown to 10 mm in diameter. After hyperthermia 
treatment at either temperature, the tumors in the 20 mice disappeared within 14 days. However, 
subcutaneous nodules of 3 mice in the 47°C group and 2 mice in the 51°C group began to relapse 
within 2 months after hyperthermia. Additionally, 7/10 mice in the 47°C group and 8/10 in the 
51°C group were alive 140 days after hyperthermia treatment. This is a significant increase in 
survival of the hyperthermia groups compared to the control. In another study by Hu et al., A549 
xenograft mice were injected with three different doses of iron oxide MNPs, which resulted in 
varying tumor temperatures of 41.3, 44.5, and 46.8°C (Hu, Ma et al. 2011). Tumor temperatures 
from 42-46°C resulted in disruption of the enzymatic system and structure of the tumor, therefore 
inducing apoptosis. Above 46°C, numerous large necrotic areas were observed within the tumors, 
and the nanoparticles were either distributed in the interstitial matrix of tumors or phagocytized by 
tumor cells.  
In addition to cellular death, thermal therapy has a variety of consequences on the tumor 
microenvironment (Kolosnjaj-Tabi, Di Corato et al. 2014) and tumor growth factor expression 
(Wang, Xu et al. 2014). In a study completed by Kolosnjaj-Tabi et al. in 2014, PEG-coated iron 
oxide nanocubes were injected intratumorally into epidermoid carcinoma xenograft mice and 
treated for three days with 30 minutes of AMF exposure (111 kHz, 23.8 kA/m), which resulted in 
a temperature rise of 7.8 ± 2.2°C (Kolosnjaj-Tabi, Di Corato et al. 2014). This hyperthermia 
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treatment resulted in the slackening of generally compact collagen fibers, which in turn increased 
nanocube penetration into the cell-rich tumor core. After MMH treatment, the intra-fibrillar space 
of the collagen matrix was shown to increase from 101 ± 17 nm to 133 ± 32 nm due to a phase 
transition of the collagen network. Thermal therapy via magnetic nanoparticles has also been shown 
to down regulate vascular endothelial growth factor (VEGF) in rats with Walker 265 breast 
carcinoma (Wang, Xu et al. 2014). Thermal treatment in the range of 50-55°C was administered 1, 
2 or 3 times for 30 minutes via AMF exposure (180 kHz, 55 G) resulting in tumor growth inhibition 
and promoting the survival of tumor bearing rats. Gene expression of VEGF and its receptors in 
the tumor were decreased, thereby inhibiting tumor angiogenesis.  
Thermal therapy using MNPs in an AMF has also been utilized as an immunotherapeutic 
treatment with promising results (Yanase, Shinkai et al. 1998, Shinkai, Yanase et al. 1999, Suzuki, 
Shinkai et al. 2003, Toraya-Brown, Sheen et al. 2014). Magnetic cationic liposomes (MCLs) were 
used for hyperthermia treatment in three of these studies due to their higher affinity for tumor cells 
than neutrally charged magnetoliposomes. In one of the first immunotherapy treatment studies via 
thermal therapy, T-9 rat glioma tumors were formed in the left flank of female rats, and MCLs were 
injected into half the tumors followed by exposure to an AMF (118 kHz, 384 Oe) for 30 minutes 
(3 times at 24 hour intervals) (Yanase, Shinkai et al. 1998). 89% of the rats treated with 
hyperthermia had complete regression. Three months later, cured rats or naïve rats were challenged 
with T-9 or malignant fibrous histiocytoma cells in the right flank.  All right flank tumors (T-9 or 
malignant fibrous histiocytoma) formed in the mice not initially treated with hyperthermia. 
Conversely, T-9 right flank tumors did not form in mice treated with hyperthermia in the T-9 left 
flank tumors. However, malignant fibrous histiocytoma cell injection into the right flank resulted 
in tumor formation. Therefore, the immune response was found to be specific for the original T9 
cells. Additionally, CD3+, CD4+, CD8+, and NK immunocytes were detected in the left and right 
tumors of mice treated with hyperthermia, but no immunocytes were found in the control group. 
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A subsequent study was completed on B16 melanoma subcutaneous tumors (Suzuki, Shinkai 
et al. 2003) and showed that 9 out of the 10 mice had complete tumor disappearance 120 days after 
two 30 minute hyperthermia treatments with MCLs in an AMF (118 kHz). Spleen cells were 
obtained from the cured mice, and in an in vitro study, these cells were shown to have increased 
cytotoxic activity against B16 cells compared to spleen cells from naïve mice. An in vivo 
immunotherapy study was also completed wherein mice were challenged with B16 melanoma cells 
120 days after treatment. In the naïve mice, tumors formed 6 days post inoculation. However, 66% 
of the cured mice rejected the melanoma cells resulting in no nodule formation. The extended time 
between hyperthermia treatment and secondary inoculation suggests that MMH has the potential 
to decrease metastatic potential of B16 melanoma cells.  
A more recent study on the immunotherapeutic effects of MMH was completed by Toraya-
Brown et al. in 2014 and showed that local hyperthermia treatment induced CD8+ T cell-mediated 
resistance against distal and secondary tumors (Toraya-Brown, Sheen et al. 2014).  B16 tumors 
were established in both the left and right flanks simultaneously, but only the left flank tumor was 
treated with MMH (43°C) for 30 minutes. Right flank tumors of the left flank heated group were 
found to grow significantly slower than the non-heated group. Another experiment examined 
secondary tumor formation in the right and left flanks after a right flank tumor was treated with 
hyperthermia and then excised three days post treatment. Secondary tumor growth was inhibited 
on both the primary tumor side and the contralateral side in the heated group compared to the non-
heated group. This study also revealed that the timing of secondary tumor inoculation plays a role 
in tumor formation. One day after hyperthermia treatment resulted in no resistance to secondary 
tumor formation while inoculation 30 days after treatment inhibited tumor growth on the primary 
side but not the contralateral side. Additionally, it was found that local hyperthermia increases 
CD8+ T cells – required for inducing resistance against secondary tumors – as the effects of heating 
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the primary tumor were completely abrogated by treating with CD8+ antibiotics to deplete CD8+ 
formation. 
In addition to the in vitro and in vivo studies completed using magnetically mediated thermal 
therapy, there have also been a few clinical trials investigating quality of life and feasibility of 
thermotherapy using magnetic nanoparticles (Johannsen, Gneueckow et al. 2007, Johannsen, 
Gneveckow et al. 2007). Maximum temperatures of 55°C were obtained in the prostate using only 
25% of the available magnetic field amplitude, and mean intra tumor temperatures were kept 
between 42 and 46°C for 60 minutes (once per week for 6 weeks). It was determined that this 
treatment was not enough to kill the cancerous cells but is applicable as a combination treatment 
(Johannsen, Gneueckow et al. 2007).  A quality of life assessment was also completed on this 
clinical trial, and it was found that quality of life was only temporarily impaired by MNP 
thermotherapy with urinary symptoms which appeared almost exclusively during the first three 
weeks of treatment (Johannsen, Gneveckow et al. 2007).  
3.2.2 Nanoscale Energy Delivery 
As discussed above, thermal therapy has been studied for decades, with various successes in 
MMH and related treatments, but this approach has yet to gain widespread clinical recognition 
either as an independent treatment or in conjunction with traditional therapies.  This section 
explores the most recent advances in the promising area of MagMED therapy, wherein MNPs are 
engineered for the selective destruction of cells and/or intracellular structures without a 
macroscopic temperature rise (Kozissnik, Bohorquez et al. 2013). 
Instead of relying on a bulk temperature rise to induce hyperthermia conditions, it was 
suggested by Gordon, et al.  in 1979 that intracellular hyperthermia would be more advantageous 
due to insulation by the cell membrane and lack of convection from blood flow which dissipates 
heat away from the tumor tissue which is especially problematic in small metastatic tumors 
(Gordon, Hines et al. 1979). Although there was a growing body of evidence suggesting that local 
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heating and energy delivery could be used to kill cancer cells, theoretical calculations by Rabin et 
al.  indicated that the heat dissipation from the nanoparticle surface through conduction is greater 
than the heat being generated by the nanoparticles (Rabin 2002). At the single nanoparticle level, 
Rabin’s calculations suggest the nanoparticle temperature difference at steady state to be no greater 
than 10-5 °C, indicating that a single nanoparticle cannot cause any thermal damage. On the macro-
scale, Rabin’s most conservative calculation indicated that the region occupied by a cluster of 
magnetic nanoparticles within a cell must be at least 1.1 mm in diameter (two orders of magnetude 
larger than the typical cancer cell) in order to induce a temperature rise of 6 °C, suggesting that a 
larger target region is required in order to achieve hyperthermia temperatures. These calculations 
were completed without taking into account the effects of blood perfusion and potentially higher 
thermal conductivity values that would both require an even larger heated region in order to reach 
the same hyperthermia levels.   
Dispite the theoretical calculations by Rabin in 2002, nanoscale heating effects of MNPs were 
continually studied, and in 2011, an especially interesting study by Creixell et al. showed the ability 
of internalized iron oxide MNPs in the presence of an AMF to induce significant cellular toxicities 
without a measureable temperature rise. Iron oxide MNPs were targeted to the epidermal growth 
factor receptor (EGFR) overexpressed on MDA MB 468 cells by conjugation of epidermal growth 
facotr (EGF) (Creixell, Bohorquez et al. 2011).  The targeted MNPs were internalized by MDA 
MB 468 breast cancer cells and in the presence of an AMF induced a significant decrease in cell 
viability without a measureable temperature rise. Additionally, the cell survival fraction 
significantly decreased with increasing field amplitude. After these ground-breaking results, the 
phrase magnetically mediated energy delivery (MagMED) was coined to describe the conversion 
of magnetic field energy to other forms such as heat or rotational work but without significantly 
increasing the bulk temperature (Kozissnik, Bohorquez et al. 2013).  
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The theoretical calculations were further disputed when Huang, et al.  utilized iron oxide 
nanoparticles targeted to proteins on the membrane of cells expressing TRPV1 to locally deliver 
heat and open cation channels (Huang, Delikanli et al. 2010). Within 15 seconds of applying the 
AMF, the cytosolic calcium concentration increased from 100 nM to 1.6 µM due to increased 
calcium influx through the thermally activated TRPV1 channel. Nanoparticle heating at the surface 
was confirmed using a tethered thermoresponsive fluorophore (DyLight549) which decreased in 
fluorescence almost immediately upon AMF exposure, indicating heating of more than 15 °C 
within 15 seconds. Golgi-targeted green fluorescence protein was used to monitor bulk cell 
temperatures, and remained virtually unchanged during AMF exposure.  In a similar study by Polo-
Corrales and Rinaldi in 2012, surface temperature of magnetic nanoparticles in the presence of an 
AMF was monitored using thermoresponsive fluorescent polymers (Polo-Corrales and Rinaldi 
2012). Iron oxide MNPs were functionalized with a polymer consisting of poly(N-
isopropylacrylamide) copolymerized with a fluorescent modified acrylamide. As temperature 
increased above 35 °C, the polymer coating changed from hydrophilic to hydrophobic, resulting in 
an increase in fluorescence intensity. In the presence of an AMF, fluorescence intensity of the 
polymer coating increased although there was negligible bulk temperature rise, suggesting that the 
nanoparticle surface temperature was above 35 °C and further contradicting the theoretical 
calculations provided by Rabin in 2002.  
Localized MNP heating has also been studied as a mechanism for timed drug release from 
liposomes. Amstad et al. fabricated liposomes containing iron oxide MNPs within their lipid bilayer 
with a Tm well above body temperature (Amstad, Kohlbrecher et al. 2011). Upon actuation of the 
MNPs by an AMF, the liposome permeability increased due to local temperature increases above 
Tm. However, the liposomal structure remained intact suggesting that the bulk temperature did not 
rise above Tm and allowed for repeated release from the liposomes.  
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In addition to the effects of surface heating of magnetic nanoparticles in an AMF, rotational 
work has also been studied as an explanation to the experimental effects of MagMED. For example, 
mechanical forces have been used to induce lysosomal permeabilization, leading to the release of 
proteolytic enzymes such as cathepsins which initiate apoptotic pathways (Linder, Erdal et al. 2005, 
Kirkegaard and Jaattela 2009, Johansson, Appelqvist et al. 2010). This technique has also been 
shown to stimulate apoptosis in apoptosis-resistant cell lines (Jaattela 2004). For example, Sanchez 
et al. functionalized a ligand of a G-protein coupled receptor which is over expressed in several 
malignant cancers to iron oxide MNPs and showed that the internalized nanoparticles decreased 
cell survival through a lysosomal pathway upon nanoparticle activation by a low power AMF (275 
kHz, 40/52 mT) (Sanchez, Diab et al. 2014). Similarly, Domenech et al. induced lysosomal 
permeabilization using EGFR-targeted MNPs in the presence of an AMF (233 kHz, 42 kA/m) 
(Domenech, Marrero-Berrios et al. 2013). In EGFR positive cells (MDA MB 231), lysosomal 
disruption was linked to increased cytoplasmic cathepsin B concentrations and increased ROS 
generation, which led to a significant decrease in viability compared to cells treated with the 
nanoparticles and no AMF. Connord et al. developed a miniaturized electromagnet to fit under a 
confocal microscope allowing for real-time analysis of MMP and AMF (53 mT) treatment 
(Connord, Clerc et al. 2015). Iron oxide MNPs coated with PEG-Amine and functionalized with 
gastrin, which specifically binds to cholecystokinin-2 receptor, were used in this study. Confocal 
images taken prior to AMF exposure indicate co-localization of Lysotracker and the MNPs. 
However, after 30 minutes of AMF treatment, the lysosomes had been permeabilized and co-
localization decreased. Another interesting but not fully understood observation was lysosomal 
alignment with the magnetic field. These results indicate the importance of real-time imaging in 
order to better understand the intracellular effects of MagMED.  
Zhang et al.  developed a dynamic magnetic field generator to induce nanoparticle rotations 
about their axis to confirm whether physical nanoparticle rotations can disrupt lysosomal 
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membranes and induce apoptosis (Zhang, Kircher et al. 2014). By functionalizing the nanoparticles 
with lysosomal-associated membrane protein-1 (LAMP1), it was found that the shear forces 
generated by oscillating torques were enough to damage the lysosomal membranes, proving that 
Brownian rotation of magnetic nanoparticles also plays an important role in MagMED treatment.  
In addition to the thermal and mechanical effects described above, the production of reactive 
oxygen species (ROS) via iron oxide nanoparticles is a potential chemical effect of MagMED. 
Several studies have correlated the production of ROS to the inherent cytotoxicity of iron oxide 
MNPs (Mahmoudi, Simchi et al. 2009, Khan, Mohammad et al. 2012, Ahamed, Alhadlaq et al. 
2013, Ahamed, Alhadlaq et al. 2013, Koenczoel, Weiss et al. 2013, Luo, Li et al. 2015). Iron oxide 
MNPs catalyze the Haber-Weiss reaction which makes use of Fenton chemistry (Kehrer 2000). The 
Fenton chemistry reaction set is shown as Equation 1 and the Haber-Weiss reaction (net reaction) 
is shown as Equation 2.  
     Fe3+ + O2· - → Fe2+ + O2 
                                                 Fe2+ +H2O2 → Fe3+ + OH- + OH·                                               [1] 
   O2· - + H2O2 → O2 + OH- + OH·                                             [2] 
When iron oxide nanoparticles enter a cell, they can stimulate the generation of ROS via one of 
two pathways: (1) the release of ions into the cytosol resulting in the iron ions participating in the 
Haber-Weiss cycle or (2) the surface of the nanoparticle may act as a catalyst (Klein, Sommer et 
al. 2012). Although this reaction can proceed without the addition of an AMF, recent work by 
Wydra et al.  demonstrated that the reaction is further catalyzed by iron oxide nanoparticles in the 
presence of an AMF (Wydra, Oliver et al. 2015). This study used the degradation of methylene 
blue by magnetite nanoparticles, and hydrogen peroxide was used to measure the reactivity of 
uncoated iron oxide MNPs in an AMF. Temperature is a driving factor of the Fenton reaction up 
to 40 °C, so by increasing the surface temperature of the MNPs, hydroxyl radical formation was 
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catalyzed, degrading methylene blue. At low nanoparticle concentrations, where the bulk 
temperature remained constant upon exposure to an AMF, local nanoscale heating effects were 
more pronounced, leading to an enhancement in methylene blue degradation compared to the 
Arrhenius prediction.  
3.3 Combination therapy 
Thermal therapy is often used in combination with conventional cancer therapies such as 
chemotherapy, radiation, surgical resection, and gene therapy to enhance the efficacy of these 
treatments. A variety of chemotherapeutics are more effective when administered in the 
hyperthermia range due to increased rate constants of alkylation, enhanced drug uptake, and 
inhibition of repair of drug-induced lethal or sub-lethal damage (Issels 2008, Hervault and Thanh 
2014). When selecting a chemotherapeutic combination therapy, an important consideration is the 
mechanism of action to make sure that it will complement the hyperthermia modality. When 
utilizing MMH, chemotherapeutics can either be administered in bulk or bound to the MNPs and 
released upon exposure to an AMF. Cisplatin (CDDP) (Lee, Rodriguez-Luccioni et al. 2011, 
Alvarez-Berrios, Castillo et al. 2013, Petryk, Giustini et al. 2013, Kruse, Meenach et al. 2014), 
bortezomib (BZ) (Alvarez-Berrios, Castillo et al. 2014, Alvarez-Berrios, Castillo et al. 2015), and 
melphalan (Brusentsov, Brusentsova et al. 2007) are common chemotherapeutics that have been 
studied for bulk combination treatments with MMH.  
Cisplatin binds to DNA, resulting, ultimately, in inter- or intra-strand crosslinking that prevents 
DNA transcription, blocks cell replication, and finally results in apoptosis. Cisplatin has been 
previously shown to be more effective when administered in the hyperthermia temperature range 
(Halamikova, Vrana et al. 2007, Issels 2008, Itoh, Yamada et al. 2010).  Lee et al. reported the 
effects of treatment sequence and heating technique (MMH or HWH) on Caco-2 cells (Lee, 
Rodriguez-Luccioni et al. 2011). The highest cytotoxicity was observed when CDDP and MMH 
were applied at the same time with an additional drug exposure period, but MMH was more 
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effective than HWH independent of treatment sequence.  The mechanism of cell death after 
combined treatment is likely to be a form of programmed cell death, such as apoptosis rather than 
necrosis. In a subsequent study (Alvarez-Berríos, Castillo et al. 2013), the enhancement of cisplatin 
in Caco-2 cells by MMH was correlated with an increase in cell membrane fluidity. The presence 
of copper inhibited CDDP uptake in control cells by hindering copper transporter-mediated active 
transport, but this same inhibition was not seen in HWH or MMH. Platinum concentration inside 
cells after MMH was significantly greater than after HWH, which corresponded to the increase in 
membrane fluidity observed after MMH. Another study by Kruse et al. used crosslinked dextran 
coated iron oxide MNPs in the presence of an AMF to administer hyperthermia treatment to A549 
lung carcinoma in combination with CDDP (Kruse, Meenach et al. 2014) (see Chapter 4). 
Hyperthermia treatment was administered for 30 minutes simultaneously with CDDP and resulted 
in an additive effect of the combined treatment when analyzed 72 hours post treatment. 
An in vivo study of MMH (60 minutes at 43°C) combined with CDDP on murine mammary 
adenocarcinoma model showed that MMH combined with CDDP was 1.7 times more effective 
than MMH alone and 1.4 times more effective than CDDP alone (Petryk, Giustini et al. 2013). 
Tumor growth was monitored over time and the control took 14 days to grow three times its original 
size whereas MMH alone resulted in a delay to 21 days, CDDP alone took 25 days and the 
combined treatment took 36 days.  
Bortezomib (BZ), an inhibitor of the chymotrypsin-like activity of the 26S proteasome in mam-
malian cells, is another chemotherapeutic that has been studied in combination with MMH 
(Alvarez-Berrios, Castillo et al. 2014, Alvarez-Berrios, Castillo et al. 2015). Alvarez-Berrios et al. 
showed that MMH enhances the cytotoxicity of BZ in both BZ sensitive (MDA MB 468 and caco-
2) and resistant (A2780) cancer cell lines (Alvarez-Berrios, Castillo et al. 2014). Carboxymethyl 
coated iron oxide MNPs (3.8 mg/mL) in the presence of an AMF (233 kHz) at 29.39 or 34.73 kA/m 
resulted in hyperthermia treatment at 43°C or 45°C, respectively. A different concentration of BZ 
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for each cell line was used in order to produce approximately the same level of proteasome 
inhibition after a pre-exposure time of 3 hours. Although BZ sensitive cells and BZ resistant cells 
showed similar levels of proteasome inhibition, thermal sensitization induced by MMH in 
combination with BZ in cells resistant to BZ resulted in significant cell death potentially due to an 
increase in cell membrane fluidity.  
BZ is a drug that increases the toxicity of proteotoxic stress in cancer cells because such cells 
produce significant amounts of misfolded and non-functional proteins, such that alternative 
mechanisms of cell protection against proteomic stress can be overwhelmed (Alvarez-Berrios, 
Castillo et al. 2015). Additionally, it has been shown that the combination of cellular effects 
induced by MMH, such as microtubule disruption and protein damage, results in progressive 
enhanced proteotoxic stress, which can lead to programmed cell death. MCF-7 cells treated with 
MMH or MMH and BZ at 43 °C (30 minute recovery time) showed more protein aggregation 
surrounding the nucleus compared to HWH or BZ with HWH, respectively. After 2.5 hours of 
recovery time, MMH had induced significant microtubule damage (43°C). It was speculated that 
the combination of microtubule damage and increased protein aggregation caused by MMH 
induces progressive enhanced proteotoxic stress, which produces significant cell death.   
As previously mentioned, chemotherapeutics can be combined with MMH by functionalizing 
the magnetic nanoparticle with a chemotherapeutic of interest – by tethering with a responsive 
linker or encapsulation within a coating matrix – resulting in controlled drug release upon exposure 
to an external stimuli such as an AMF (as discussed in greater detail in section 2.1 above) or change 
in pH. Huang et al. recently synthesized pH sensitive cisplatin-loaded magnetite hydroxyapatite 
nanoparticles (Huang, Chen et al. 2015). In a low pH environment, 20% of the CDDP was released 
compared to 5% at a pH of 7. After treatment with the nanoparticles at 300 µg/mL for 48 hours, 
A549 viability was significantly decreased, and further decreased in the presence of an AMF for 
30 minutes resulting in a temperature increase to 43°C. Additionally, in an in vivo subcutaneous rat 
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model, tumor growth was completely inhibited in the group treated with the nanoparticle system 
combined with AMF treatment. In another study by Babincova et al., iron oxide nanoparticles were 
coated with a hydrophilic starch polymer coupled with phosphate functional groups (Babincova, 
Altanerova et al. 2008). The negative coating charge allowed for ionic binding of positively charged 
species such as cisplatin. A 20 minute hyperthermia treatment was induced using an AMF (3 MHz, 
1.5 mT), and during this time, almost all of the drug was released from the nanoparticle. The 
combined MMH and CDDP treatment from the drug loaded iron oxide nanoparticle resulted in a 
relative viability of 23.6 ± 8.6%. This is significantly less than either the hyperthermia treatment 
(85.2 ± 7.5%) or the equivalent CDDP treatment (73.8 ± 5.6%) alone, indicating a synergistic 
toxicity of CDDP and MMH.  
5-fluorouracil (5-FU) has also been conjugated to iron oxide nanoparticles for combination 
therapy.  Li et al. functionalized a magnetite core with PMSA followed by covalent modification 
with poly-A15 (Li, Huang et al. 2013). The nanoparticles were then functionalized with 5-FU and 
tagged with a HER2 antibody. A subcutaneous model with a bladder cancer cell line (MBT-2) was 
used to evaluate the efficacy of combined 5-FU and 15 minute thermal therapy treatment. For small 
tumors, hyperthermia treatment alone was able to significantly reduce the tumor volume. However, 
for larger tumors, only the combined treatment of using 5-FU functionalized nanoparticles for 
MMH resulted in a decrease in tumor volume. A complementary result was seen when the targeted, 
drug functionalized nanoparticles were injected through the tail vain followed by AMF exposure. 
The nanoparticles without AMF treatment did not inhibit tumor growth (likely due to no 5-FU 
release) nor did treatment with an equivalent dose of 5-FU. The drug loaded nanoparticles with 
AMF exposure led to complete tumor regression two days after the last treatment.  In another study, 
5-FU and curcumin were functionalized to magnetic nanoparticles, and when exposed to an AMF, 
the dual drug release combined with thermal therapy led to an enhanced efficacy compared to either 
drug treatment alone (Balasubramanian, Girija et al. 2014). This is thought to be due to increased 
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efficiency of drug diffusion from the nanoparticles or to the fact that injured cells could not 
recuperate from the impairment induced by thermal treatment owing to the combined treatment of 
5-FU and curcumin. 
Heat shock protein (HSP) inhibitors are of particular interest due to up regulation of heat shock 
proteins during hyperthermia treatment. Geldanamycin, a HSP 90 inhibitor, was conjugated to iron 
oxide nanoparticles via a thermally cleavable linker for controlled release upon exposure to an 
AMF (Yoo, Jeong et al. 2013). An in vitro study on MDA MB 231 cells showed geldanamycin 
functionalized iron oxide MNPs negated the increased HSP 90 expression seen with MMH alone, 
and an in vivo study resulted in complete tumor regression 8 days after treatment when the 
geldanamycin functionalized MNPs were used for MMH.  
Additional studies have been completed using methotrexate (Gao, Yan et al. 2012), 
doxorubicin (Xu, Karmakar et al. 2012), and erlotinib (Xu, Karmakar et al. 2012) functionalized 
magnetic nanoparticles for combination therapy. These studies also indicate that drug combined 
with hyperthermia via MNPs in an AMF is more effective than either treatment alone. Methotrexate 
combined with MMH resulted in a synergistic treatment of MCF-7 cells in vitro (Gao, Yan et al. 
2012) while doxorubicin efficacy was significantly increased when combined with MMH (Xu, 
Karmakar et al. 2012).  
MMH can also be combined with radiation and gene therapy for enhanced efficacy. There are 
several studies that address hyperthermia combined with radiation (Horsman and Overgaard 2007, 
Hurwitz, Hansen et al. 2011, Neshasteh-Riz, Rahdani et al. 2014), but minimal studies that utilize 
MMH with radiation therapy. Hyperthermia has been shown to increase blood supply to the tumor, 
which increases the local oxygen levels and the efficacy of radiation therapy is tied to the formation 
of free radicals more so than DNA damage. In an orthotopic tumor model of R3327 Dunning tumor 
cell line, MNPs with an aminosilane shell were used for two rounds of MMH for 30 minutes each 
combined with 20 Gy, 40 Gy or 60 Gy total radiation therapy (Johannsen, Thiesen et al. 2006). 
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Thermal therapy viability inhibition alone was 44.1-51.7% whereas the combined treatment (20 Gy 
radiation total with hyperthermia) had an inhibition of 87.5-89.2% compared to the control. A 
clinical trial was also completed in which 59 patients with recurrent glioblastoma received a direct 
injection of iron oxide MNPs followed by 30 minutes of heating (43°C) in an AMF (100 kHz, 2-
15 kA/m) (Maier-Hauff, Ulrich et al. 2011). A median radiation dose of 30 Gy was given to the 
patients immediately before or following hyperthermia treatment. The combined therapy resulted 
in an extension of the median overall survival after primary tumor diagnosis from 14.6 to 23.2 
months. There was also a gain of 7.2 months for survival following tumor recurrence. Although 
there are differences between the treatments of the patients, the increase in survival time can be 
attributed to the combination of thermo-radiotherapy.  
Thermal therapy via magnetic nanoparticles combined with gene therapy is a recently 
developed area in this field. A review of heat responsive gene expression utilizing thermal therapy 
via other methods than MNPs was published in 2009 (Walther and Stein 2009). More recently in 
2014, Shah et al. evaluated the efficacy of pro-apoptotic amphipathic tail-anchoring peptide 
(ATAP) delivery by MNPs. MMH was used to increase pro-apoptotic proteins in glioblastoma 
multiforme cells and metastatic breast cancer cells, while the ATAP peptide selectively targeted 
mitochondria and induced cytochrome c release through disruption of the mitochondrial membrane. 
The result of gene therapy treatment combined with MMH resulted in enhanced toxicity compared 
to ATAP therapy alone, which is likely due to an increase in peptide solubility upon conjugation 
to the nanoparticles. In another study completed by Yin et al. in the same group, lethal-7a miRNA 
was conjugated to MNPs, as lethal-7a is a known tumor suppressor that inhibits malignant growth 
by targeting factors such as the BRCA family, RAS, IGF1R and c-Myc, which all overlap with 
downstream regulation of heat shock proteins (Yin, Shah et al. 2014). Combined thermal therapy 
via MMH and gene therapy with lethal-7a showed an additive effect, resulting in significantly more 
apoptosis in brain cancer cells than either treatment alone. Overall, gene therapy combined with 
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MMH is a promising avenue for combination therapy and can potentially result in more 
personalized treatment of cancer.  
3.4 Conclusions  
Thermal therapy using MNPs has been shown to decrease cancer cell growth both in vivo and 
in vitro to a greater extent than thermal therapy administered by external methods such as HWH. 
In addition, immunotherapeutic effects of thermal therapy have been observed and show promise 
for future development. However, due to the bulk concentration of nanoparticles required to heat 
tissue into the hyperthermia range, translation to clinical trials has been minimal. Additionally, 
applications of MMH as a viable treatment modality is limited by tumor size due to heat transfer 
from small tumors (i.e. metastases) to the surrounding tissue. In order to improve thermal therapy 
via MNPs, in vivo heating properties need to be improved and specific strategies for targeting to 
tumor tissue to decrease non-specific accumulation need to be developed.  
Energy delivery on the nanoscale provides another avenue of thermal therapy where only 
intracellular nanoparticles are actuated by an AMF, resulting in subcellular heating effects without 
a macroscopic temperature rise. Energy delivery on the nanoscale has been shown to result in 
destabilization of lysosomal membranes and toxic effects to other organelles. Previously, the focus 
of MNP development was improving the heating capabilities to overcome the thermal delivery 
limitations, but in addition to this need for other therapy strategies, many researchers are now 
exploring intracellular targets for nanoscale thermal therapy applications.  Further studies need to 
be performed to gain a better fundamental understanding of the mechanisms at play.  However, an 
exciting prospectus is to combine the knowledge gained through combined chemotherapy with this 
new therapy strategy.  Novel nanoparticle architectures should be synthesized to deliver 
therapeutics intracellularly, relying on nanoscale thermal effects to improve efficacy.   
Thermal therapy as a single treatment is often insufficient to induce irreparable cellular 
damage, but when combined with a secondary treatment, the combination therapy is often found to 
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be more effective than either treatment alone. A variety of chemotherapeutics are more effective 
when administered at elevated temperatures due to increased rate constants of alkylation, increased 
drug uptake, and repair inhibition of drug-induced lethal or sub-lethal damage. Thermal therapy 
also increases oxygen content within tissue, making radiation more effective. Therefore, as a 
combination treatment, thermal therapy via MNP activation in an AMF has greater application. 
However, the same limitations such as concentration dependence, heating properties, and AMF 
parameters still remain. As the field progresses, it will be important to develop targeted MNPs with 
excellent heating properties in order to overcome some of these limitations and, as previously 
mentioned, explore nanoscale thermal therapy in combination with conventional treatments.  
In the last several years, there have been many exciting developments in the use of MNPs and 
their composites for remote controlled therapies.  These include novel remote controlled drug 
delivery systems at various scales for modulated release and magnetic field guidance, controlled 
energy release for thermal therapy and nanoscale energy therapy, and thermal therapy in 
combination with other treatments such as chemotherapy or radiation.  With numerous in vivo 
demonstrations of efficacy, these remote controlled therapies are starting to progress to the clinic, 
and they are expected to greatly impact the treatment of various diseases in the future. 
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Chapter 4 Synthesis and characterization of CREKA-conjugated iron oxide nanoparticles 
for hyperthermia applications 
 
The dextran-coated iron oxide nanoparticle system were synthesized via a one-step co-precipitation 
reaction. The dextran surface was then crosslinked and functionalized with the CREKA peptide. 
The physicochemical properties of the nanoparticles were characterized at each step of the synthesis 
process. The goal of this work was to analyze the physicochemical properties of the nanoparticle 
system and to complete a proof-of-concept magnetically mediated hyperthermia study. The chapter 
is taken directly or adapted from work published in Kruse, Meenach, et al. (2014) Copyright 2014 
Elsevier B.V. Used with permissions from Anastasia M. Kruse, Samantha A. Meenach, Kimberly 
W. Anderson and J. Zach Hilt, “Synthesis and characterization of CREKA-conjugated iron oxide 
nanoparticles for hyperthermia applications”, Acta Biomaterialia and Elsevier B.V. 
4.0 Abstract 
One of the current challenges in the systemic delivery of nanoparticles in cancer therapy 
applications is the lack of effective tumor localization. Iron oxide nanoparticles coated with 
crosslinked dextran were functionalized with the tumor homing peptide CREKA, which binds to 
fibrinogen complexes in the extracellular matrix of tumors. This allows for the homing of these 
nanoparticles to tumor tissue. The iron oxide nanoparticle core allows for particle heating upon 
exposure to an alternating magnetic field (AMF) while the dextran coating stabilizes the particles 
in suspension and decreases the cytotoxicity of the system. Magnetically mediated hyperthermia 
(MMH) allows for the heating of tumor tissue to increase the efficacy of traditional cancer 
treatments using the iron oxide nanoparticles. While MMH provides the opportunity for localized 
heating, this method is currently limited by the lack of particle penetration into tumor tissue, even 
after effective targeted delivery to the tumor site. The CREKA-conjugated nanoparticles presented 
were characterized for their size, stability, heating capabilities and biocompatibility. The particles 
had a hydrated diameter of 52 nm, were stable in PBS and media with 10% v/v FBS over at least 
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twelve hours, and generated enough heat to raise solution temperatures well into the hyperthermia 
range (41 – 45 °C) when exposed to an AMF due to an average specific absorption rate (SAR) of 
83.5 W/g. Cytotoxicity studies demonstrated that the particles have low cytotoxicity over long 
exposure times at low concentrations. A fibrinogen clotting assay was used to determine the binding 
affinity of CREKA-conjugated particles, which was significantly greater than the binding affinity 
of dextran, only coated iron oxide nanoparticles demonstrating the potential for this particle system 
to effectively home to a variety of tumor locations. Finally, it was shown that in vitro MMH 
increased the effects of cisplatin compared to cisplatin or MMH treatments alone.  
4.1 Introduction 
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the United 
States each year (ACS 2013). Survival without treatment for stage IV NSCLC is 6 months if left 
untreated and only 9 to 12 months with treatment. Hyperthermia, the heating of tissue to 41-45 °C, 
has been shown to be effective in treating lung cancer when used in conjunction with radiation or 
chemotherapy (Vertrees, Das et al. 2005, Itoh, Yamada et al. 2010, Lee, Rodriguez-Luccioni et al. 
2011). Current hyperthermia treatments (e.g., whole body and regional hyperthermia) have several 
disadvantages, including damaging healthy tissue, limited penetration of heat into the body, under-
dosage of heat, and complications such as increased heart rate and increased cardiac output 
(Zwischenberger, Vertrees et al. 2004, Issels 2008, Kumar and Mohammad 2011). Hyperthermia 
treatments are further challenged by deep seated tumors and lack the ability to penetrate 
surrounding tissues to raise the tumor tissue into the hyperthermia range (Dennis, Jackson et al. 
2009). Although various limitations exist, treatment of cancer via hyperthermia in conjunction with 
cisplatin was shown to have synergistic effects (Babincova, Altanerova et al. 2008) and 
sensitization of cisplatin-resistant cell lines (Hettinga, Lemstra et al. 1995). Cisplatin (20 µg/mL or 
200 µg/mL) combined with mild incubator-induced hyperthermia at 41 °C was shown to 
significantly decrease the surviving fraction of T24 bladder cancer cells in vitro (Itoh, Yamada et 
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al. 2010). In another study completed by Hettinga and coworkers, murine tumor cells were mutated 
in vitro for cisplatin resistance (Hettinga, Lemstra et al. 1995). The cisplatin-resistant cell line was 
exposed to cisplatin (0 - 10 µg/mL) for 45 minutes at either 37 °C or 44 °C. Hyperthermia with 
cisplatin exposure resulted in a significant decrease in the percentage of cell survival of the 
cisplatin-resistant cells. A second experiment demonstrated that the cisplatin-resistant cells were 
sensitized by hyperthermia by pre-heating the cells at 44 °C for 10 minutes prior to 45 minutes of 
cisplatin exposure at 37 °C. This treatment sequence further decreased the cell survival of the 
cisplatin-resistant cells (Hettinga, Lemstra et al. 1995).   
In the presence of an alternating magnetic field (AMF), iron oxide magnetic nanoparticles 
generate heat and can induce hyperthermia. Magnetically-mediated hyperthermia, which is the 
heating of tissue using heat generated by magnetic nanoparticles in the presence of an AMF, shows 
great promise in overcoming the limitations of current hyperthermia treatments due to the ability 
of nanoparticles to deliver heat directly to the tumor site, therefore limiting the heat exposure to 
surrounding tissues. Iron oxide nanoparticles (IONPs) have the ability to passively or actively target 
tumors, and in the presence of an external AMF, can generate heat via multiple possible loss 
mechanisms including Néel paramagnetic switching, friction losses from Brownian rotation, and 
hysteresis (Dennis, Jackson et al. 2009). IONPs have been studied as imaging agents, drug delivery 
systems, and therapeutic enhancers due to their inherent biocompatibility, magnetic properties, and 
lack of protein adsorption after proper coating (Laurent, Dutz et al. 2011). In cancer therapy 
applications of IONPs, the main limitation to treating solid tumors is the limitations of particle 
localization. Vascularization and the enhanced permeation and retention (EPR) effect allow for 
passive targeted delivery of nanoparticles to the periphery of solid tumors. However, active 
targeting through peptides or ligands can result in higher local concentrations of nanoparticles and 
lower systemic concentrations, which is required for more effective treatment (Ruoslahti, Bhatia et 
al. 2010).  
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CREKA, a tumor homing peptide, recognizes fibrin-associated plasma proteins, which are 
overexpressed in cancerous tissue but not in normal, healthy tissue. The walls of tumor vessels and 
the interstitial space within tumors contain these fibrin-fibronectin complexes due to protein 
seepage from the leaky vasculature of the tumor (Ruoslahti, Bhatia et al. 2010).  It was shown that 
CREKA can specifically target fibrin-fibronectin complexes as demonstrated by the lack of the 
peptide targeting to syngeneic B16F1 melanoma tumors grown in mice null of fibrinogen or lacking 
plasma fibronectin but significant homing to syngeneic B16F1 melanoma tumors in wild-type mice 
of the same litter (Simberg, Duza et al. 2007). CREKA is a small, linear peptide of five amino 
acids, which makes it attractive to use for conjugation with nanoparticles since multiple peptides 
can be conjugated to a single nanoparticle (Simberg, Duza et al. 2007). IONPs do not require 
internalization into cancer cells to be effective at heating the tumor tissue. Internalization of IONPs 
has been shown to enhance the anti-cancer effects of thermal energy dissipation compared to bulk 
hyperthermia methods (Creixell, Bohorquez et al. 2011). Intracellular hyperthermia does not result 
in a bulk temperature rise but rather relies on the ability of individual nanoparticles to raise the 
temperature of their immediate surroundings (Krpetic, Nativo et al. 2010). Although targeting 
promoted uptake of IONPs can enhance their intracellular concentration, the targeting peptides, 
such as EGFR, are still cell line specific. Therefore, CREKA conjugation to IONPs is advantageous 
over other peptides in that it binds to complexes within the tumor vasculature rather than specific 
integrins on the surface of cells (Ruoslahti, Bhatia et al. 2010).  
In this study, peptide-conjugated dextran-coated IONPs for enhanced tumor homing have been 
developed and characterized. Physicochemical characterization and in vitro biocompatibility 
studies are imperative for rationally developing and understanding a nanoparticle system. Prior to 
in vivo studies, the properties of this nanoparticle system such as size, stability, heating profiles, 
toxicity, and fibrinogen binding affinity need to be optimized. The desired size range for our 
nanoparticles is around 50 nm, which is expected to allow for tumor penetration and initial 
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accumulation to tumor tissue via the EPR effect. Stability in media is an important property for 
systemically delivered nanoparticles, and the heating properties must be sufficient to induce 
hyperthermia conditions upon exposure to an AMF with substantial SAR values. Nanoparticle 
systems used for biological applications such as these must be screened for toxicity at low 
concentrations over long time frames, and for this specific peptide-conjugated IONP system, the 
binding affinity of the particles to fibrinogen complexes was important to verify since fibrinogen 
complexes within the tumor vasculature are the target of this system. A proof-of-concept study was 
then completed to show that this nanoparticle system could be used to enhance the effectiveness of 
cisplatin through magnetically mediated hyperthermia. This peptide-conjugated IONP has optimal 
physical characteristics, such as size (Fox, Szoka et al. 2009, Phillips, Gran et al. 2010) and 
stability, for tumor homing via fibrin-fibronectin complexes and heating capabilities, which can be 
utilized for the hyperthermia treatment of lung cancer, in combination with chemotherapy.   
Although this study focuses on CREKA-conjugated IONPs for the treatment of lung cancer, this 
nanoparticle system has the ability to treat a multitude of cancerous tumors since it recognizes 
fibrinogen complexes rather than specific surface integrins, which are often cell line dependent. 
4.2 Materials and Methods 
4.2.1 Materials 
Iron (III) chloride hexahydrate (FeCl3·6H2O), iron (II) chloride (FeCl2·4H2O), 9 – 11 kDa dextran, 
epichlorohydrin (ECH), cisplatin (CDDP), fibrinogen, di-methyl sulfoxide (DMSO), and thrombin 
were obtained from Sigma Aldrich (St. Louis, MO). Ammonium hydroxide (NH4OH) was 
purchased from EMD Chemicals (Gibbstown, NJ). N-α-maleimidoacet-oxysuccinimide ester 
(AMAS) linker was obtained from Thermo Scientific (Rochester, NY). CREKA peptide conjugated 
with 5-fluorescein isothiocyanate-aminohexanoic acid (FITC-CREKA) was custom ordered 
through Biomatik (Cambridge, Ontario). Fetal bovine serum (FBS) was purchased from Fisher 
Scientific (Florence, KY). Dulbecco’s Modified Eagle Medium (DMEM), pen-strep, L-glutamine, 
 
60 
 
Fungizone®, and sodium pyruvate were all purchased from Invitrogen (Grand Island, NY), and 
trypsin was purchased from American Type Culture Collection (ATCC, Manassas, VA). 190 proof 
ethanol was purchased from Pharmco-Aaper (Shelbyville, KY) and phosphate buffered saline 
solution (PBS) (10X) was purchased from EMD Millipore (Billerica, MA). All materials were used 
as received. 
4.2.2 Crosslinked dextran coated iron oxide nanoparticle synthesis 
A modified one-pot co-precipitation method (Frimpong, Dou et al. 2010) was used to prepare 
dextran coated IONPs. FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams 
and 0.8 grams, respectively) and dissolved in 25 mL deionized (DI) water and sealed in a three-
neck flask under vigorous stirring and an inert nitrogen environment. 11 grams of dextran was 
solubilized in 50 mL of DI water and added to the three-neck flask.  The solution was heated to 85 
°C at which 5 ml of NH4OH was injected into the vessel. The reaction was carried out for 1 hour 
at 85 °C.  The particles were centrifuged at 1000 rpm for 10 minutes to remove large agglomerates. 
The remaining particles were then dialyzed against DI water for 24 hours. Dextran coated IONPs 
were crosslinked using ECH for increased stability (Stephen Palmacci 1993). The particle colloid 
(9 mL, 1 mmol Fe) was added to 9 mL 5M NaOH and 2 mL ECH. The reaction was carried out for 
24 hours at room temperature under continuous agitation. The particles were then dialyzed against 
DI water for 24 hours to remove excess ECH. Crosslinked IONPs were then aminated to allow for 
peptide conjugation. This was accomplished by reacting 0.2 mL of 30% ammonium hydroxide with 
the particles (5 mL, 0.2 mmol Fe) for 24 hours at room temperature under continuous agitation. 
The particles were then dialyzed against DI water for 24 hours.  
4.2.3 CREKA conjugation of iron oxide nanoparticles 
Amine conjugated IONPs were further conjugated with AMAS linker. The primary amines on the 
nanoparticles react with the N-hydroxysuccinimide of the linker, and CREKA can then be 
conjugated to the particle surface by reacting the sulfhydryl group on the cysteine with the 
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maleimide group of the linker. Particles were re-suspended at a concentration of 1 mg Fe/mL in 
PBS, and 2.5 mg AMAS per 2 mg Fe were dissolved in DMSO prior to addition to the nanoparticle 
suspension (Simberg, Duza et al. 2007). After the AMAS addition under vortexing, the reaction 
was carried out for 40 minutes at room temperature. Particles were then washed three times with 
PBS on 100,000 MWCO cellulose Millipore filtration columns. FAM-CREKA was then added to 
the particle suspension at 25 mg per 4 mg Fe (Simberg, Duza et al. 2007). Particles were incubated 
overnight at 4°C and then washed again with PBS. To serve as a control for the CREKA-conjugated 
IONPs, fluorescein isothiocyanate (FITC) was conjugated to amine groups on crosslinked dextran 
IONPs. FITC was added in a 1:10 molar ratio to iron oxide (0.434 mmol Fe3O4 and 0.0434 mmol 
FITC) and dissolved in 5 mL ethanol. The reaction was carried out for six hours at room 
temperature. The particles were then washed with DI water and concentrated using ultrafiltration 
columns. A summary of the systems investigated is included in Table 4.1, and a schematic of the 
systems synthesized is included in Figure 4.1. 
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Figure 4.1 Iron oxide nanoparticle synthesis process for the (a) dextran coating, (b) epichlorohydrin 
crosslinking, (c) amine conjugation, and (d) conjugation with an AMAS linker, connecting the 
FAM-labeled CREKA to the primary amine. 
4.2.4 Particle characterization 
Transmission electron microscopy (TEM). TEM was completed using a JEOL 2010F system 
operating at 200 KeV. Iron oxide nanoparticles were diluted to 200 µg/mL Fe in DI water and then 
dried on carbon TEM grids prior to analysis.    
Ultraviolet (UV)-Visible spectroscopy. The stability of the nanoparticles was analyzed using a 
CaryWin 50 probe UV-visible spectrophotometer. IONPs were diluted to 200 µg/mL Fe in PBS or 
DMEM with 10% FBS. Sample absorbance was read at 540 nm over 12 hours.  
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Thermogravimetric analysis (TGA).  TGA was used to quantify the mass percent of the iron oxide 
core in the particle systems using a Netzsch Instruments STA 449A system. Approximately 5 mg 
of particle sample was heated at a rate of 5 °/minute. At 100 °C, the sample was held isothermally 
for 20 minutes to vaporize residual water.  The samples were heated at 5 °/minute until reaching 
500 °C where they were held isothermally for an additional 20 minutes. The reported mass loss 
reported was the actual mass loss normalized to the initial sample mass after isothermal heating at 
100 °C.  
Dynamic light scattering (DLS).  DLS measurements were obtained using a Beckman Coulter Delsa 
Nano C particle analyzer.  Nanoparticle solutions were diluted to 200 µg/mL and were sonicated 
in a water bath prior to size analysis.   
Alternating magnetic field (AMF) heating.  The nanoparticle heating profiles were obtained using 
a custom made Taylor Winfield magnetic induction source, and the temperature was measured with 
a fiber optic temperature sensor (Luxtron FOT Lab Kit from LumaSense).  Nanoparticle 
suspensions were diluted in DI water to a concentration of 5 mg/ml iron oxide.  One milliliter of 
suspension in a 2 ml microcentrifuge tube was placed in the center of the AMF induction coil.  The 
suspension was heated at a field amplitude of 58 kA/m and frequency of 292 kHz until the 
temperature of the suspension reached steady-state. The specific absorption rate (SAR) values of 
the nanoparticle suspensions were then calculated using the following equation:  
 
𝑆𝐴𝑅 =  
𝐶𝑝,𝐹𝑒𝑚𝐹𝑒+ 𝐶𝑝,𝐻2𝑂𝑚𝐻2𝑂
𝑚𝐹𝑒
 𝑑𝑇
𝑑𝑡
        [4.1] 
 
where Cp,Fe is the heat capacity of iron, mFe the mass of iron, Cp,H2O the heat capacity of water, mH2O 
the mass of water, and dT/dt the initial slope of the heating profile.  
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4.2.5 Cytotoxicity analysis of particle systems 
A549 lung carcinoma cells obtained from ATCC were cultured from passages 5 - 10 in DMEM 
supplemented with 10% FBS, 10 μg/ml Fungizone®, 2 μg/ml penicillin-streptomycin, and 4mM 
L-glutamine. Cells were seeded into 96-well plates at 4,000 cells/well and incubated for 24 hours.  
The cells were then exposed to nanoparticles in complete cell media at concentrations of 50, 100, 
350, and 500 µg Fe/ml.  Cytotoxicity was determined using a calcein red fluorescent stain (1 µM, 
λex=540nm and λem=590nm) after 24 and 48 hours. Cell viability was analyzed using a Biotek 
SynergyMx microplate reader and the fluorescence of the cells exposed to the nanoparticle 
solutions was normalized to the fluorescence of the control cells.  
4.2.6 CREKA and CREKA IONP binding affinity to fibrinogen clots 
To synthesize fibrinogen clots, 75 µL of fibrinogen solution (2 mg/mL) in 0.9% NaCl was added 
to a 96-well plate. 30 µL of a 2.5 U/mL thrombin solution in 0.9% NaCl was subsequently added 
to the same 96-well plates. The plates were placed in an incubator shaker at 37°C for 5 minutes, 
and then gels were formed after four hours incubation at 37°C. Binding affinity of fluorescently 
labeled CREKA conjugated IONPs (CREKA-IONP) was compared to the binding affinity of 
unconjugated CREKA (CREKA only) and FITC conjugated iron oxide nanoparticles without 
CREKA (FITC-IONP).  CREKA-IONP and FITC-IONP systems were diluted by taking 5, 10, 25, 
and 50 µL of nanoparticle solution and diluting to a total volume of 50 µL with DI water. The exact 
nanoparticle concentration was not necessary as taking the fluorescence ratio of the bound to free 
particles was determined at the same concentration. CREKA was diluted to 50, 100, 250 and 500 
µM. 50 µL of solution (particle or CREKA only) was added to each clot. After one hour, half of 
the samples were washed twice with 120 µL of DI water to remove any CREKA or IONPs not 
bound to the fibrinogen clots, and the fluorescence of the plate was read on the microplate reader 
(λex=488 nm and λem=520 nm). The bound CREKA or FITC fluorescence (washed gels) was 
normalized to the corresponding free (unwashed gels) solution for each sample.  
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4.2.7 In vitro magnetically mediated hyperthermia and cisplatin combined treatment 
One mL of A549 lung carcinoma cells (passage 15) was suspended in complete cell culture media 
in a 1.5 ml microcentrifuge tube at a concentration of 300,000 cells. The vials were then centrifuged 
at 800 x g for 5 minutes to pellet the cells. The media supernatant was removed and the cells were 
resuspended in 1 mL of the respective treatment solutions. The six treatments are outlined in Table 
4.3. Cisplatin treatments were administered at 100 µM, IONP were administered at a concentration 
of 3 mg/mL, and hyperthermia was induced by the presence of an alternating magnetic field (51-
58 kA/m). Treatments lasted 30 minutes, and all controls were also exposed to experimental 
conditions (i.e. room temperature) for 30 minutes. After treatment, the vials were centrifuged at 
800 x g for 5 minutes, the treatment solution was removed, and replaced with fresh media. A second 
centrifugation cycle was completed to further wash the cells of the treatment solutions. The treated 
cells were then seeded into 48-well plates at 30,000 cells/mL (250 µL/well). The viability of the 
cells was analyzed 48 and 72 hours post-treatment using a calcein AM assay (2 µM, λex=494 nm 
and λem=517 nm) analyzed by a microplate reader. The fluorescence of the cells exposed to the 
various treatments was normalized to the fluorescence of the control cells at each time point. 
Additional analyses were completed to determine the type of effect MMH and cisplatin had on 
A549 cells after 72 hours using the following equations (Babincova, Altanerova et al. 2008): 
synergistic, [MMH + CDDP] < [MMH] x [CDDP]/100; additive, [MMH + CDDP] = [MMH] x 
[CDDP]/100; sub-additive, [MMH] x [CDDP]/100 < [MMH + CDDP] < [MMH]; if [MMH] < 
[CDDP]; interference, [MMH] < [MMH + CDDP] < [CDDP], if [MMH] < [CDDP]; and 
antagonistic, [CDDP] < [MMH + CDDP], if [MMH] < [CDDP], where [MMH] represents the cell 
viability percentage exposed to magnetically mediated hyperthermia alone, [CDDP] represents the 
cell viability percentage exposed to cisplatin alone, and [MMH+CDDP] represents the cell viability 
percentage exposed to combined magnetically mediated hyperthermia and cisplatin. 
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4.2.8 Statistical analysis 
Statistical analysis was completed using Daniel’s XL Toolbox in Microsoft Excel. A 1-way 
ANOVA test was used to determine the statistical differences of the cytotoxicity analysis and 
magnetically mediated hyperthermia study. A Student’s t-test was used to determine the statistical 
differences of the fibrinogen binding study.  
4.3 Results and Discussion 
4.3.1 Particle characterization 
The iron oxide nanoparticles exhibited diameters of 5 – 13 nm as shown by the TEM images 
in Figure 4.2. The clustering of the iron oxide suggests that multiple cores are encapsulated by the 
dextran coating for each nanoparticle. Due to the low density (i.e., low contrast) of the dextran 
coating, no differences were observed between the TEM images of the Fe3O4+Dx and Fe3O4+Dx-
ECH nanoparticles. As seen in Table 4.1, size analysis indicated that the number average hydrated 
diameters of the nanoparticle systems were approximately 52 nm. All polydispersity indexes were 
below 0.2 indicating uniform nanoparticle sizes.  
 
Figure 4.2 TEM images of (a) dextran coated iron oxide nanoparticles (Fe3O4+Dx) and (b) dextran-
epichlorohydrin crosslinked iron oxide nanoparticles (Fe3O4+Dx-ECH).  
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Table 4.1 Nanoparticle systems synthesized and characterized, their size as analyzed via DLS, and 
SAR values from AMF heating. Size of Fe3O4+Dx-ECH-Amine-CREKA via DLS could not be 
completed due to the fluorescent tag but minimal difference from the other systems is expected.  
 
 
 
 
Particles of this size have been shown to extravasate into tumor tissue and have been used in 
passive tumor targeting by taking advantage of the leaky vasculature of the tumor and the enhanced 
permeation and retention effect (Fox, Szoka et al. 2009, Phillips, Gran et al. 2010).  
Ensuring the stability of nanoparticles in various types of solutions over time is very important, 
especially for the systemic delivery of therapeutics. Particle-particle interactions can induce 
aggregation and particle settling which can adversely affect the properties of the nanoparticles, such 
as heating capabilities and tumor targeting. Particle aggregates greater than 200 nm not only settle 
out of solution, but also attract opsonin proteins in vivo which label the particles for removal 
through the mononuclear phagocyte system (MPS)/reticuloendothelial system (RES) (Fox, Szoka 
et al. 2009).  Using UV-visible spectroscopy, it was shown that the nanoparticles were stable in 
both PBS and DMEM supplemented with 10% v/v FBS for each stage of particle synthesis over a 
time period of 12 hours (Figure 4.3), with the normalized absorbance indicating minimal to no 
particle settling in solution. Overall, these results indicate the high stability of the evaluated particle 
systems in multiple solutions. 
Nanoparticle System Size (nm) SAR (W/g) 
Fe3O4+Dx 52 ± 16 81 ± 19 
Fe3O4+Dx-ECH 56 ± 11 98 ± 16 
Fe3O4+Dx-ECH-Amine 52 ± 8 89 ± 9 
Fe3O4+Dx-ECH-Amine-CREKA --- 66 ± 18 
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Figure 4.3 Normalized absorbance (at 540 nm) of the iron oxide nanoparticle systems in (a) PBS 
and (b) DMEM with 10% v/v FBS over 12 hours using UV-visible spectroscopy. 
Thermogravimetric analysis was used to confirm the presence of the dextran coating on the 
iron oxide nanoparticles. This showed that the coating accounted for 59 - 64% of the nanoparticle 
mass prior to CREKA conjugation. The coating weight percentage was calculated by subtracting 
the final mass fraction from the initial normalized mass. As depicted in Figure 4.4, crosslinking of 
the dextran coating with ECH was confirmed by the shift of the mass loss profile to the right where 
an increase in the temperature at which the greatest mass loss occurred shifted from 285 °C 
(Fe3O4+Dx) to 306 °C, (Fe3O4+Dx-ECH and Fe3O4+Dx-ECH-Amine), indicating a greater thermal 
stability of the coating. The observed single drop in particle mass with increasing temperature 
confirms a single dextran layer on the surface of the particles, as this abrupt change in weight has 
been previously associated with a monolayer of dextran (Bautista, Bomati-Miguel et al. 2005) . 
The dextran coating of the final CREKA-IONP only accounted for 30% of the nanoparticle mass 
due to the dissolution of free dextran and AMAS linker in DMSO during the final CREKA 
conjugation process. Dextran has a very high affinity for DMSO resulting in any free or weakly 
bound dextran solubilizing in the DMSO and being washed from the nanoparticle system during 
the washing process. As indicated by UV-visible spectroscopy, the CREKA-IONP remained stable 
in PBS and DMEM indicating that dextran was still present on the surface of the particles. 
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Figure 4.4 Normalized mass loss of each nanoparticle system in the synthesis process via TGA. 
4.3.2 Remote controlled heating of iron oxide magnetic nanoparticles via AMF 
In the presence of an AMF (58 kA/m, 292 kHz), the iron oxide nanoparticle systems (5 mg/mL 
Fe3O4) heated the bulk solution into or above the hyperthermia range (41 - 45 °C) as seen in Figure 
4.5. Fe3O4+Dx, Fe3O4+Dx-ECH, and Fe3O4+Dx-ECH-Amine particles heated to 41 °C within 300 
seconds. The final CREKA-IONP system took longer to reach the hyperthermia range and heated 
to a lower final temperature than the other systems. The iron concentration of the nanoparticles was 
determined using an iron assay prior to dilution for heating in the AMF except for the CREKA-
IONP system. The exact iron concentration of the CREKA-IONP could not be determined due to 
low volume of particles so the initial iron concentration used in the synthesis of the CREKA-IONP 
was used. Therefore, if any iron oxide nanoparticles were lost in the ultracentrifugation washing 
steps post CREKA conjugation, the actual iron concentration of the AMF heating samples would 
be lower than calculated, accounting for the lower final temperature and decreased initial slope of 
the heating profile. The SAR values are reported in Table 4.1 and indicate the energy being 
produced per gram of iron oxide. The lower SAR value for the CREKA-IONP is rationalized by 
the previous explanation of the concentration discrepancy. The AMF amplitude and frequency 
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correspond to a field frequency product of 1.7 x 1010A/(m·s) which is significantly greater than the 
often quoted limit for use in humans (Atkinson, Brezovich et al. 1984). The high field frequency 
product may be an issue for future use in humans, but, the cited value is only an estimation.  There 
is a need for further studies to determine the effects of alternating magnetic fields on healthy tissues 
in order to more accurately determine the limitations of AMF exposure (Kozissnik, Bohorquez et 
al. 2013).  
 
Figure 4.5 Heating profiles of each nanoparticle system in the synthesis process (5 mg/mL Fe3O4) 
in the presence of an alternating magnetic field at 58 kA/m and 292 kHz (n = 3). The gray box 
indicates the target hyperthermia range.    
4.3.3 Cytotoxicity analysis of particles 
The cytotoxicity of the particles produced in each step in the particle synthesis was evaluated 
using A549 lung carcinoma cells. A549 cells were exposed to low doses of iron oxide nanoparticles 
for 24 and 48 hours, and the viability of the cells was analyzed using a calcein AM stain. As 
depicted in Figure 4.6, the particles exhibited no toxicity (at least 100% viability) after 24 hours. 
Dextran is a hydrophilic, water-soluble polymer which is inert in biological systems, therefore 
decreasing protein adsorption to the nanoparticle surface which would lead to toxicity (Imren, 
Gumusderelioglu et al. 2006). After 48 hours, the particles were still mostly non-toxic at these 
concentrations, but there was a significant difference between the control and the CREKA-IONP 
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at 100, 350, and 500 µg Fe/mL as determined via a 1-way ANOVA test. However, the viability of 
the A549 cells after exposure to these concentrations for 48 hours is still above 80%, indicating 
that the particles are minimally toxic even though the difference from the control is significant.  
 
Figure 4.6 Normalized viability of each nanoparticle system in the synthesis process on A549 lung 
cancer cells after (a) 24 hours of exposure and (b) 48 hours of exposure.  Error bars represent 
standard error (n = 4) and * indicates a significant difference (p < 0.05) using a 1-way ANOVA 
test. 
4.3.4 Fibrinogen binding affinity 
CREKA-IONPs were shown to bind to fibrin clots with a significantly greater bound-to-free 
fluorescence ratio than fluorescently tagged iron oxide nanoparticles (FITC-IONP) (Table 4.2). The 
bound-to-free fluorescence ratios of free CREKA and CREKA-IONPs were not significantly 
different, indicating that conjugation to the nanoparticle surface does not inhibit the binding 
properties of CREKA. The sulfhydryl group on the cysteine of CREKA is not required for binding 
to fibrinogen clots. Therefore, conjugation to the nanoparticle surface through a Michael addition 
reaction with an AMAS linker does not influence the fibrinogen binding properties of CREKA. 
These results indicate that CREKA can be functionalized to the IONP in order to localize the 
nanoparticles at the tumor site through binding with fibrinogen complexes in the extracellular 
matrix. CREKA-IONPs do not bind to specific integrins on the cell surface providing the 
opportunity to target a wider range of cancers. Additionally, CREKA-IONPs have resulted in 
amplified homing by inducing localized tumor clotting in vivo (Simberg, Duza et al. 2007). These 
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clots then attract more CREKA-IONPs, and the cycle continues. This amplified homing of CREKA 
to the fibrin complexes within the tumor make it attractive for localizing high concentrations of 
IONPs at the tumor site for magnetically mediated hyperthermia.  
Table 4.2 Bound-to-free fluorescence for each system to fibrin clots represented by average ± 
standard error (n = 4). The * indicates a significant difference from the FITC-IONP bound-to-free 
fluorescence ratio (p<0.05). 
System Bound-to-free fluorescence 
CREKA only 0.69* ± 0.03 
CREKA-IONP 0.62* ± 0.03 
FITC-IONP 0.42 ± 0.04 
 
4.3.5 Magnetically-mediated hyperthermia 
The heating properties of the magnetic iron oxide nanoparticles were utilized to induce in vitro 
hyperthermia conditions on A549 lung carcinoma, and the effects of combined MMH and cisplatin 
treatments were evaluated since MMH is known to increase cisplatin efficacy at elevated 
temperatures (Lee, Rodriguez-Luccioni et al. 2011, Alvarez-Berrios, Castillo et al. 2013). Five 
treatments plus a control were evaluated as seen in Table 4.3 and cell viability 48 and 72 hours 
post-treatment was determined to allow time for cellular response to the treatments. After 48 hours 
(Figure 4.7), there was no significant difference between MMH treatment alone and combined 
cisplatin and MMH treatment (CDDP+MMH). However, at this time point there was also no 
difference between the viability of cells exposed to cisplatin and the control, indicating that the 
cells had not responded to the cisplatin treatment. As seen in Figure 4.8, after 72 hours there was a 
significant difference (p < 0.01) between the viability of cells exposed to MMH treatment alone 
and combined cisplatin and MMH treatment (CDDP+MMH). At this time point, the cells had 
responded to the cisplatin treatment, as shown by the significantly decreased viability of cells 
exposed to cisplatin compared to the control. Additionally, cell morphology dramatically changed 
when the cells were treated with cisplatin combined with MMH compared to either treatment alone. 
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Images in Figures 4.7 and 4.8, show the cell with blebs, or localized decoupling of the cytoskeleton 
from the cell membrane, which is an indicator of apoptosis, or programmed cell death (Charras, 
Coughlin et al. 2008). Therefore, cisplatin combined with MMH had a significantly greater effect 
on cell viability than either treatment alone. 
Table 4.3 Magnetically mediated hyperthermia treatments and controls. 
Treatment Description 
Control Media only 
IONP 3 mg/mL Fe3O4 (Fe3O4+Dx-ECH) 
MMH 3 mg/mL Fe3O4 plus 30 minutes AMF exposure 
CDDP 100 µM cisplatin 
CDDP+IONP 100 µM cisplatin plus 3 mg/mL Fe3O4 
CDDP+MMH 100 µM cisplatin plus 3 mg/mL Fe3O4 and 30 minutes AMF exposure 
 
The type of effect induced by the combined MMH and CDDP treatment was analyzed using 
the equations outlined in section 4.2.7. Seventy-two hours after treatment, the percent viability of 
the combined treatment was 23.7 ± 2.9 and [MMH] x [CDDP]/100 equaled 26.2 ± 2.1, where the 
error represents standard error (n = 12). Therefore, the combined treatment of hyperthermia and 
cisplatin was determined to be additive since these values are not significantly different, as 
indicated by a Student’s t-test. This analysis was not completed on the 48 hour post-treatment data 
due to the cell viability of cisplatin only treatment not being different from the control.  
There are several theories as to how the effects of cisplatin are enhanced by hyperthermia. 
Cisplatin operates by binding to DNA forming inter- or intra-strand crosslinks and interfering with 
the transcription DNA for protein synthesis, therefore preventing cell division and ultimately 
leading to cell death (Butour, Alvinerie et al. 1991).  In vitro studies have shown that hyperthermia 
increases the intracellular concentration of cisplatin (Ohno, Siddik et al. 1994, Takahashi, Emi et 
al. 2002) due to increased permeability of the cell membrane (Alvarez-Berrios, Castillo et al. 2013). 
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Therefore, the number of DNA-cisplatin crosslinks is also increased (Meyn, Corry et al. 1980). 
Additionally, inhibition of cellular resistance to cisplatin has been observed when combined with 
hyperthermia (Hettinga, Lemstra et al. 1997). In vivo, hyperthermia results in increased blood flow 
and vascular permeability allowing for greater drug uptake and improved oxygenation of the tumor 
tissue (Issels 2008). Hyperthermia has been shown to promote cell death by increasing the fluidity 
of membranes causing adverse intracellular and surface events, inactivating microtubule processes 
and by enhancing cellular antigen expression or antigen antibody complexation (Hetzel and Dunn 
1984). The efficacy of hyperthermia alone is not enough to replace any of the current chemotherapy 
standards, but its effects are sufficient to enhance the toxic effects of many chemotherapeutics. 
Therefore, by combining magnetically mediated hyperthermia and cisplatin, the effective dosage 
of cisplatin can be decreased, and thereby potentially decreasing the toxic side effects of the 
chemotherapeutic.  
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Figure 4.7 Relative viability of A549 lung cancer cells 48 hours post magnetically mediated 
hyperthermia treatment. Error bars represent standard error (n = 12) and ** indicates a significant 
difference (p < 0.01).  Representative images of A549 cells stained with calcein AM after 48 hours 
for: (a) Control, (b) IONP, (c)MMH, (d) CDDP, (e) CDDP+IONP, and (f) CDDP+MMH.   
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Figure 4.8 Relative viability of A549 lung cancer cells 72 hours post magnetically mediated 
hyperthermia treatment. Error bars represent standard error with n = 12 and ** indicates a 
significant difference (p < 0.01).  Representative images of A549 cells stained with calcein AM 
after 72 hours for: (a) Control, (b) IONP, (c) MMH, (d) CDDP, (e) CDDP+IONP, and (f) 
CDDP+MMH.   
4.4 Conclusion 
CREKA-conjugated dextran coated iron oxide nanoparticles were successfully developed and 
characterized for their use in targeted hyperthermia applications. The nanoparticles have properties 
suitable for systemic tumor targeting through the enhanced permeation and retention effect such as 
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stability in cell culture media and a size of approximately 50 nm (Fox, Szoka et al. 2009, Phillips, 
Gran et al. 2010). In the presence of an alternating magnetic field, the particles generated sufficient 
heat to increase the bulk solution temperature into the hyperthermia range. CREKA-conjugated 
nanoparticles were shown to bind to fibrinogen clots with a higher affinity than FITC-conjugated 
iron oxide nanoparticles, suggesting that the nanoparticles can be effective at targeting fibrinogen 
overexpressed in tumor tissues. The binding affinity of CREKA was not inhibited by conjugation 
to the iron oxide nanoparticles as shown by similar bound-to-free ratios of fluorescence. Low 
concentrations of the nanoparticle systems were non-toxic over long periods of time, indicating that 
the particles can be used for biological applications. When magnetically mediated hyperthermia 
was administered in conjunction with cisplatin, an enhanced cytotoxic effect was observed 
compared to cisplatin or hyperthermia alone. This peptide-conjugated nanoparticle system can be 
further studied to assess its ability to localize at tumor sites at sufficient concentrations to induce 
hyperthermia conditions upon exposure to an external alternating magnetic field.   
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Chapter 5 The effects of synthesis method on the physical and chemical properties of 
dextran coated iron oxide nanoparticles 
 
The heating properties of the dextran-coated iron oxide nanoparticles synthesized in Chapter 4 were 
inferior compared to other nanoparticle systems synthesized by the co-precipitation method. This 
was thought to be due to dextran increasing the solution viscosity and preventing crystal growth 
after nucleation. Therefore, the goal of this chapter was to analyze how the timing of dextran 
addition into the co-precipitation reaction affected the physicochemical properties of the 
nanoparticles. The chapter is taken directly or adapted from work published in Hauser, Mathias, 
et al. (2015) Copyright 2015 Elsevier B.V. Used with permissions from Anastasia K. Hauser, 
Ronita Mathias, Kimberly W. Anderson and J. Zach Hilt, “The effects of synthesis method on the 
physical and chemical properties of dextran coated iron oxide nanoparticles”, Materials Chemistry 
and Physics and Elsevier B.V. 
5.0 Abstract 
 
Iron oxide nanoparticles coated with dextran were synthesized via four variations on the co-
precipitation method. The methods ranged from in situ formation of the nanoparticles within the 
dextran solution to the adsorption of dextran to the nanoparticle surface following nucleation and 
extensive washing. The timing of the addition of dextran into the reaction mixture was found to 
greatly influence the physical and chemical properties of the magnetic nanoparticles. Batches of 
dextran coated iron oxide nanoparticles were synthesized by each method in triplicate, and the 
nanoparticles were further crosslinked with epichlorohydrin. The properties of the nanoparticles 
such as size, percentage of dextran coating, stability in solution, crystallinity, and magnetic 
properties were evaluated. The simultaneous semi-two-step method injected the reducing agent and 
the dextran solution into the reaction vessel at the same time.  This method resulted in the greatest 
batch-to-batch reproducibility of nanoparticle properties and the least variation in nanoparticles 
synthesized in the same batch. The two-step method resulted in the greatest variation of the 
characteristics examined between batches. The one-step method was used with both five grams and 
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one gram of dextran to investigate the effects of solution viscosity on the resulting nanoparticle 
characteristics. The one-step method with five grams of dextran resulted in nanoparticles with 
significantly smaller crystal sizes (5.4 ± 1.9 nm) and lower specific adsorption rate (SAR) values 
(138.4 ± 13.6 W/g) in an alternating magnetic field (58 kA/m, 292 kHz). However, this method 
resulted in nanoparticles that were very stable in PBS over 12 hours, which is most likely due to 
the greater dextran coating (60.0 ± 2.7 weight percent). For comparison, the simultaneous semi-
two-step method generated nanoparticles 179.2 ± 18.3 nm in diameter (crystal size 12.1 ± 0.2 nm) 
containing 18.3 ± 1.2 weight percent dextran with a SAR value of 321.1 ± 137.3 W/g.  
5.1 Introduction 
Nanoparticle research has been driven by the need for new technological applications in data 
storage, biomedical sciences, drug delivery, and therapeutics. Iron oxide nanoparticles represent a 
class of materials with such applications and are very promising due to their potential 
biocompatibility and magnetic properties which can be used for magnetic resonance imaging, 
magnetically mediated hyperthermia, etc. (Andrade, Souza et al. 2010, Frimpong and Hilt 2010). 
The magnetic differences of iron oxide nanoparticles compared to the bulk material are a 
consequence of inter and intra particle interactions. Additionally, when the iron oxide nanoparticles 
are of a single domain, they exhibit superparamagnetism by which they do not retain magnetization 
in the absence of an externally applied magnetic field (Yoffe, Leshuk et al. 2013).  
While the increased surface-to-volume ratio is an attractive property of superparamagnetic iron 
oxide nanoparticles, it also leads to considerable difficulty as a result of the  tendency of 
nanoparticles to aggregate to reduce their surface energy by forming strong magnetic dipole 
interactions between the particles (Easo and Mohanan 2013).  Monodispersed particles with high 
magnetic saturation are required for many biological applications, so it is often of interest to 
functionalize the nanoparticles with a coating layer to prevent agglomeration (Mahmoudi, Simchi 
et al. 2009). The coating layer can also be designed to increase the circulation time and the 
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biocompatibility of the nanoparticles for use as MRI contrast agents and magnetically mediated 
hyperthermia (Laurent, Dutz et al. 2011, Saraswathy, Nazeer et al. 2014). Dextran is a 
biocompatible long chain hydrophilic polymer composed of glucose with mostly α-1, 6 glycoside 
linkages (Sreeja and Joy 2011) that strongly physisorb to magnetite nanoparticles in alkaline 
solutions via non-covalent interactions of the abundant hydroxyl groups resulting in enmeshed 
nanoparticle cores (Yoffe, Leshuk et al. 2013).  The hydroxyl groups of dextran can then be easily 
crosslinked and functionalized with primary amines to attach various targeting ligands, peptides, 
or probes (Simberg, Duza et al. 2007, Park, Von Malzahn et al. 2008, Ayala, Herrera et al. 2013, 
Kruse, Meenach et al. 2014). Functionalization with primary amines throughout the nanosctructure 
allows for increased loading capacity and the potential for attachment of multiple targeting ligands, 
imaging agents or therapeutics into one system (Tassa, Shaw et al. 2011).  
Iron oxide nanoparticles can be synthesized by various methods including co-precipitation 
(Massart 1981, Kang, Risbud et al. 1996, Frimpong, Dou et al. 2010), microemulsion (Lee, Lee et 
al. 2005), thermal decomposition (Park, An et al. 2004, Sun, Zeng et al. 2004, Lee, Woo et al. 2008, 
Buyukhatipoglu and Clyne 2010, Sharapova, Uimin et al. 2010, Ayala, Herrera et al. 2013), and 
mechanical synthesis (Janot and Guerard 2002, Arbain, Othman et al. 2011). The co-precipitation 
method has traditionally been the most common method and is the primary method by which 
clinically approved iron oxide nanoparticles are synthesized (Qiao, Yang et al. 2009). Co-
precipitation requires the reaction to be performed in an inert atmosphere to prevent oxidation of 
the Fe2+ ions and oxidation of magnetite nanoparticles to maghemite. The surface of magnetite 
nanoparticles will oxidize to maghemite in the presence of oxygen which reduces the magnetic 
saturation of the material (Gupta and Gupta 2005). The process of co-precipitation involves initial 
nucleation followed by slow growth as the solutes diffuse to the surface of the crystal (Easo and 
Mohanan 2013). Within the co-precipitation method, there are various procedures that alter 
parameters of the reaction in order to tune the properties of the iron oxide nanoparticles produced. 
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Variables such as pH, temperature, reaction time, and iron ion ratios have been examined to 
determine their effects on the size, stability, and heating properties of the nanoparticles. Vayssieres 
et al. (Vayssieres, Chaneac et al. 1998) varied the pH of the reaction solution between 8.5 and 12 
and found that the resulting iron oxide nanoparticles became smaller as the solution increased in 
alkalinity. It was also determined that a minimum pH of 10-11 is required for the nanoparticle size 
to remain stable over time. Murbe et al. (Murbe, Rechtenbach et al. 2008) addressed the effect of 
reaction temperature on the physical and chemical properties of iron oxide nanoparticles showing 
that as the temperature at which initial nucleation occurred increased from 25 to 70°C, the 
nanoparticle size also increased from 16 to 39 nm. Additionally, the magnetic saturation of the 
nanoparticles increased from 76 to 88 emu/g. Frimpong et al. (Frimpong, Dou et al. 2010) 
addressed the effects of reaction temperature and staged reactions on the magnetic properties of 
citrate capped iron oxide nanoparticles, and they also found that as temperature increased, the 
nanoparticle crystal size also increased. The saturation magnetization was also influenced by the 
reaction temperature and method as the one-step method resulted in nanoparticles with a lower 
magnetic saturation value and decreased heating capabilities than the two-step reactions. A 
significant amount of research has been completed on dextran coated iron oxide nanoparticles, 
specifically on varying the molecular weight of the dextran. Xu et al. (Xu, Shen et al. 2005) formed 
iron oxide nanoparticles in the presence of dextran with a molecular weight of 20 or 40 kDa. The 
40 kDa dextran resulted in a viscous reaction solution, so the 20 kDa dextran coated nanoparticles 
were preferred. However, the magnetic saturation of the nanoparticles was lower than expected due 
to significant agglomeration of the nanoparticles and a wide range of hydrodynamic radii. Although 
the effects of reaction temperature, time, pH, and dextran molecular weight have been analyzed, 
the time and method of dextran addition into the reaction solution have not yet been evaluated. 
Therefore, this chapter sought to determine the effects of the timely addition of dextran to the 
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reaction mixture on the physical and chemical properties of the dextran coated iron oxide 
nanoparticles.  
It is important to understand the effects of dextran on the properties of iron oxide nanoparticles 
in order to develop a synthesis protocol that results in consistent and desirable physicochemical 
properties. As depicted in Figure 5.1, four co-precipitation methods were developed to synthesize 
dextran coated iron oxide nanoparticles that were further crosslinked with epichlorohydrin to 
increase the thermodynamic stability of the dextran on the surface of the nanoparticles (Palmacci 
and Josephson 1993).  The methods varied by the time of dextran addition to the reaction mixture: 
from in situ formation of the iron oxide nanoparticles to formation followed by extensive washing 
prior to dextran adsorption. Three batches of nanoparticles were synthesized via each method in 
order to address the variability within a single method as well as the differences between the 
methods. All other parameters such as pH, reaction temperature, and dextran molecular weight 
were kept constant among the methods. After synthesis, both the dextran coated and 
epichlorohydrin crosslinked nanoparticles were characterized for size, dextran weight percent, 
stability, crystallinity, and heating ability in the presence of an alternating magnetic field. Each of 
these properties is important to evaluate prior to in vivo studies should the nanoparticles be used 
for biological applications. It is also important to develop protocols for iron oxide nanoparticle 
synthesis that result in consistent properties of the nanoparticles such as desired size, stability in 
solution, crystallinity to allow for heating in an AMF as well as image contrast, and dextran coating 
to increase circulation and biocompatibility. This article addresses the development of a synthesis 
method that results in consistent and desirable properties of iron oxide nanoparticles.  
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Figure 5.1 Schematic of iron oxide nanoparticle synthesis methods. The co-precipitation reaction 
for each of the methods is completed at 85 °C for one hour after the addition of the reducing agent 
(ammonium hydroxide). 
5.2 Materials and Methods 
5.2.1 Materials 
Iron (III) chloride hexahydrate (FeCl3·6H2O), iron (II) chloride (FeCl2·4H2O), 9 – 11 kDa dextran, 
epichlorohydrin (ECH) were obtained from Sigma Aldrich (St. Louis, MO). Ammonium hydroxide 
(NH4OH) was purchased from EMD Chemicals (Gibbstown, NJ). Phosphate buffered saline 
solution (PBS) (10X) was purchased from EMD Millipore (Billerica, MA). All materials were used 
as received. 
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5.2.2 Dextran coated iron oxide nanoparticle synthesis via two-step method  
 
A modified one-pot co-precipitation method (Frimpong, Dou et al. 2010) was used to prepare 
dextran coated IONPs. FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams 
and 0.8 grams, respectively) and dissolved in 40 mL deionized (DI) water and sealed in a three-
neck flask under vigorous stirring and an inert nitrogen environment. 5 grams of dextran was 
solubilized in 20 mL of DI water.  The solution was heated to 85 °C at which 5 mL of NH4OH was 
added dropwise to the reaction vessel. The reaction was carried out for 1 hour at 85 °C.  The 
particles were magnetically decanted and washed three times with DI water. The nanoparticles were 
then re-suspended in 45 mL DI water and added to a three next flask. The dextran solution was 
added to the reaction vessel and the vessel was purged with nitrogen. The nanoparticles and dextran 
solution were stirred vigorously at room temperature for 24 hours. After 24 hours, the nanoparticles 
were magnetically decanted and washed three times with DI water. Finally, the nanoparticles were 
dialyzed against DI water for 24 hours (100 kDa molecular weight cutoff) then probe sonicated for 
10 minutes and centrifuged at 1000 rpm for 5 minutes to remove large agglomerates.  
5.2.3 Dextran coated iron oxide nanoparticle synthesis via semi-two-step method  
 
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams, 
respectively) and dissolved in 40 mL deionized (DI) water and sealed in a three-neck flask under 
vigorous stirring and an inert nitrogen environment. 5 grams of dextran was solubilized in 20 mL 
of DI water.  The solution was heated to 85 °C at which 5 ml of NH4OH was added dropwise to the 
reaction vessel. The dextran solution was then injected dropwise into the vessel. The reaction was 
carried out for 1 hour at 85 °C.  The particles were magnetically decanted and washed three times 
with DI water. The nanoparticles were then re-suspended in DI water and dialyzed against DI water 
for 24 hours (100 kDa molecular weight cutoff). After dialysis, the nanoparticles were probe 
sonicated for 10 minutes and then centrifuged at 1000 rpm for 5 minutes to remove large 
agglomerates.  
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5.2.4 Dextran coated iron oxide nanoparticle synthesis via simultaneous semi-two-step method  
 
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams, 
respectively) and dissolved in 40 mL deionized (DI) water and sealed in a three-neck flask under 
vigorous stirring and an inert nitrogen environment. 5 grams of dextran was solubilized in 20 mL 
of DI water.  The reaction solution was heated to 85 °C at which 5 ml of NH4OH was added to the 
dextran solution and the combined solution was injected dropwise into the vessel. The reaction was 
carried out for 1 hour at 85 °C.  The particles were magnetically decanted and washed three times 
with DI water. The nanoparticles were then re-suspended in DI water and dialyzed against DI water 
for 24 hours (100 kDa molecular weight cutoff). After dialysis, the nanoparticles were probe 
sonicated for 10 minutes and then centrifuged at 1000 rpm for 5 minutes to remove large 
agglomerates.  
5.2.5 Dextran coated iron oxide nanoparticle synthesis via one-step method  
 
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams, 
respectively) and dissolved in 40 mL deionized (DI) water and sealed in a three-neck flask under 
vigorous stirring and an inert nitrogen environment. Five grams of dextran or one gram of dextran 
was solubilized in 20 mL of DI water and added to the three-neck flask.  The solution was heated 
to 85 °C at which 5 ml of NH4OH was injected dropwise into the vessel. The reaction was carried 
out for 1 hour at 85 °C.  The particles were magnetically decanted and washed three times with DI 
water and then dialyzed against DI water for 24 hours (100 kDa molecular weight cutoff).  After 
dialysis, the nanoparticles were probe sonicated for 10 minutes and then centrifuged at 1000 rpm 
for 5 minutes to remove large agglomerates.  
5.2.6 Epichlorohydrin crosslinking of dextran coated iron oxide nanoparticles 
 
Dextran coated IONPs were crosslinked using ECH for increased stability (Palmacci and Josephson 
1993). The particle colloid (9 mL, 1 mmol Fe) was added to 9 mL 5M NaOH and 1.5 mL ECH. 
The reaction was carried out for 24 hours at room temperature under continuous agitation. The 
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particles were then magnetically decanted and dialyzed against DI water (100 kDa molecular 
weight cutoff) for 24 hours to remove excess ECH. 
5.2.7 Particle characterization 
 
Dynamic light scattering (DLS).  DLS measurements were obtained using a Beckman Coulter Delsa 
Nano C particle analyzer.  Nanoparticle solutions were diluted to 200 µg/mL and were sonicated 
in a water bath prior to size analysis.   
Ultraviolet (UV)-Visible spectroscopy. The stability of the nanoparticles was analyzed using a 
CaryWin 50 probe UV-visible spectrophotometer. IONPs were diluted to 200 µg/mL Fe in PBS. 
Sample absorbance was read at 540 nm over 12 hours.  
Fourier transform infrared (FTIR) spectra. Attenuated total reflectance FTIR (ATR-FTIR) was 
used to determine surface functionalization with a Varian Inc. 7000e spectrometer. Dried samples 
were placed on the diamond ATR crystal and the spectrum was obtained between 700 and 4000 
cm−1 for 32 scans. 
Thermogravimetric analysis (TGA).  TGA was used to quantify the mass percent of the iron oxide 
core in the particle systems using a Netzsch Instruments STA 449A system. Approximately 5 mg 
of particle sample was heated at a rate of 5 °/minute. At 100 °C, the sample was held isothermally 
for 20 minutes to vaporize residual water.  The samples were heated at 5 °/minute until reaching 
500 °C where they were held isothermally for an additional 20 minutes. The reported mass loss 
was the actual mass loss normalized to the initial sample mass after isothermal heating at 100 °C.  
Transmission electron microscopy (TEM). TEM was completed using a JEOL 2010F system 
operating at 200 keV. IONPs were diluted to 1 mg/ml Fe in DI water and then dried on carbon 
TEM grids prior to analysis. 
X-ray diffraction (XRD). XRD patters were obtained by a Siemens D-500 X-ray  spectrometer with 
a CuKα radiation source (λ = 1.54 Ǻ) at 40 kV and 30 mA scanning from 5° to 65° at a scan rate 
of 1° per minute. The XRD patterns were used to confirm the magnetite crystal structure of the iron 
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oxide nanoparticles. The XRD patterns are in coherence with JCPDS card (19-0629). The crystal 
domain size was estimated using the Scherrer equation [5.1]  
                                                                      𝜏 =
𝐾𝜆
𝛽𝑐𝑜𝑠𝛩
                                                                                    [5.1] 
where τ is the mean size of the ordered (crystalline) domains K is a dimensionless shape factor with 
a value close to unity(0.8396 for iron oxide)  λ is the X-ray wavelength, β is the line broadening at 
half the maximum intensity (FWHM) after subtracting the instrumental line broadening, in radians 
and θ is the Bragg angle (17.72 °). 
Alternating magnetic field (AMF) heating.  The nanoparticle heating profiles were obtained using 
a custom made Taylor Winfield magnetic induction source, and the temperature was measured with 
a fiber optic temperature sensor (Luxtron FOT Lab Kit from LumaSense).  Nanoparticle 
suspensions were diluted in DI water to a concentration of 3 mg/ml iron oxide.  One milliliter of 
suspension in a 2 ml microcentrifuge tube was placed in the center of the AMF induction coil.  The 
suspension was heated at a field amplitude of 58 kA/m and frequency of 292 kHz until the 
temperature of the suspension reached steady-state. The specific absorption rate (SAR) values of 
the nanoparticle suspensions were then calculated using the following equation:  
𝑆𝐴𝑅 =  
𝐶𝑝,𝐹𝑒𝑚𝐹𝑒+ 𝐶𝑝,𝐻2𝑂𝑚𝐻2𝑂
𝑚𝐹𝑒
 𝑑𝑇
𝑑𝑡
                    [5.2] 
where Cp,Fe is the heat capacity of iron, mFe is the mass of iron, Cp,H2O is the heat capacity of water, 
mH2O is the mass of water, and dT/dt is the initial slope of the heating profile. The intrinsic loss 
power (ILP) of the nanoparticle systems was calculated using the following equation: 
𝐼𝐿𝑃 =
𝑆𝐴𝑅
𝐻2𝑓
                                                                       [5.3] 
where H is the magnetic field strength and f is the field frequency. This value will allow for the 
heating properties of these systems to be compared more accurately to other systems in literature.  
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5.3 Results and Discussion 
The hydrodynamic diameter of the nanoparticles was analyzed via dynamic light scattering and 
reported as the z-average while the variability of particle size within the batches was quantified by 
the polydispersity index (PDI) in Table 5.1. The two-step method resulted in particles with the 
largest hydrodynamic diameter along with the greatest deviation between batches. The PDI of the 
nanoparticles synthesized by the two-step method was also the largest of the methods tested. After 
crosslinking with epichlorohydrin, the hydrodynamic diameter of the nanoparticles decreased 
significantly. This is likely due to the extra processing during crosslinking resulting in the loss of 
larger nanoparticle agglomerates. The one-step method with five grams of dextran resulted in the 
smallest nanoparticles most likely due to the high viscosity of the solution during nucleation 
inhibiting the transport of the iron ions to the nanoparticle surface. The high viscosity solution helps 
to prevent agglomeration of the nanoparticles but their formation is hindered due to transport 
limitations during the nucleation process. Although the one-step nanoparticles were smaller in 
hydrodynamic diameter which is advantageous for tumor targeting, their other properties such as 
heating abilities suffered from the high viscosity solution. The one-step method with one gram of 
dextran resulted in larger nanoparticles than the one-step method with five grams of dextran. 
Additionally, there was greater variability in the nanoparticle sizes between the batches. The 
simultaneous semi-two-step method resulted in nanoparticles with the most consistent sizes within 
a single batch as indicated by the low PDI after crosslinking, as well as the greatest batch to batch 
reproducibility as indicated by the lowest standard deviation. The batch-to-batch reproducibility is 
thought to be due to the simultaneous semi-two-step method being the easiest method to control 
since it involves a single injection of the ammonium hydroxide in a solution of dextran. The 
viscosity of the solution is also that of water when initial nucleation occurs allowing for iron ions 
to transport to the nucleation sites more effectively. Previous studies by Xu, et al. (Xu, Shen et al. 
2005) found that lower molecular weight dextran (20kDa vs. 40kDa) was advantageous due to 
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lower solution viscosity leading to more optimal nanoparticle characteristics. It is also important to 
note that low molecular weight dextran can precipitate acute renal failure so it is important to coat 
the nanoparticles with enough dextran to increase cytocompatibility and stability but not so much 
that excess dextran is administered (Feest 1976). In another study by Saraswathy et al. 70kDa 
dextran was used to coat iron oxide nanoparticles resulting in a 50 nm diameter and 12 nm core 
size. The high molecular weight dextran was offset by a using a low weight percentage dextran 
(3%) in water (Saraswathy, Nazeer et al. 2014). By using a high molecular weight dextran, the 
potential to cause osmotic nephropathy is decreased, but the amount of dextran coating the 
nanoparticle surface decreases, which could impact nanoparticle stability.  
 
Table 5.1 Size analysis via dynamic light scattering of iron oxide nanoparticles synthesized by the 
various methods represented by average ± standard deviation (three independent batches and three 
samples from each batch). 
Method Nanoparticle Size (nm) PDI 
two-step 
Fe3O4+Dx 382.4 ± 163.2 0.35 ± 0.14 
Fe3O4+Dx-ECH 237.8 ± 28.8 0.16 ± 0.02 
semi-two-step 
Fe3O4+Dx 233.9 ± 25.2 0.19 ± 0.03 
Fe3O4+Dx-ECH 244.1 ± 54.7 0.20 ± 0.08 
simultaneous semi-two-step 
Fe3O4+Dx 179.2 ± 18.3 0.18 ± 0.02 
Fe3O4+Dx-ECH 185.6 ± 23.8 0.02 ± 0.03 
one-step (5 grams Dx) 
Fe3O4+Dx 171.4 ± 30.9 0.22 ± 0.09 
Fe3O4+Dx-ECH 121.7 ± 24.7 0.14 ± 0.02 
one-step (1 gram Dx) 
Fe3O4+Dx 248.0 ± 69.0 0.20 ± 0.05 
Fe3O4+Dx-ECH 244.2 ± 34.4 0.16 ± 0.05 
 
Different synthesis methods also have an effect on dextran adsorbed to the surface of the iron 
oxide nanoparticles. The presence of dextran on the surface of the iron oxide nanoparticles was 
confirmed via FTIR spectroscopy (Figure 5.2). The synthesis methods resulted in similar spectra 
with all spectra containing a broad peak between 3500-3200 cm-1 indicating the structural O-H in 
the dextran chains. The peak associated with the asymmetrical stretching vibration of C-H in CH2 
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is found at 2918 cm-1. Peaks at 1450, 1350, and 1273 cm-1 can be assigned to the deformation 
vibration of H-C-OH of the dextran chains.  Finally, the asymmetrical and symmetrical vibrations 
of C-O-C can be found at 1157 and 849 cm-1, respectively.   
Quantification of the dextran coating was completed using thermogravimetric analysis (TGA) 
as shown in Table 5.2. The one-step method with 5 grams of dextran resulted in the greatest dextran 
adsorption to the nanoparticle surface with approximately 60% of the nanoparticle weight being 
composed of dextran. On the contrary, the one-step method with one gram of dextran resulted in 
the least dextran adsorption and no significant change after crosslinking with epichlorohydrin as 
depicted in Figure 5.3e. The two-step method and the semi-two-step method resulted in the most 
variability between batches in the amount of dextran coating. In the semi-two-step method, this is 
most likely due to the multiple injections of ammonium hydroxide and dextran and slight variability 
in timing. Again, the simultaneous semi-two-step resulted in the most consistent dextran 
adsorption. All of the weight loss profiles displayed a single drop in mass as temperature increased 
indicating a single layer of dextran or crosslinked dextran on the nanoparticle surface (Figure 5.3). 
Additionally, after crosslinking, the mass due to the coating decreased or remained the same most 
likely due to further dialysis after crosslinking. The right shift in the temperature at which the 
greatest mass loss occurs confirmed that dextran had been crosslinked as more energy was required 
to break the covalent bonds prior to degrading the coating.  
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Figure 5.2 FTIR spectra of dextran coated iron oxide nanoparticles synthesized by the various 
methods. 
 
Table 5.2 Dextran weight percentage via thermogravimetric analysis of iron oxide nanoparticles 
synthesized by the various methods (n=3). 
Synthesis Method Nanoparticle Coating Weight%  
two-step 
Fe3O4+Dx 23.7 ± 7.8 
Fe3O4+Dx-ECH 19.0 ± 11.3 
semi-two-step 
Fe3O4+Dx 29.3 ± 6.1 
Fe3O4+Dx-ECH 16.7 ± 9.8 
simultaneous semi-two-step 
Fe3O4+Dx 18.3 ± 1.2 
Fe3O4+Dx-ECH 15.7 ± 5.0 
one-step (5 grams Dx) 
Fe3O4+Dx 60.0 ± 2.7 
Fe3O4+Dx-ECH 58.0 ± 7.2 
one-step (1 gram Dx) 
Fe3O4+Dx 12.7 ± 1.7 
Fe3O4+Dx-ECH 13.0 ± 1.7 
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Figure 5.3 Mass loss and d%/dT with increasing temperature of dextran coated and epichlorohydrin 
crosslinked iron oxide nanoparticles synthesized via the (a) two-step method, (b) semi-two-step 
method, (c) simultaneous semi-two-step method, (d) one-step method with 5 grams dextran, and 
(e) one-step method with 1 gram dextran. 
 
Stability of the nanoparticles in solution is very important if the nanoparticles are to be used 
for biological applications as agglomeration could lead to blockage of the circulatory system or 
lack of targeting ability to the tissue of interest. Therefore, the stability of the nanoparticles in 
phosphate buffered saline was analyzed over a 12 hour time period for both the dextran coated and 
crosslinked systems synthesized by each of the methods (Figure 5.4). Dextran coated iron oxide 
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nanoparticles synthesized by the one-step method with 5 grams of dextran were the most stable 
both before and after epichlorohydrin crosslinking. This is due to the steric interactions of dextran 
with the surrounding medium. Since nanoparticles produced by the one-step with 5 grams of 
dextran had the greatest amount of dextran on the surface, it is expected that these nanoparticles 
would also be the most stable. However, the two-step, semi-two-step, and the simultaneous semi-
two-step methods, resulted in relatively stable nanoparticles in PBS after crosslinking.  
 
Figure 5.4 Stability of dextran coated and epichlorohydrin crosslinked iron oxide nanoparticles 
synthesized via the (a) two-step method, (b) semi-two-step method, (c) simultaneous semi-two-step 
method, (d) one-step method with 5 grams dextran, and (e) one-step method with 1 gram dextran 
in PBS over 12 hours analyzed by UV-visible spectroscopy (λ=540). 
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The XRD patterns (Figure 5.5) of the iron oxide nanoparticles synthesized by each method are 
in coherence with JCPDS card (19-0629) associated with magnetite. The sharp peaks indicate a 
highly crystalline structure has been formed by each method. The broad peak at approximately 2Θ 
equal to 17° is due to the presence of dextran which is confirmed by the XRD pattern of dextran 
only (Figure 5.5f). This peak has the greatest intensity in the one-step method with five grams of 
dextran which also has the greatest weight percent of dextran. Slight shoulders are seen in the XRD 
patters of the other synthesis methods confirming the presence of dextran, but the lower intensity 
matches the data obtained via thermogravimetric analysis. The highest intensity peak at 2Θ equal 
to 35.44° corresponds to the (3 1 1) plane of the iron oxide crystal structure. This peak was used to 
calculate the crystal size of the nanoparticles using the Scherrer equation and these crystal sizes 
correspond well with the crystal sizes shown in TEM (Figure 5.6). Table 5.3 displays the calculated 
crystal sizes from XRD spectra and the Scherrer equation along with the crystal sizes from TEM 
while Figure 5.5 depicts the XRD patterns. All the crystal sizes of the iron oxide nanoparticles 
synthesized were much smaller than the reported hydrodynamic diameter. This is due to multiple 
crystals being encapsulated within the dextran coating.  The crystal size of the nanoparticles 
synthesized via the one-step method with 5 grams of dextran was significantly smaller than the 
crystal sizes of the nanoparticles synthesized by the other methods as shown by both XRD (Figure 
5.5d) and TEM (Figure 5.6d). This is thought to be due to the concentrated dextran during 
nucleation. TEM images show the crystal size of nanoparticles synthesized via the two-step and 
semi-two step were larger than the other methods, which is due to dextran addition taking place 
post nucleation. Previous work has shown that crystal growth is retarded by the chemisorption of 
poly(vinyl alcohol) to the surface of the particles when synthesized by a one-step method 
(Mahmoudi, Simchi et al. 2009). Work completed by Pardoe et al. (Pardoe, Chua-anusorn et al. 
2001) has shown that iron oxide nanoparticles coated with dextran are significantly smaller than 
the control uncoated nanoparticles. Additionally, the polymer chosen to coat the nanoparticles 
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influences the crystal size of the particles. For example, nanoparticles coated with PVA resulted in 
larger crystals than dextran coated particles but both were smaller than uncoated nanoparticles 
(Pardoe, Chua-anusorn et al. 2001). A similar effect was observed by Bee et al. (Bee, Massart et 
al. 1995) in which iron oxide nanoparticle formation was prevented by either chelation of citrate 
ions with metal ions and therefore  preventing nucleation or by adsorption of the citrate ions on the 
nuclei inhibiting growth of the nuclei.  Without a high dextran concentration and therefore a lower 
viscosity reaction solution, the iron oxide crystals had diameters closer to the other synthesis 
methods. Once again, the two step method resulted in the most variability in crystal size while the 
simultaneous semi-two-step was the most consistent.  
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Figure 5.5 XRD patters of dextran coated iron oxide nanoparticles synthesized via the (a) two-step 
method, (b) semi-two-step method, (c) simultaneous semi-two-step method, (d) one-step method 
with 5 grams dextran, (e) one-step method with 1 gram dextran and (f) dextran only. 
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Table 5.3 Iron oxide crystal size estimated using XRD spectra and the Scherrer equation and TEM 
images of iron oxide nanoparticles synthesized by the various methods (mean ± st. dev. n=3 for 
XRD and n=150 for TEM). 
Synthesis Method XRD Size (nm) TEM Size (nm) 
two-step 10.0 ± 2.1 14.5 ± 4.2 
semi-two-step  11.2 ± 1.0 14.7 ± 4.6  
simultaneous semi-two-step 12.1 ± 0.2 8.9 ± 2.2  
one-step (5 grams Dx) 5.4 ± 1.9 6.8 ± 1.4 
one-step (1 gram Dx) 12.4 ± 1.3 10.1 ± 3.1 
 
 
Figure 5.6 TEM images of dextran coated iron oxide nanoparticles synthesized via the (a) two-step 
method, (b) semi-two-step method, (c) simultaneous semi-two-step method, (d) one-step method 
with 5 grams dextran, and (e) one-step method with 1 gram dextran. 
The crystalline structure of iron oxide nanoparticles enables heating in the presence of an 
alternating magnetic field via multiple possible loss mechanisms including Néel paramagnetic 
switching, friction losses from Brownian rotation, and hysteresis (Dennis, Jackson et al. 2009). 
Table 5.4 summarizes the specific absorption rates of the nanoparticles in the presence of an AMF 
(58 kA/m, 292 kHz) and the corresponding intrinsic loss power (ILP). The one-step method with 
five grams of dextran resulted in nanoparticles with the lowest SAR values which are again due to 
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dextran chemisorption to the surface of the nanoparticles after nucleation (Sreeja and Joy 2011). 
Nanoparticles produced by other methods had greater SAR values as well as increased variability. 
The increased SAR value is thought to be due to nanoparticle agglomeration which would allow 
for ferromagnetic contributions resulting in increased heating. The excess dextran coating on the 
one-step method with 5 grams of dextran could also form a “dead layer” which would reduce the 
total effective moment of the nanoparticles (Kodama 1999, Pardoe, Chua-anusorn et al. 2001). 
Daou et al. (Daou, Greneche et al. 2008) established a similar effect by synthesizing magnetite 
nanoparticles and showing that carboxylate coupling to the nanoparticle surface could induce spin 
canting at the surface and reduce the saturation magnetization of the nanoparticles. Additionally, 
this effect has been observed with citrate capped magnetite nanoparticles synthesized via the co-
precipitation method in a one or two-step procedure (Frimpong, Dou et al. 2010). The decrease in 
SAR value after crosslinking with epichlorohydrin is most likely an artifact of the nanoparticles 
becoming more stable in solution and the additional probe sonication after dialysis. The 
nanoparticles are not significantly agglomerating and therefore heating via ferromagnetic 
contributions in addition to Neel paramagnetic switching and Brownian rotation. The ILP of these 
systems ranged from 0.16 to 0.39 nHm2/kg with the one-step (5 grams Dx) being the lowest and 
the semi-two-step being the highest, but with the most variability. Kallamadil et al. compared the 
ILP of commercial ferrofluids of various hydrodynamic sizes and found that for hydrodynamic 
diameters ranging from 100 to 170 nm and crystal sizes of approximately 7 nm, the ILP varied 
between 0.15 and 0.35 nHm2/kg (Kallumadil, Tada et al. 2009). Therefore, these systems have 
heating properties comparable to those commercially available even though the alternating 
magnetic field strength may be slightly higher than others have used (Hergt, Hiergeist et al. 2004, 
Fortin, Wilhelm et al. 2007).  
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Table 5.4 Specific absorption rates (W/g) of iron oxide nanoparticles (3 mg/mL Fe3O4) heating in 
an alternating magnetic field (58 kA/m, 292 kHz) of iron oxide nanoparticles synthesized by the 
various methods (n=3). 
Method Nanoparticle SAR (W/g) ILP (nHm2/kg) 
two-step 
Fe3O4+Dx 323.6 ± 134.1 0.33 ± 0.14 
Fe3O4+Dx-ECH 297.6 ± 102.5 0.30 ± 0.10 
semi-two-step 
Fe3O4+Dx 384.3 ± 37.6 0.39 ± 0.04 
Fe3O4+Dx-ECH 313.4 ± 50.9 0.21 ± 0.05 
simultaneous semi-two-step 
Fe3O4+Dx 321.1 ± 137.3 0.33 ± 0.14 
Fe3O4+Dx-ECH 211.0 ± 46.6 0.21 ± 0.05 
one-step (5 grams Dx) 
Fe3O4+Dx 138.4 ± 13.6 0.14 ± 0.01 
Fe3O4+Dx-ECH 158.2 ± 51.1 0.16 ± 0.05 
one-step (1 gram Dx) 
Fe3O4+Dx 313.9 ± 42.1 0.32 ± 0.04 
Fe3O4+Dx-ECH 228.3 ± 32.4 0.23 ± 0.03 
 
5.4 Conclusions 
Overall, the simultaneous semi-two-step method of synthesizing dextran coated iron oxide 
nanoparticles was the most consistent method and had the greatest batch-to-batch reproducibility. 
The nanoparticles synthesized by this method were stable in PBS for 12 hours, had hydrodynamic 
diameters less than 200 nm, generated sufficient heat in the presence of an AMF, and exhibited 
crystallinity consistent with magnetite. All of these properties can be tuned to varying degrees by 
simply altering the timing of dextran addition to the reaction. The amount of dextran also alters the 
properties of the nanoparticles. The one-step reaction was completed with both one and five grams 
of dextran to evaluate these effects. It was found that the nanoparticles synthesized with five grams 
of dextran are more stable, adsorb a greater amount of dextran on their surfaces, and have smaller 
hydrated diameters than the nanoparticles synthesized with one gram of dextran. However, the poor 
heating properties and small crystal sizes suggested that the one-step method with 5 grams of 
dextran may not be the preferred method for synthesizing the nanoparticles.  
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The one-step method with 1 gram of dextran yielded nanoparticles with improved heating 
properties and larger crystal sizes but larger and more inconsistent hydrolyzed diameters and 
decreased stability.  The semi-two step and two-step methods resulted in nanoparticles with 
inconsistent physicochemical properties batch-to-batch. The heating properties were improved 
compared to the one-step with 5 grams dextran, but the size was larger with greater polydispersity 
indices.  Also, the stability in PBS was decreased. Therefore, the method by which the dextran 
coated iron oxide nanoparticles are synthesized greatly affects the physical and chemical properties 
of the nanoparticles and thus, it is critical that the co-precipitation method for the preparation of 
magnetic nanoparticles is carefully developed and controlled to get desired properties for specific 
applications.  
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Chapter 6 Peptide conjugated magnetic nanoparticles for magnetically mediated energy 
delivery  
 
Limitations of magnetically mediated hyperthermia have led to increased interest in magnetically 
mediated energy delivery which does not rely on a bulk temperature increase for therapy, but rather 
on magnetic nanoparticles internalized within cells exerting nanoscale heating or rotational forces 
intracellularly. The goal of this chapter was to synthesize magnetic nanoparticles functionalized 
with a cell penetrating peptide and analyze the cellular effects upon internalization and activation 
via an alternating magnetic field. The chapter is taken directly or adapted from work recently 
submitted to Future Nanomedicine. Used with permissions from Anastasia K. Hauser, Kimberly 
W. Anderson and J. Zach Hilt, “Peptide conjugated magnetic nanoparticles for magnetically 
mediated energy delivery.” 
6.0 Abstract 
Iron oxide nanoparticles have been extensively studied for magnetically mediated 
hyperthermia applications, although one of the main limitations of this therapy is the high 
nanoparticle concentration required to increase the tumor tissue temperature into the hyperthermia 
range (42-45 °C). Therefore, it has been suggested that magnetically mediated energy delivery 
(MagMED), or the use of magnetic nanoparticles to locally convert alternating magnetic field 
(AMF) energy into other forms of energy (e.g., heat and rotational work) is a potential alternative 
strategy. MagMED relies on internalized magnetic nanoparticles and does not require a bulk 
temperature rise to induce cellular effects. Here, dextran-coated iron oxide nanoparticles 
functionalized with a cell penetrating peptide (TAT peptide) were synthesized. Uptake of the 
nanoparticle systems into A549 and H358 lung carcinoma was evaluated along with the 
intracellular effects of MagMED on the two cell lines such as reactive oxygen species (ROS) 
generation, lysosomal permeability, mitochondrial membrane depolarization, and initiation of 
Caspase 3/7 apoptotic pathways. Long term cell viability was also analyzed following MagMED 
treatment. In both A549 and H358 cells, the novel TAT functionalized nanoparticles and AMF 
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exposure increased ROS generation compared to the nanoparticle system alone. The TAT 
functionalized nanoparticles also induced lysosomal membrane permeability and mitochondrial 
membrane depolarization, but these effects were cell line dependent and were not further enhanced 
by AMF treatment. Although not statistically significant, there are trends suggesting an increase in 
apoptosis via the Caspase 3/7 pathways when cells are exposed to TAT functionalized nanoparticles 
combined with AMF, and although intracellular effects of MagMED treatment were observed, 
there was no statistical decrease in cell viability 48 hours following treatment.  
6.1 Introduction 
Iron oxide nanoparticles have been studied for a wide variety of biological applications 
including magnetic resonance imaging (MRI), cell separation techniques, drug delivery, 
mangetically mediated hyperthermia (MMH), and in the treatment of anemia (Dennis, Jackson et 
al. 2009, Hu, Ma et al. 2011, Laurent, Dutz et al. 2011, McCormack 2012, Plouffe, Murthy et al. 
2015). In magnetically mediated hyperthermia, iron oxide nanoparticles convert energy from an 
alternating magnetic field (AMF) to heat via Neél relaxation and Brownian rotation (Dennis, 
Jackson et al. 2009). MMH targets a bulk temperature rise between 42-45 °C which can lead to 
adverse cellular effects, and although MMH has been extensively studied, its translation into the 
clinic has been limited. MMH studies completed in vitro utilize high nanoparticle concentrations 
to achieve hyperthermia conditions in monolayer cells or cell suspensions (Laurent, Dutz et al. 
2011, Rodriguez-Luccioni, Latorre-Esteves et al. 2011, Wydra, Kruse et al. 2013, Kruse, Meenach 
et al. 2014) and most in vivo experiments directly inject nanoparticles into tumors (usually 
subcutaneous) due to the need for high local concentrations to generate a bulk temperature rise (Hu, 
Ma et al. 2011, Wang, Dong et al. 2012). Since direct injection is not suitable for many tumors and 
metastases, there is a gap between bench scale MMH studies and clinical relevance. 
Instead of relying on a bulk temperature rise to induce hyperthermia conditions, it was 
suggested by Gordon, et al.  in 1979 that intracellular hyperthermia would be more advantageous 
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due to insulation by the cell membrane and lack of convection from blood flow which dissipates 
heat away from the tumor tissue. This is especially problematic in small metastatic tumors (Gordon, 
Hines et al. 1979). Nanoscale heating effects of the nanoparticles have the ability to induce cellular 
toxicities as shown by Creixell et al.  in 2011, where internalized iron oxide nanoparticles in the 
presence of an AMF induced a significant decrease in cell viability without a measureable 
temperature rise (Creixell, Bohorquez et al. 2011). Therefore, the phrase magnetically mediated 
energy delivery (MagMED) was coined to describe the conversion of magnetic field energy to other 
forms such as heat or rotation work but without significantly increasing the bulk temperature 
(Kozissnik, Bohorquez et al. 2013).  
Although there is a growing body of evidence suggesting that local heating and energy delivery 
can be used to kill cancer cells, theoretical calculations by Rabin et al.  indicate that the heat 
dissipation from the nanoparticle surface through conduction is greater than the heat being 
generated by the nanoparticles (Rabin 2002). These theoretical calculations were disputed when 
Huang, et al.  utilized iron oxide nanoparticles targeted to proteins on the membrane of cells 
expressing TRPV1 to locally deliver heat and open cation channels (Huang, Delikanli et al. 2010). 
Nanoparticle heating at the surface was confirmed using a tethered thermoresponsive fluorophore 
which fluoresced almost immediately upon AMF exposure.  
In addition to the effects of surface heating of magnetic nanoparticles in an AMF, rotational 
work has also been studied as an explanation to the experimental effects of MagMED. For example, 
mechanical forces have been used to induce lysosomal permeabilization (Sanchez, Diab et al. 2014, 
Connord, Clerc et al. 2015), leading to the release of proteolytic enzymes such as cathepsins which 
initiate apoptotic pathways (Linder, Erdal et al. 2005, Kirkegaard and Jaattela 2009, Johansson, 
Appelqvist et al. 2010). This technique has also been shown to stimulate apoptosis in apoptosis-
resistant cell lines (Jaattela 2004). Zhang, et al.  developed a dynamic magnetic field generator to 
induce nanoparticle rotations about their axis to examine whether physical nanoparticle rotations 
 
104 
 
can disrupt lysosomal membranes and induce apoptosis (Zhang, Kircher et al. 2014). By 
functionalizing the nanoparticles with antibodies for the lysosomal protein marker, it was found 
that the shear forces generated by oscillating torques were enough to damage the lysosomal 
membranes, proving that Brownian rotation of magnetic nanoparticles also plays an important role 
in MagMED treatment. 
In addition to the thermal and mechanical effects described above, the production of reactive 
oxygen species (ROS) via iron oxide nanoparticles is a potential chemical effect of MagMED. Iron 
oxide nanoparticles catalyze the Haber-Weiss reaction which makes use of Fenton chemistry, and 
this reaction is considered a major mechanism by which the highly reactive hydroxyl radical is 
generated in biological systems (Kehrer 2000). The Fenton chemistry reaction set is shown as 
Equation 6.1 and the Haber-Weiss reaction (net reaction) is shown as Equation 6.2.  
Fe3+ + O2· - → Fe2+ + O2 
Fe2+ +H2O2 → Fe3+ + OH- + OH·                                           [6.1] 
   O2· - + H2O2 → O2 + OH- + OH·                                                [6.2] 
When iron oxide nanoparticles enter a cell, they can stimulate the generation of ROS via one of 
two pathways: (1) the release of ions into the cytosol resulting in the iron ions participating in the 
Haber-Weiss cycle or (2) the surface of the nanoparticle may act as a catalyst for the Haber-Weiss 
cycle and the Fenton Reaction (Klein, Sommer et al. 2012). Although this reaction can proceed 
without the addition of an AMF, recent work by Wydra, et al.  demonstrated that the reaction is 
further catalyzed by iron oxide nanoparticles in the presence of an AMF (Wydra, Oliver et al. 2015). 
In order to increase intracellular concentrations of iron oxide nanoparticles and therefore 
increase the efficacy of MagMED, magnetic nanoparticles can be functionalized with ligands, 
peptides, or antibodies, in order to target and penetrate into the cells. Here, the TAT peptide 
(sequence: YGRKKRRQRRR) was of particular interest due to its cell penetrating properties and 
associated ability to avoid receptor mediated endocytosis, as well as its nuclear localizing signal. 
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The TAT peptide contains a characteristic lysine-arginine sequence, and biomolecules with this tag 
are known to bind to importin α and β in the cytoplasm which facilitate active transportation to the 
nuclear pore complex (NPC) and, if attached to a small enough molecule or particle, through the 
NPC into the nucleus (Austin, Kang et al. 2011). The positive charge of the NLS peptide also 
destabilizes the endosome/lysosome membrane leading to nanoparticle and proteolytic enzyme 
escape from the vesicles, which plays a role in apoptosis initiation. Previous work by Pan et al.  in 
2012 showed that functionalization of doxorubicin (DOX) loaded silica nanoparticles with the TAT 
peptide facilitated DOX accumulation within the nuclear membrane (Pan, He et al. 2012). Another 
study by Austin et al.  proved that TAT-functionalized silver nanospheres were up taken in to HSC-
3 cancer cells at significantly greater concentrations than PEG functionalized nanospheres (Austin, 
Kang et al. 2011). Several studies have utilized the TAT peptide as a cell internalization mechanism 
(Josephson, Tung et al. 1999, Lewin, Carlesso et al. 2000, Rao, Reddy et al. 2008, Torchilin 2008, 
Wang, Qiao et al. 2012) as well as a nuclear targeting moiety (Vives, Brodin et al. 1997, de la 
Fuente and Berry 2005, Oyelere, Chen et al. 2007, Xu, Xie et al. 2008, Yang, Neshatian et al. 2014). 
Due to the size of the iron oxide nanoparticles being larger than the upper limit of the nuclear pore 
complex (20―70 nm), it was of interest to use the TAT peptide to escape endosome/lysosomes 
and facilitate interaction with other organelles such as the mitochondria (Pan, He et al. 2012).  
In this study, dextran coated iron oxide nanoparticles were functionalized with a cell penerating 
peptide, TAT, and characterized for their physical and chemical properties. Uptake studies into 
A549 and H358 non-small cell lung carcinoma cells indicated that attachment of the TAT peptide 
to iron oxide nanoparticles significanly increased cell internalization of the nanoparticles. The 
effects of internalized iron oxide nanoparticles in combination with AMF exposure on A549 and 
H358 cells were evaluated. Although A549 and H358 are both non-small cell lung carcinoma cells, 
this treatment is applicable to a wide variety of cancers, and these cells lines were chosen to assess 
cell line variability of the treatment. Intracellular generation of ROS, lysosomal membrane 
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permeability, mitochondrial membrane depolarization, and apoptosis via the Caspase 3/7 pathway 
were all evaluated. Finally, cell viability was analyzed to determine the toxicity effects of the 
treatment. Figure 6.1 depicts the three main mechanisms by which MagMED can affect cells. After 
internalization of the TAT conjugated iron oxide nanoparticles, the lysosomal/endosomal 
membranes are permeabilized and facilitate nanoparticle escape into the cytosol.  Upon actuation 
by an AMF, nanoparticles dissipate energy through Neel relaxations, frictional energy via 
Brownian rotation, and catalyze ROS generation. All three of these mechanisms can play a role in 
the efficacy of MagMED.  
 
Figure 6.1 TAT-conjugated iron oxide nanoparticles are internalized by cancer cells and 
permeabilize endosomal/lysosomal membranes due to the positive charge of the peptide. Upon 
exposure to an AMF, the nanoparticles generate the hydroxyl radical via Fenton chemistry, friction 
from Brownian rotaion and nanoscale heat effects by Neél relaxation. 
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6.2 Materials and Methods 
6.2.1 Materials 
Iron (III) chloride hexahydrate (FeCl3·6H2O), iron (II) chloride (FeCl2·4H2O), 9 – 11 kDa dextran, 
epichlorohydrin (ECH) were obtained from Sigma Aldrich (St. Louis, MO). Ammonium hydroxide 
(NH4OH) was purchased from EMD Chemicals (Gibbstown, NJ). Phosphate buffered saline 
solution (PBS) (10X) was purchased from EMD Millipore (Billerica, MA). The activation buffer 
2-[N-morpholino] ethane sulfonic acid (MES), N-hydroxysulfosuccinimide (sulfo-NHS) and 1-
ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) were purchased from 
Thermo scientific (Rockford, IL). The TAT peptide was purchased from Biomatik. Phosphate 
buffered saline (PBS), Dulbecco’s Modified Eagle Medium (DMEM), pen-strep, L-glutamine, 
Fungizone®, sodium pyruvate, CellEvent Caspase 3/7 Assay, JC-1, and calcein AM were obtained 
from Invitrogen (Frederick, MD).  Acridine orange was purchased from Nexcelom Bioscience 
(Lawrence, MA) and A549 lung carcinoma and trypsin were purchased from American Type 
Culture Collection (ATCC, Manassas, VA). All materials were used as received. 
6.2.2 Synthesis of uncoated iron oxide nanoparticles  
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams, 
respectively) and dissolved in 60 mL deionized (DI) water and sealed in a three-neck flask under 
vigorous stirring and an inert nitrogen environment. The reaction solution was heated to 85 °C at 
which 5 ml of NH4OH was diluted to 40 mL with DI water and the combined solution was injected 
dropwise into the vessel. The reaction was carried out for 1 hour at 85 °C.  The particles were 
magnetically decanted and washed three times with DI water. The nanoparticles were then re-
suspended in DI water and dialyzed against DI water for 24 hours (100 kDa molecular weight 
cutoff). After dialysis, the nanoparticles were probe sonicated for 10 minutes and then centrifuged 
at 1000 rpm for 5 minutes to remove large agglomerates.  
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6.2.3 Synthesis of dextran coated iron oxide nanoparticles (Fe3O4 + Dx) 
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams, 
respectively) and dissolved in 40 mL deionized (DI) water and sealed in a three-neck flask under 
vigorous stirring and an inert nitrogen environment. 5 grams of dextran was solubilized in 20 mL 
of DI water.  The reaction solution was heated to 85 °C at which 5 ml of NH4OH was added to the 
dextran solution and the combined solution was injected dropwise into the vessel. The reaction was 
carried out for 1 hour at 85 °C.  The particles were magnetically decanted and washed three times 
with DI water. The nanoparticles were then re-suspended in DI water and dialyzed against DI water 
for 24 hours (100 kDa molecular weight cutoff). After dialysis, the nanoparticles were probe 
sonicated for 10 minutes and then centrifuged at 1000 rpm for 5 minutes to remove large 
agglomerates.  
6.2.4 Epichlorohydrin (ECH) crosslinking of dextran coated iron oxide nanoparticles (Fe3O4 + 
Dx-ECH) 
Dextran coated iron oxide nanoparticles were crosslinked using ECH for increased stability 
(Palmacci and Josephson 1993). The particle colloid (9 mL, 1 mmol Fe) was added to 9 mL 5M 
NaOH and 1.5 mL ECH. The reaction was carried out for 24 hours at room temperature under 
continuous agitation. The particles were then magnetically decanted and dialyzed against DI water 
(100 kDa molecular weight cutoff) for 24 hours to remove excess ECH. 
6.2.5 Amine functionalization of crosslinked dextran coated iron oxide nanoparticles (Fe3O4 + 
Dx-ECH-Amine) 
An equal volume of ammonium hydroxide to mmol iron from Fe3O4 + Dx-ECH were combined 
and placed on the shaker table for 24 hours. After 24 hours, the nanoparticles were dialyzed against 
DI H2O for an additional 24 hours, with their water changed 3 times during this time period.  
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6.2.6 TAT peptide conjugation to iron oxide nanoparticles (Fe3O4 + TAT) 
10 mg of the TAT-peptide was dissolved in 10 mL MES buffer (2-[N-morpholino] ethane sulfonic 
acid) and 4 mg EDC and 11 mg sulfo-NHS were also added to the solution. After 15 minutes of 
continuous agitation, 14 µL of 2- mercaptoethanol was added to the reaction in order to quench 
excess EDC. Amine-functionalized iron oxide nanoparticles were diluted to 1 mg Fe3O4/mL with 
PBS. The iron oxide suspension was added to the TAT-peptide solution and reacted over night 
under continuous agitation. After the TAT-iron oxide nanoparticles reaction was complete, the 
particles were washed with PBS via magnetic decanting until the washing solution was clear. This 
protocol was adapted from Pan, et al.  (Pan, He et al. 2012).  
6.2.7 Iron concentration assay  
Between each step of synthesizing a new system of iron oxide nanoparticles, an iron assay was 
used to determine the iron concentration of the nanoparticles. 20x, 50x, and 100x dilutions of the 
iron oxide nanoparticles were made in DI water and 10 µL of each dilution was added to 10 µL 6M 
HCl and allowed to sit for 3 hours. After this time, 500 µL of 1M acetic acid, 100 µL of 
hydroxylamine hydrochloride, 100 µL of 1, 10 phenanthroline, and 280 µL of DI water were added 
to each dilution. Solutions were left overnight. After 24 hours, the absorbance of each solution (λ 
= 511 nm) was used to calculate the iron concentration based on a standard curve.  
6.2.8 Iron oxide nanoparticle characterization 
Dynamic light scattering (DLS).  DLS measurements were obtained using a Beckman Coulter Delsa 
Nano C particle analyzer Nanoparticle solutions were diluted to 200 µg/mL in DI water or cell 
culture media and were sonicated in a water bath for five minutes prior to size analysis. The reported 
nanoparticle sizes in cell culture media were recorded 10 minutes after bath sonication.   
Zeta Potential. Zeta potential measurements were obtained using a Beckman Coulter Delsa Nano 
C particle analyzer. Nanoparticle solutions were diluted to 200 µg/mL in 2mM NaCl and were 
sonicated in a water bath prior to analysis. 
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X-ray Diffraction (XRD). XRD patters were obtained by a Siemens D-500 X-ray  spectrometer with 
a CuKα radiation source (λ = 1.54 Ǻ) at 40 kV and 30 mA scanning from 5° to 65° at a scan rate 
of 1° per minute. The XRD patterns were used to confirm the magnetite crystal structure of the iron 
oxide nanoparticles. The XRD patterns are in coherence with JDPCS card (19-0629). The crystal 
domain size was estimated using the Scherrer equation [6.3]  
                                                        𝜏 =
𝐾𝜆
𝛽𝑐𝑜𝑠𝛩
                                                                                    [6.3] 
where τ is the mean size of the ordered (crystalline) domains K is a dimensionless shape factor with 
a value close to unity (0.8396 for iron oxide),  λ is the X-ray wavelength, β is the line broadening 
at half the maximum intensity (FWHM) in radians after subtracting the instrumental line 
broadening, and θ is the Bragg angle (17.72 °). 
Fourier transform infrared (FTIR) spectra. Attenuated total reflectance FTIR (ATR-FTIR) was 
used to determine surface functionalization with a Varian Inc. 7000e spectrometer. Dried samples 
were placed on the diamond ATR crystal and the spectrum was obtained between 700 and 4000 
cm−1 for 32 scans. 
6.2.9 Cell Culture 
A549 and H358 cells were cultured between passages 5-11 in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% of Fetal Bovine Serum (FBS), 1mM sodium pyruvate, 4 mM L-
glutamine, Pen-Strep (100 µg /mL penicillin and 100 µg/mL streptomycin), and 10 μg/ml of 
Fungizone. Cells incubated at 37 °C and 5% CO2.    
6.2.10 Iron oxide nanoparticle uptake 
A549 and H358 cells were seeded into 6 well plates at a density of 100,000 cells/mL and 2 mL/well. 
After 24 hours, cells were exposed to the nanoparticle systems (uncoated Fe3O4, Fe3O4+Dx-ECH, 
or Fe3O4+TAT) at a concentration of 500 µg/mL for 2 hours. After two hours, the nanoparticles 
were removed and the cells were washed twice with PBS to remove any nanoparticles not 
internalized within the cells. Cells were then detached from the 6 well plates and counted using a 
 
111 
 
Nexcelom Cellometer to determine the cell concentration in each well. Cells were then centrifuges 
and the media supernatant was removed. The cell pellets were dried overnight then dissolved in 
6M HCl for 72 hours. After 72 hours, 10 µL of the dissolved cell pellet was transferred to a new 
microcentrifuge tube and the iron concentration assay was completed (Section 2.7). The iron 
concentration was then normalized to the number of cells in the sample.  
6.2.11 Reactive Oxygen Species (ROS) Generation 
A549 and H358 cells were seeded at 150,000 cells/mL and 2 mL/well in 6 well plates. After 24 
hours of growth, the cells were exposed to various nanoparticle systems (uncoated Fe3O4, 
Fe3O4+Dx-ECH, or Fe3O4+TAT) at a concentration of 500 μg/mL iron oxide for 2 hours. After 2 
hours of exposure to the nanoparticles, the nanoparticle solutions were removed and cells were 
washed 2 times with PBS, prior to trypsinizing and transferring the cells to microcentrifuge tubes. 
The cells were then centrifuged and re-suspended in 1 mL of 50 μM carboxy-DCF solution. The 
cells were incubated in the carboxy-DCF solution for 30 minutes to facilitate internalization of the 
dye. Half of the samples were then exposed to an alternating magnetic field (AMF) (292 kHz, 56 
kA/m) for 30 minutes or 1 hour with 30 minutes post incubation. Carboxy-DCF fluorescence was 
measured using an Accuri Flow Cytometer in FL-1.  
6.2.12 Acridine orange lysosomal permeabilization experiments 
A549 and H358 cells were seeded at 150,000 cells/mL and 2 mL/well into 6 well plates. Cells were 
exposed to the nanoparticle systems (uncoated Fe3O4, Fe3O4+Dx-ECH, or Fe3O4+TAT) for two 
hours at a concentration of 500 µg/mL iron oxide then rinsed to remove any nanoparticles not 
associated with the cells. The cells were trypsinized, the trypsin was neutralized with cell culture 
media, and then the cells were transferred to 1.5 mL microcentrifuge tubes. Half the cells were 
exposed to an AMF (292 kHz, 56 kA/m) for one hour, then the cells were stained with acridine 
orange (10 µg/mL) for ten minutes at 37 °C prior to analysis using an Accuri Flow Cytometer (FL-
3).  
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6.2.13 Mitochondrial membrane depolarization studies (JC-1) 
A549 and H358 cells were seeded at 150,000 cells/mL and 2 mL/well into 6 well plates. Cells were 
exposed to the nanoparticle systems (uncoated Fe3O4, Fe3O4+Dx-ECH, or Fe3O4+TAT) for two 
hours at a concentration of 500 µg/mL iron oxide then rinsed to remove any nanoparticles not 
associated with the cells. The cells were trypsinized, the trypsin was neutralized with cell culture 
media, and then the cells were transferred to 1.5 mL microcentrifuge tubes. Half the cells were 
exposed to an AMF (292 kHz, 56kA/m) for one hour, then the cells were centrifuged, re-suspended 
in PBS, and stained with JC-1 (2 µM) for 30 minutes at 37 °C prior to analysis using an Accuri 
Flow Cytometer (FL-1 and FL-3).  
6.2.14 Caspase 3/7 apoptosis studies 
A549 and H358 cells were seeded at 150,000 cells/mL and 2 mL/well into 6 well plates. Cells were 
exposed to the nanoparticle systems (uncoated Fe3O4, Fe3O4+Dx-ECH, or Fe3O4+TAT) for two 
hours at a concentration of 500 µg/mL iron oxide then rinsed to remove any nanoparticles not 
associated with the cells. The cells were trypsinized, the trypsin was neutralized with cell culture 
media, and then the cells were transferred to 1.5 mL microcentrifuge tubes. Half the cells were 
exposed to an AMF (292 kHz, 56kA/m) for one hour. At 12 or 24 hours post AMF treatment, the 
cells were centrifuged, re-suspended in PBS, and stained with CellEvent per manufacturer’s 
instructions (1 µL CellEvent/mL cell solution (500 nM)) for 30 minutes at 37 °C prior to analysis 
using an Accuri Flow Cytometer (FL-1). Cells were gated into two populations: non-apoptotic and 
apoptotic, with the apoptotic group being higher in FL-1 fluorescence and decreased in forward 
scatter as confirmed by a CDDP (100 µM) positive control population.  
6.2.15 Viability studies 
A549 and H358 cells were seeded at 150,000 cells/mL and 2 mL/well into 6 well plates. Cells were 
exposed to the nanoparticle systems (uncoated Fe3O4, Fe3O4+Dx-ECH, or Fe3O4+TAT) for two 
hours at a concentration of 500 µg/mL iron oxide then rinsed to remove any nanoparticles not 
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associated with the cells. The cells were trypsinized, the trypsin was neutralized with cell culture 
media, and then the cells were transferred to 1.5 mL microcentrifuge tubes. Half the cells were 
exposed to an AMF (292 kHz, 56kA/m) for one hour. The cells were then re-seeded into black 
walled 96 well plates at 15,000 cells/mL and 100 µL/well and allowed to grow for 48 hours prior 
to staining the cells with 2 µM calcein AMF and reading fluorescence on a plate reader (ex/em: 
485/528 nm). Fluorescence was normalized to the fluorescence of the control (no nanoparticles and 
no AMF treatment).  
6.3 Results and Discussion 
6.3.1 Iron oxide nanoparticle characterization 
Iron oxide nanoparticles were synthesized via a one-pot co-precipitation method using a 2:1 
molar ratio of iron salts and 30% ammonium hydroxide as the reducing agent. Figure 6.2 depicts 
the subsequent surface functionalization strategy to conjugate the TAT peptide to the nanoparticle 
surface via EDC/sulfo-NHS crosslinking. Size and zeta potential measurements are summarized in 
Table 6.1. The number average hydrated diameter of the nanoparticles ranged from 127 nm for the 
Fe3O4 + TAT to 177 nm for the Fe3O4 + Dx-ECH in water. The crosslinked dextran coating on the 
nanoparticle surface stabilizes the nanoparticles at physiological pH by introducing steric 
interactions and a relatively neutral surface charge, as indicated by the zeta potential (Lewin, 
Carlesso et al. 2000, Ayala, Herrera et al. 2013). The decrease in size between the Fe3O4 + Dx-
ECH and Fe3O4 + TAT is a result of the additional washing steps required to remove unconjugated 
TAT peptide after the reaction, which also removes loosely attached dextran which was not 
crosslinked or removed in previous washing steps.  The size of these nanoparticle systems is 
appropriate for cell internalization while being above the cut-off of renal excretion (Ogawara, 
Yoshida et al. 1999, Petters, Bulcke et al. 2014). DLS was also completed in cell culture media to 
gauge nanoparticle sizes during cell culture studies. The nanoparticles were stored suspended in DI 
water at 4 °C, diluted in cell culture media and bath sonicated for five minutes prior to recording 
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DLS measurements over ten minutes. The larger size associated with uncoated Fe3O4 and Fe3O4 + 
Dx-ECH-Amine nanoparticles in cell culture medium is an indication that agglomeration of the 
nanoparticles during storage is not easily reversible. In addition, protein adsorption to the 
nanoparticle surface likely caused the nanoparticles to increase in size and agglomerate. There is a 
slight increase in size of the Fe3O4 + Dx-ECH and Fe3O4 + TAT nanoparticles when suspended in 
cell culture media compared to DI water likely due to protein adsorption. However, the 
nanoparticles are stabilized by the dextran crosslinked coating and charge repulsion from the TAT 
peptide which allows the nanoparticles to be easily re-suspended upon bath sonication. The increase 
in zeta potential between the Fe3O4 + Dx-ECH-Amine (-7.45 mV) and Fe3O4 + TAT (14.8 mV) 
indicates successful attachment of the TAT peptide to the surface of the nanoparticle (Rao, Reddy 
et al. 2008). 
FTIR was also completed on the Fe3O4 + Dx-ECH-Amine and Fe3O4 + TAT systems to confirm 
TAT attachment to the surface (Li, Dong et al. 2014). As shown in Figure 6.3a, there are slight 
changes in the FTIR spectra, most notably a change in the N-H peak at 3300 cm-1 indicating a 
decrease in primary amines in the coating due to conjugation of the TAT peptide using EDC/sulfo-
NHS crosslinking. TEM and XRD were used to determine iron oxide crystal size. Example TEM 
images of the dextran coated iron oxide nanoparticles are shown in Figure 6.3b. The images shown 
depict multiple nanoparticle crystals of approximately 8.9 ± 2 nm (average ± standard deviation as 
determined by ten images at 60 nanoparticles per image) in size encapsulated within the dextran 
coating. The crystalline size is not expected to change with further functionalization of the surface. 
XRD (Figure 6.3c) confirmed the crystalline structure of the nanoparticles to be iron oxide (likely 
a combination of magnetite and maghemite due to oxidation), and the Scherrer equation (Equation 
6.3) and the (311) peak was used to calculate the average crystal length to be approximately 12.1 
± 0.2 nm (n=3 individual batches), which is comparable to the crystal length determined via TEM 
imaging. Although bulk heating was not the focus of this work, the specific absorption rate (SAR) 
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is an indication of how the nanoparticles interact with an AMF. Previous characterization of the 
crosslinked-dextran coated iron oxide nanoparticles indicated a SAR value of 211.0 ± 46.6 W/g (58 
kA/m, 292 kHz), confirming the ability of the nanoparticles to respond to an AMF (Hauser, Mathias 
et al. 2015). 
 
Figure 6.2. Iron oxide nanoparticle synthesis and functionalization of the TAT peptide.  
Table 6.1. Iron oxide nanoparticle size from dynamic light scattering in DI water and cell culture 
media and zeta potential represented as average ± standard deviation (n=3).  
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Figure 6.3 Nanoparticle characterization. a. FTIR spectra of amine functionalized and TAT 
conjugated iron oxide nanoparticles. b. TEM images of dextran coated iron oxide nanoparticles to 
confirm Fe3O4 crystalline structure. c. X-ray diffraction pattern of dextran coated iron oxide 
nanoparticles.  
6.3.2 Cellular uptake of iron oxide nanoparticles 
A549 and H358 lung cancer cells were exposed to three nanoparticle systems of interest at a 
concentration of 500 µg/mL for two hours. This exposure time and concentration were kept 
constant throughout the studies completed. As shown in Figure 6.4, Fe3O4 + TAT uptake was 
significantly greater than the other nanoparticle systems in both cell lines due to the TAT peptide 
being a cell penetrating peptide and positively charged, which enhances internalization of its 
attached cargo (Thorek and Tsourkas 2008, Torchilin 2008, Villanueva, Canete et al. 2009, Wang, 
Qiao et al. 2012, Ayala, Herrera et al. 2013). The uncoated Fe3O4 nanoparticles were internalized 
to a significantly greater extent than Fe3O4 + Dx-ECH in A549 cells and slightly greater in H358 
cells. This is likely due to the positive zeta potential associated with uncoated Fe3O4 (Osaka, 
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Nakanishi et al. 2009). The Fe3O4 + Dx-ECH system did not result in significant uptake, as the iron 
concentration is not different from that of the control, and this is likely a result of the slightly 
negative surface charge which limits uptake (Villanueva, Canete et al. 2009). It was expected that 
the effects of Fe3O4 + TAT nanoparticles in the presence of an AMF will be greater than the other 
nanoparticle systems studied due to increased intracellular concentrations.  
 
 
Figure 6.4 Uptake of Fe3O4 nanoparticles into a.) A549 and b.) H358 lung cancer cells. Error bars 
represent standard error (n=3) and significant differences are indicated by * (p<0.05) and ** 
(p<0.01) via a one-way ANOVA. 
6.3.3 Intracellular reactive oxygen species formation 
Iron oxide nanoparticles have the ability to catalyze the formation of the hydroxyl radical via 
Fenton chemistry. It has been previously shown that hydroxyl radical formation is enhanced in the 
presence of an AMF due to energy dissipation by Brownian rotation and Neél relaxation resulting 
in cellular stress (Wydra, Oliver et al. 2015). Figure 6.5a shows carboxy-DCF fluorescence of A549 
lung carcinoma exposed to the three nanoparticle systems and a control followed by 30 minutes or 
one hour AMF treatment, which did not result in a measureable temperature rise. AMF treatment 
for 30 minutes significantly enhanced ROS production in A549 cells exposed to uncoated Fe3O4 
and Fe3O4 + TAT. The surface of uncoated Fe3O4 is not shielded and therefore can interact with the 
cell environment and catalyze hydroxyl radical formation through Fenton chemistry. Enhancement 
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of ROS generation via uncoated Fe3O4 in the presence of an AMF was previously shown by Wydra 
et al., where methylene blue decolorization was enhanced in the presence of uncoated Fe3O4 and 
an AMF compared to the theoretical degradation associated with bulk temperature rise (Wydra, 
Oliver et al. 2015).   
Fe3O4 + TAT nanoparticles are potentially inducing local heating effects or frictional effects 
from Brownian rotation and therefore causing cell stress and increasing ROS production. Only the 
Fe3O4 + TAT increased ROS production in A549 lung carcinoma when exposed to an AMF for 
both 30 minutes and one hour, which is likely due to the increased concentration of intracellular 
nanoparticles and, therefore, greater local heating and frictional effects. Although not significant, 
uncoated Fe3O4 combined with one hour AMF exposure slightly increased intracellular ROS 
production. The convergence in ROS production between uncoated Fe3O4 and uncoated Fe3O4 with 
one hour AMF can be explained by the inherent ability of the nanoparticle to increase intracellular 
ROS production through Fenton chemistry at the surface even without local energy dissipation 
(Wydra, Oliver et al. 2015). The longer AMF exposure time increased the amount of time that the 
internalized nanoparticles were able to interact intracellularly, which could cause a convergence in 
ROS generation between the no AMF and one hour AMF treatments for cells exposed to uncoated 
Fe3O4.  
It should also be noted that the A549 control cells, which were not exposed to iron oxide 
nanoparticles, still generate ROS through natural cellular respiration. By increasing AMF exposure 
time, carboxy-DCF exposure time also increased resulting in increased fluorescence being 
associated with the longer AMF exposure. By doubling the AMF exposure time, the carboxy-DCF 
exposure nearly doubled, resulting in a near two-fold increase in fluorescence of control A549 cells. 
However, this was not observed in H358 cells as shown in Figure 6.5b. Increased H358 incubation 
time with carboxy-DCF did not show the same increase in fluorescence indicating that the cells 
were potentially operating at their maximal ROS generation rate. The difference in inherent ROS 
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production between A549 and H358 cells was determined by incubating the cells with 50 µM 
carboxy-DCF for two hours and then measuring the raw fluorescence of the cells via flow 
cytometry. As shown in Figure 6.6, H358 cells operated at a higher level of reactive oxygen species 
than A549 cells. Previous work by Trachootham, et al.  in 2006 showed that increased oxidative 
stress in cancer cells is associated with oncogenic transformation by transfecting T72 ovarian cells 
with the Ras gene (Trachootham, Zhou et al. 2006). Oncogenic transformation resulted in increased 
oxidative stress as well as increased sensitivity to ROS inducing agents. Therefore, increased 
oxidative stress results in greater dependence upon antioxidant systems causing the cells to be more 
sensitive to exogenous agents, which threaten this delicate balance (Trachootham, Zhou et al. 2006, 
Wang and Yi 2008, Klein, Sommer et al. 2012, Huang, Chen et al. 2013). 
 
Figure 6.5 Normalized carboxy-DCF fluorescence of a.) A549 and b.) H358 lung cancer cells after 
treatment with Fe3O4 nanoparticles with and without 30 minutes or 1 hour AMF exposure. Error 
bars represent standard error (n=3) and significant difference is indicated by * (p<0.05) via a two-
way ANOVA. 
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Figure 6.6 Average fluorescence of A549 and H358 cells after 2 hours of exposure to 50 µM 
carboxy-DCF. Error bars represent standard error (n=5) and * indicates a significant difference 
(p<0.05) via a t-test. 
6.3.4 Intracellular effects of internalized iron oxide nanoparticles and AMF exposure 
There are a multitude of intracellular properties and pathways that can be affected by increased 
ROS production. Therefore, we have evaluated lysosomal permeability, mitochondrial membrane 
permeability, apoptosis via the Caspase 3/7 pathway, and cell viability of A549 and H358 lung 
cancer cells after exposure to the nanoparticle systems with and without one hour of AMF exposure. 
AMF exposure did not result in a measurable temperature rise.  
An increase in lysosome permeability is associated with several apoptosis pathways. 
Destabilization of the lysosomal membranes releases lysosomal contents such as proteolytic 
enzymes (e.g., cathepsins) into the cytosol, which then induces mitochondrial damage by enhancing 
the production of superoxide radicals and hydrogen peroxide, further increasing lysosome 
permeability, resulting in an amplifying feedback loop (Zhao, Antunes et al. 2003). Acridine orange 
(AO) is a metachromatic fluorophore which gives a distinct red fluorescence at high lysosomal 
concentrations and a weakly green fluorescence at the low cytosolic concentration and can therefore 
be used to measure lysosomal membrane permeability, with a decrease in the red fluorescence 
channel corresponding to an increase in lysosome permeability (Terman, Kurz et al. 2006). AO red 
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fluorescence was measured for A549 (Figure 6.7a) and H358 (Figure 6.7b) immediately following 
iron oxide nanoparticle internalization and one hour of AMF exposure, and these fluorescence 
intensities were then normalized to the control with no AMF exposure. Lysosome permeability 
increased with Fe3O4 + TAT treatment in both A549 and H358 cells. However, the permeability 
was not further increased by AMF exposure. This could be a result of saturating the assay as the 
Fe3O4 + TAT nanoparticles permeabilized the lysosomal membranes to the same extent as the 100 
µM hydrogen peroxide positive control (data not shown), and thus, the effects of the AMF could 
not increase the permeability further.  In A549 lung carcinoma, all of the nanoparticles significantly 
increased lysosome permeability. This could be due to the uncoated Fe3O4 nanoparticles generating 
ROS within the lysosome, leading to destabilization of the membrane (Terman, Kurz et al. 2006). 
 
Figure 6.7 Relative acridine orange (AO) fluorescence of a.) A549 and b.) H358 lung cancer cells 
after treatment with Fe3O4 nanoparticles with and without 1 hour AMF exposure. Error bars 
represent standard error (n=3) and significant difference from the control is indicated by * (p<0.05) 
via a two-way ANOVA. 
The JC-1 assay employs a cationic dye that exhibits potential dependent accumulation in 
mitochondria. At high concentrations, such as those in the mitochondria, the JC-1 dye aggregates 
to form red-fluorescent J-aggregates. Depolarization of the mitochondrial membrane results in 
lower JC-1 concentrations and therefore the formation of green-fluorescent monomers. 
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Mitochondrial membrane potential can be monitored using the JC-1 ratio (red/green fluorescence). 
A decrease in the red/green fluorescence ratio is the result of mitochondrial membrane 
depolarization, which occurs in the early stages of apoptosis (Ly, Grubb et al. 2003). Figure 6.8 
shows the percentage of cells with mitochondrial membrane depolarization, which resulted in a 
decreased JC-1 ratio. In A549 lung carcinoma, Fe3O4 + TAT treatment resulted in a significant 
increase in the percentage of the cell population with depolarized mitochondrial membranes. 
However, this was not significantly increased with the addition of AMF treatment. As previously 
mentioned, mitochondrial integrity can be compromised by increases in lysosomal permeability 
due to the escape of toxins and proteolytic enzymes into the cytosol. Therefore, it is hypothesized 
that the Fe3O4 + TAT nanoparticles permeabilized the lysosomal membranes which then affected 
the mitochondrial integrity of the A549 lung carcinoma. There is also the possibility that the Fe3O4 
+ TAT nanoparticles fully escaped the lysosomes, interacted with the mitochondria, and catalyzed 
ROS formation at the mitochondria. However, it should be noted that this effect is cell line 
dependent as the Fe3O4 + TAT nanoparticles did not disrupt the mitochondrial membrane integrity 
in H358 lung carcinoma.  
 
Figure 6.8 Percentage of a.) A549 and b.) H358 cells with depolarized mitochondrial membranes 
as indicated by a decrease in the ratio between FL3/FL1 (JC1 ratio). Error bars represent standard 
error (n=3) and * indicates a significant difference (p<0.05) compared to the control as determined 
via a two-way ANOVA. 
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An increase in lysosome membrane permeability and depolarization of the mitochondrial 
membrane are both found upstream in many apoptotic pathways (Brunk, Neuzil et al. 2001, Ly, 
Grubb et al. 2003). Therefore, the effects of the iron oxide nanoparticle systems and subsequent 
AMF exposure on the Caspase 3/7 apoptotic pathway were evaluated. Due to the cells being in 
different stages of the cell cycle at the time of treatment, the time between treatment and analysis 
of the apoptotic population was delayed to 12 and 24 hours post treatment. These time points were 
determined using hydrogen peroxide controls and evaluating the peak times of apoptosis following 
treatment (data not shown). Although there were no statistically significant differences between the 
percent of apoptotic cells when comparing the nanoparticle systems to one another and the 
individual systems with and without AMF treatment, there were trends in the data that are 
interesting and warrant further exploration of these potential effects. In Figure 6.9, both A549 lung 
carcinoma and H358 bronchi alveolar appeared to increase in apoptosis when the nanoparticles 
were combined with AMF, although not significant. Additionally, H358 cells appear to have 
increased apoptosis compared to A549 in all treatments. This could be a result of the H358 cells 
being more sensitive to the treatment as well as the processing procedure of the experiment. It also 
appeared as though uncoated Fe3O4 and Fe3O4 + TAT resulted in greater apoptosis than the Fe3O4 
+ Dx-ECH in H358 cells which corresponds to the ROS generation data provided previously. The 
significant error observed in this assay prevents firm conclusions about differences between the 
treatments. However, as previously mentioned, there were notable trends in the data.  In future 
studies, additional assays, such as Annexin V/Propidium iodide (PI), will be used as the variability 
in the current assay limit the conclusions that can currently be made. Additionally, prior work by 
Wydra, et al.  used the Caspase 3/7 assay to show a significant increase in apoptosis of CT26 colon 
cancer cells when uncoated, citric acid coated and glucose functionalized iron oxide nanoparticles 
were combined with AMF (292 kHz, 56 kA/m) exposure for 1 hour compared to the nanoparticle 
systems alone (Hauser, Wydra et al. , Wydra, Rychahou et al. 2015).The effect was larger in this 
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case and found to be statistically significant, which further confirms that the efficacy of MagMED 
treatment is cell line dependent as expected.  
 
Figure 6.9 Percentage apoptosis of a.) A549 and b.) H358 lung cancer cells 12 and 24 hours after 
treatment with Fe3O4 nanoparticles with and without 1 hour AMF. Error bars represent standard 
error (n=3) and significant difference from the control is indicated by * (p<0.05) via a two-way 
ANOVA. 
A549 and H358 viability 48 hours following treatment with the nanoparticle systems with and 
without AMF were evaluated and shown in Figure 6.10. In A549 lung carcinoma, there is no 
significant difference between the nanoparticle systems and the control or within a nanoparticle 
system with and without AMF treatment. In the H358 cells, only the uncoated Fe3O4 nanoparticles 
resulted in a decrease in cell viability compared to the control, but there was no additional decrease 
in viability as a result of AMF treatment. Although intracellular effects of the nanoparticle systems 
combined with AMF were observed (e.g., especially in intracellular ROS generation), the 
intracellular effects were not enough to induce a decrease in cell viability. Previous work by 
Creixell et al. showed a significant decrease in cell viability when internalized EGFR targeted iron 
oxide nanoparticles were combined with an AMF for 2 hours (Creixell, Bohorquez et al. 2011). 
However, there was significant toxicity of the EGFR targeted nanoparticles alone which could have 
sensitized the cells to additional treatment with the AMF. Additionally, the AMF treatment time 
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was two hours instead of the one hour used in these studies. Another study completed by Domenech 
et al. demonstrated that intracellular energy delivery is cell line dependent. MDA-MB 231 and 184-
85 cells were incubated with EGF targeted, carboxymethyl dextran coated iron oxide nanoparticles 
and then exposed to an AMF (233 kHz, 41.75 kA/m) for 1 hour (Domenech, Marrero-Berrios et al. 
2013). A decrease in viability of MDA-MB-231 cells was observed with the addition of AMF 
treatment however, while 184-85 cell viability was not affected by AMF treatment. Future work 
will explore utilizing intracellular energy delivery as a combinational treatment in order to enhance 
the efficacy of conventional treatments such as chemotherapy and radiation. It is possible that 
intracellular energy delivery can act as a sensitizer to additional treatments resulting in a synergistic 
combinational effect.  
 
Figure 6.10 Relative viability of a.) A549 and b.) H358 lung cancer cells 48 hours after treatment 
with Fe3O4 nanoparticles with and without 1 hour AMF. Error bars represent standard error (n=3) 
and significant difference from the control is indicated by * (p<0.05) via a two-way ANOVA. 
6.4 Conclusions 
Dextran coated iron oxide nanoparticles were successfully functionalized with the TAT peptide 
and characterized for their physicochemical properties. The nanoparticles ranged in size from 
approximately 130-180 nm and successful conjugation of the TAT peptide was confirmed by 
changes in nanoparticle zeta potential and FTIR spectra. TAT functionalization to dextran coated 
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iron oxide nanoparticles resulted in a novel nanoparticle system in that the nanoparticles were 
internalized within cells at significantly greater concentrations but were not internalized via 
receptor-mediated endocytosis. Uncoated Fe3O4 and Fe3O4 + TAT increased cellular ROS 
generation in both A549 and H358 cell lines upon exposure to an AMF. Lysosomal permeability 
was increased in both cell lines following treatment with Fe3O4 + TAT nanoparticles due to the 
TAT peptide destabilizing the lysosomal membranes. In A549 cells, the mitochondrial integrity 
was compromised by the Fe3O4 + TAT nanoparticles but this was not enhanced by AMF exposure 
or observed in H358 cells, indicating a cell dependent response to treatment. Apoptosis response 
was also cell line dependent, and although not statistically significant, trends were observed that 
suggested an increase in apoptosis when nanoparticle systems were combined with AMF treatment. 
However, there was no difference in the treatments when cell viability was analyzed 48 hours post 
treatment. Future work will aim to increase consistency of apoptosis assays and increase the scope 
of tested cell lines. Targeting the nanoparticles to specific organelles could also improve the 
efficacy of MagMED, especially if the particles were targeted to vital organelles such as the 
mitochondria.  
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Chapter 7 Targeted iron oxide nanoparticles for the enhancement of radiation therapy 
Iron oxide nanoparticles have the ability to catalyze the Fenton reaction to generate reactive oxygen 
species (ROS). Radiation therapy promotes mitochondrial respiration which leads to increased 
superoxide anion production. In the presence of iron oxide nanoparticles, the superoxide anion is 
converted to the highly reactive hydroxyl radical. The goal of this chapter was to evaluate the 
cellular effects of radiation combined with the peptide functionalized nanoparticles developed in 
Chapter 6. The chapter is taken directly or adapted from work recently submitted to Biomaterials. 
Used with permissions from Anastasia K. Hauser, Mihail I. Mitov, Emily F. Daley, Kimberly W. 
Anderson and J. Zach Hilt, “Targeted iron oxide nanoparticles for the enhancement of radiation 
therapy.” 
7.0 Abstract 
To increase the efficacy of radiation, iron oxide nanoparticles can be utilized for their ability 
to produce reactive oxygen species (ROS). Radiation therapy promotes mitochondrial respiration 
which is often linked to higher cellular energy production and leads to an increase in mitochondrial 
production of the superoxide anion which is converted to hydrogen peroxide by superoxide 
dismutase. Iron oxide nanoparticles can then catalyze the reaction from hydrogen peroxide to the 
highly reactive hydroxyl radical. Therefore, the overall aim of this project was to utilize iron oxide 
nanoparticles conjugated to a cell penetrating peptide, TAT, to escape lysosomal encapsulation 
after internalization by cancer cells and catalyze hydroxyl radical formation. It was determined that 
TAT functionalized iron oxide nanoparticles and uncoated iron oxide nanoparticles resulted in 
permeabilization of the lysosomal membranes. Additionally, mitochondrial integrity was 
compromised when A549 cells were treated with both TAT-functionalized nanoparticles and 
radiation. Pre-treatment with TAT-functionalized nanoparticles also significantly increased the 
ROS generation associated with radiation. A long term viability study showed that TAT-
functionalized iron oxide nanoparticles combined with radiation resulted in a synergistic 
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combination treatment. This is likely due to the TAT-functionalized nanoparticles sensitizing the 
cells to subsequent radiation therapy, because the nanoparticles alone did not result in significant 
toxicities.  
7.1 Introduction 
Iron oxide nanoparticles have been previously studied for their multitude of biological 
applications, magnetic properties, and lack of protein adsorption after proper coating (Laurent, Dutz 
et al. 2011). Iron oxide nanoparticles have been utilized in magnetically mediated hyperthermia for 
the treatment of cancer, contrast agents in magnetic resonance imaging, and treatment of anemia 
(Dennis, Jackson et al. 2009, Hu, Ma et al. 2011, Laurent, Dutz et al. 2011, McCormack 2012). 
However, recent work suggests that inherent toxicities of the nanoparticles can be utilized to 
enhance current cancer treatments via the generation of reactive oxygen species (ROS) (Koenczoel, 
Weiss et al. 2013, Luo, Li et al. 2015).  
Cancer cells are more susceptible to oxidative insults compared to normal cells due to fast cell 
proliferation and metabolism so additional ROS stress induced by exogenous agents can 
overwhelm the relatively low antioxidant capacity and disrupt the redox homeostasis inside cancer 
cells leading to selective tumor cell toxicity (Huang, Chen et al. 2013, Luo, Li et al. 2015). 
Trachootham et al. transfected T72 cells with the Ras gene and showed that oncogenic cells 
containing the Ras gene operated at increased ROS stress compared to non-transfected cells 
(Trachootham, Zhou et al. 2006). This increased oxidative stress caused the T72 Ras cells to be 
more sensitive to PEITC, an exogenous ROS generating agent. ROS have the ability to result in 
DNA and lipid damage and disturb signal transduction, which can lead to cell death if the damage 
is severe enough that it cannot be repaired (Kehrer 2000). Therefore, sensitization of cancer cells 
to radiation by inducing oxidative stress has the potential to synergistically increase treatment 
efficacy.  
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The Haber-Weiss reaction results in generation of the highly reactive hydroxyl radical from the 
reaction between superoxide and hydrogen peroxide. This reaction is thermodynamically un-
favorable in biologic systems, and with a second order rate constant of zero in aqueous solution, it 
was found to require a catalyst to proceed (Kehrer 2000). The iron catalyzed Haber-Weiss reaction, 
which makes use of Fenton chemistry, is now considered the major mechanism by which the highly 
reactive radical is generated in biological systems (Kehrer 2000). The Fenton chemistry reaction 
set is shown as Equation 7.1, and the Haber-Weiss reaction (net reaction) is shown as Equation 7.2.  
Fe3+ + O2· - → Fe2+ + O2 
Fe2+ +H2O2 → Fe3+ + OH- + OH·                                               [7.1] 
O2· - + H2O2 → O2 + OH- + OH·                                                                  [7.2] 
Under normal conditions, only trace amounts of iron exist outside of physiologic sinks such as 
transferrin or ferritin. Proteins sequester iron ions so that the ions circulate bound to transferrin and 
accumulate within cells in the form of ferritin. The absorption of iron is finely regulated to prevent 
an excess storage and oxidative attack (Emerit, Beaumont et al. 2001). Iron oxide nanoparticles 
have been previously studied for their multitude of biological applications, and recent work 
suggests that the uptake of iron oxide nanoparticles can lead to a concentration increase of 
intracellular unbound iron which may result in cell injury or death (Weissleder, Stark et al. 1989, 
Klein, Sommer et al. 2012, Alarifi, Ali et al. 2014), especially when combined with additional 
therapies (Klein, Sommer et al. 2012, Huang, Chen et al. 2013, Klein, Sommer et al. 2014, Luo, Li 
et al. 2015). When iron oxide nanoparticles are taken up by a cell, they stimulate the generation of 
ROS via one of two pathways: the release of ions into the cytosol where chelation by citrate or 
adenosine phosphate takes place resulting in the iron ions participating in the Haber-Weiss cycle 
or the surface of the iron oxide nanoparticle may act as a catalyst for the Haber-Weiss cycle and 
the Fenton reaction (Auffan, Achouak et al. 2008, Lewinski, Colvin et al. 2008, Voinov, Pagan et 
al. 2011, Klein, Sommer et al. 2012). Both pathways result in the formation of the highly reactive 
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hydroxyl radical. Iron oxide nanoparticles can exist in many forms with two of the most common 
forms of iron oxide nanoparticles being magnetite (Fe3O4) and maghemite (Fe2O3). It was suggested 
by Aranda et al. that magnetite nanoparticles would lead to greater ROS formation and oxidative 
stress due to iron being present as both Fe3+ and Fe2+ ions within magnetite while maghemite has 
mostly ferric iron ions (Aranda, Sequedo et al. 2013). Therefore, these studies focus on magnetite 
iron oxide nanoparticles for the generation of intracellular ROS.  
There are multiple pathways within the cell that naturally generate ROS. The pathway of 
particular interest is mitochondrial respiration which produces the superoxide anion (Kehrer 2000). 
The superoxide anion is converted to hydrogen peroxide through natural superoxide dismutase, and 
in the presence of iron ions, the conversion of hydrogen peroxide to the highly reactive hydroxyl 
radical is catalyzed (Koenczoel, Weiss et al. 2013). Although the exact mechanism remains unclear, 
radiation promotes mitochondrial respiration and therefore increases production of the superoxide 
anion (Kam and Banati 2013). Yamamori et al. showed that A549 lung carcinoma exhibited 
increased oxygen consumption rates as well as increased rates of mitochondrial ROS production at 
6 and 12 hours following 5 Gy radiation (Yamamori, Yasui et al. 2012). If the intracellular 
concentration of the superoxide anion is increased following radiation and iron oxide nanoparticles 
are present to catalyze hydroxyl radical formation, it is hypothesized that the hydroxyl radical 
concentration will subsequently be increased, resulting in increased toxicity.  
Iron oxide nanoparticles are usually taken up by cells through endocytosis resulting in the 
nanoparticles being encapsulated in endosomes/lysosomes. Due to the acidic nature of these 
subcellular compartments, the nanoparticles can be degraded prior to fulfilling their purpose. 
However, if a cell penetrating peptide (CPP) is conjugated to the surface of the iron oxide 
nanoparticle, the nanoparticle can avoid receptor mediated endocytosis (Vives, Brodin et al. 1997). 
In this work, the CPP of particular interest is the TAT peptide (sequence: YGRKKRRQRRR), 
which contains a characteristic lysine and arginine sequence. Biomolecules with this tag are known 
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to bind to importin α and β in the cytoplasm allowing for active transportation to the nuclear pore 
complex (NPC) and, if small enough, through the NPC into the nucleus (Austin, Kang et al. 2011). 
Several studies have utilized the TAT peptide as a cell internalization mechanism (Josephson, Tung 
et al. 1999, Lewin, Carlesso et al. 2000, Rao, Reddy et al. 2008, Torchilin 2008, Wang, Qiao et al. 
2012) as well as a nuclear targeting moiety (Vives, Brodin et al. 1997, de la Fuente and Berry 2005, 
Oyelere, Chen et al. 2007, Xu, Xie et al. 2008, Yang, Neshatian et al. 2014).  
Although lysosomes may eventually uptake TAT-conjugated nanoparticles residing in the 
cytosol, the TAT peptide is positively charged and can destabilize lysosomal membranes leading 
to release of lysosomal contents, including proteolytic enzymes and the nanoparticles (Terman, 
Kurz et al. 2006). An increase in lysosome membrane permeability is an upstream event in many 
apoptotic pathways, as the proteolytic enzymes lead to mitochondrial damage by enhancing the 
production of superoxide radicals and hydrogen peroxide, which in turn increases lysosomal 
membrane permeability, resulting in an amplifying feedback loop (Zhao, Antunes et al. 2003, 
Kirkegaard and Jaattela 2009). Due to the size of our iron oxide nanoparticles being larger than the 
upper limit of the nuclear pore complex (20―70 nm), it was of particular interest to escape 
endosome/lysosomes in order to interact with other organelles such as the mitochondria (Pan, He 
et al. 2012). 
In this study, dextran coated iron oxide nanoparticles were functionalized with the TAT peptide 
and this nanoparticle system was used to enhance the efficacy of radiation. The TAT peptide 
increased intracellular concentrations of the nanoparticles compared to uncoated nanoparticles as 
shown by transmission electron microscopy (TEM).  TEM images also indicate that uncoated iron 
oxide nanoparticles were encapsulated within lysosomes after cell internalization. However, TAT-
functionalized nanoparticles were found in the cytoplasm as well as in lysosomes with destabilized 
membranes. Lysosomal membrane permeability studies confirmed the ability of the TAT peptide 
to destabilize the lysosomes, and cell respiration studies indicated that TAT-functionalized 
 
132 
 
nanoparticles combined with radiation resulted in a loss of mitochondrial integrity, causing the cells 
to operate at lower metabolic levels. When combined with radiation, the TAT-functionalized 
nanoparticles increased reactive oxygen species generation to a greater extent than radiation alone. 
The combined treatment also resulted in synergistic cytotoxic effects on A549 lung carcinoma, as 
shown by a long term viability study. Therefore, it has been concluded that TAT-conjugated iron 
oxide nanoparticles have the ability to destabilize lysosomal membranes, releasing their toxic 
contents into the cytosol and causing the cells to be more sensitive to radiation therapy. 
Additionally, after radiation therapy when the mitochondria have increased respiration levels and 
are producing greater amounts of the superoxide anion, the iron oxide nanoparticles can catalyze 
the formation of the highly reactive hydroxyl radical. This hypothesis is depicted in Figure 7.1. 
 
Figure 7.1 TAT-conjugated iron oxide nanoparticles are internalized into the cell, followed by 
lysosomal membrane permeabilization. This results in release of proteolytic enzymes as well as the 
nanoparticles into the cytoplasm where they can interact with organelles such as the nucleus and 
mitochondria and catalyze the formation of the hydroxyl radical. 
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7.2 Materials and Methods 
7.2.1 Materials 
Iron (III) chloride hexahydrate (FeCl3·6H2O), iron (II) chloride (FeCl2·4H2O), 9 – 11 kDa dextran, 
epichlorohydrin (ECH) were obtained from Sigma Aldrich (St. Louis, MO). Ammonium hydroxide 
(NH4OH) was purchased from EMD Chemicals (Gibbstown, NJ). Phosphate buffered saline 
solution (PBS) (10X) was purchased from EMD Millipore (Billerica, MA). The activation buffer 
2-[N-morpholino] ethane sulfonic acid (MES), N-hydroxysulfosuccinimide (sulfo-NHS) and 1-
ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) were purchased from 
Thermo scientific (Rockford, IL). The TAT peptide was purchased custom from Biomatik. 
Phosphate buffered saline (PBS), Dulbecco’s Modified Eagle Medium (DMEM), pen-strep, L-
glutamine, Fungizone®, sodium pyruvate, and calcein AM were obtained from Invitrogen 
(Frederick, MD).  Acridine orange was purchased from Nexcelom Bioscience (Lawrence, MA) and 
A549 lung carcinoma and trypsin were purchased from American Type Culture Collection (ATCC, 
Manassas, VA). All materials were used as received. 
7.2.2 Synthesis of uncoated iron oxide nanoparticles (uncoated Fe3O4)  
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams, 
respectively) and dissolved in 60 mL deionized (DI) water and sealed in a three-neck flask under 
vigorous stirring and an inert nitrogen environment. The reaction solution was heated to 85 °C at 
which 5 ml of NH4OH was diluted to 40 mL with DI water and the combined solution was injected 
dropwise into the vessel. The reaction was carried out for 1 hour at 85 °C.  The particles were 
magnetically decanted and washed three times with DI water. The nanoparticles were then re-
suspended in DI water and dialyzed against DI water for 24 hours (100 kDa molecular weight 
cutoff). After dialysis, the nanoparticles were probe sonicated for 10 minutes and then centrifuged 
at 1000 rpm for 5 minutes to remove large agglomerates.  
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7.2.3 Synthesis of dextran coated iron oxide nanoparticles (Fe3O4 + Dx) 
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams, 
respectively) and dissolved in 40 mL deionized (DI) water and sealed in a three-neck flask under 
vigorous stirring and an inert nitrogen environment. 5 grams of dextran was solubilized in 20 mL 
of DI water.  The reaction solution was heated to 85 °C at which 5 ml of NH4OH was added to the 
dextran solution and the combined solution was injected dropwise into the vessel. The reaction was 
carried out for 1 hour at 85 °C.  The particles were magnetically decanted and washed three times 
with DI water. The nanoparticles were then re-suspended in DI water and dialyzed against DI water 
for 24 hours (100 kDa molecular weight cutoff). After dialysis, the nanoparticles were probe 
sonicated for 10 minutes and then centrifuged at 1000 rpm for 5 minutes to remove large 
agglomerates.  
7.2.4 Epichlorohydrin (ECH) crosslinking of dextran coated iron oxide nanoparticles (Fe3O4 + 
Dx-ECH) 
Dextran coated iron oxide nanoparticles were crosslinked using ECH for increased stability 
(Palmacci and Josephson 1993). The particle colloid (9 mL, 1 mmol Fe) was added to 9 mL 5M 
NaOH and 1.5 mL ECH. The reaction was carried out for 24 hours at room temperature under 
continuous agitation. The particles were then magnetically decanted and dialyzed against DI water 
(100 kDa molecular weight cutoff) for 24 hours to remove excess ECH. 
7.2.5 Amine functionalization of crosslinked dextran coated iron oxide nanoparticles (Fe3O4 + 
Dx-ECH-Amine) 
An equal volume of ammonium hydroxide to mmol iron from Fe3O4 + Dx-ECH were combined 
and placed on the shaker table for 24 hours. After 24 hours, the nanoparticles were dialyzed against 
DI H2O for an additional 24 hours, with their water changed 3 times during this time period.  
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7.2.6 TAT peptide conjugation to iron oxide nanoparticles (Fe3O4 + TAT) 
10 mg of the TAT-peptide was dissolved in 10 mL MES buffer (2-[N-morpholino] ethane sulfonic 
acid). 4 mg EDC and 11 mg sulfo-NHS were also added to the solution. Solution was reacted for 
15 minutes with continuous agitation after which 14 µL of 2- mercaptoethanol was added to the 
reaction in order to quench excess EDC. Amine-functionalized iron oxide nanoparticles were 
diluted to 1 mg Fe3O4/mL with PBS. The iron oxide suspension was added to the TAT-peptide 
solution and reacted over night under continuous agitation. After the TAT-iron oxide nanoparticle 
reaction was complete, and particles were washed with PBS via magnetic decanting until the 
washing solution was clear.  
7.2.7 Iron Concentration Assay  
Between each step of synthesizing a new system of iron oxide nanoparticles, an iron assay was 
used to determine the iron concentration of the nanoparticles. 20x, 50x, and 100x dilutions of the 
iron oxide nanoparticles were made in DI water and 10 µL of each dilution was added to 10 µL 6M 
HCl and allowed to sit for 3 hours. After this time, 500 µL of 1M acetic acid, 100 µL of 
hydroxylamine hydrochloride, 100 µL of 1, 10 phenanthroline, and 280 µL of DI water were added 
to each dilution. Solutions were left overnight. After 24 hours, the absorbance of each solution (λ 
= 511 nm) was used to calculate the iron concentration based on a standard curve.  
7.2.8 Cell Culture 
A549 cells were cultured between passages 5-11 in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% of Fetal Bovine Serum (FBS), 1mM sodium pyruvate, 4 mM L-glutamine, 
Pen-Strep (100 µg /mL penicillin and 100 µg/mL streptomycin), and 10 μg/ml of Fungizone. Cells 
incubated at 37 °C and 5% CO2.  
7.2.9 Transmission electron microscopy  
A549 cells were seeded into 6 well plates at 13,000 cells/cm2 and grown for 24 hours. Cells were 
then exposed to 500 µg/mL iron oxide of either uncoated iron oxide nanoparticles or Fe3O4 + TAT 
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for 24 hours. After 24 hours, the nanoparticles suspensions were removed and the cells were rinsed 
with media to remove non-internalized nanoparticles. Half of the samples were then exposed to 5 
Gy radiation. After treatment, the cells were washed with PBS to remove media then fixed in 3.5% 
glutaraldehyde in 0.1 M Sorenson’s buffer for 75 minutes at 4 °C. Cells were then washed 4 times 
with 0.1 M Sorenson’s containing 5% sucrose, post fixed with 1% osmium tetraoxide for 45 
minutes at 4 °C, then washed again with 0.1 M Sorenson’s. Cells were dehydrated in graded 
ethanols (50-100%) then absolute ethanol twice at 4 °C. Cells were then embedded in Eponate 12 
resin and polymerized at 60 °C prior to slicing and mounting for imaging (Philips BioTwin 12 
Transmission Electron Microscope).  
7.2.10 Acridine orange lysosomal permeabilization experiments 
A549 lung carcinoma cells were seeded at 80,000 cells/mL and 2 mL/well into 6 well plates. Cells 
were exposed to the nanoparticle systems for three hours at a concentration of 500 µg/mL iron 
oxide then rinsed to remove any nanoparticles not associated with the cells. Half the cells were 
exposed to 5 Gy radiation then the cells were stained with acridine orange (10 µg/mL) for ten 
minutes at 37 °C prior to analysis via flow cytometry (FL-3).  
7.2.11 Mitochondrial stress test 
A549 lung carcinoma cells were seeded at densities of 30,000 per well in Seahorse XF96 
microplates and allowed to grow overnight. The cells were then exposed to the nanoparticle systems 
for 3 hours at 500 µg/mL iron oxide then rinsed to remove any nanoparticles not associated with 
the cells. Half of the samples were then treated with 5 Gy radiation. Mitochondrial stress was then 
measured using the Seahorse XF 96 Extracellular Flux Analyzer to measure in vitro oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR). The bioenergetic baseline 
profiles can be determined by plotting the ECAR vs OCR signal for the last measurement of base 
line (or just before adding Oligomycin A to the cells as shown in Figure 7.2). To expand, cells were 
incubated for one hour prior to the start of analysis at 37 °C in XF modified assay medium 
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containing 25mM Glucose and 1mM Pyruvate. Three baseline OCR and ECAR values were taken 
over 16 minutes representing the basal respiration rate, which is the total base line OCR minus the 
non-mitochondrial respiration.  The next three measurements were taken for a period over 20 
minutes, after the addition of an ATP synthase inhibitor (Oligomycin 1uM) which helps to calculate 
the amount of oxygen used for ATP turnover. Next, mitochondrial uncoupler, FCCP (0.6 µM) was 
added to force the cells to operate at their maximal respiration rates for 3 measurements over 20 
minutes. Finally, antimycin A and rotenone were added to inhibit the electron transport chain of 
oxidative phosphorylation and therefore disrupt the formation of the proton gradient across the 
inner membrane, leading to complete cessation of oxygen consumption by the mitochondria, after 
which three values were taken in 14 minutes. All measurements were normalized to protein using 
bicinchoninic acid (BCA) assay. Analysis of the effects of Fe3O4 nanoparticle systems combined 
with radiation on each component of the OCR profile can be found in the supplementary 
information section.  
 
Figure 7.2 Bioenergetic profile of control A549 cells over time. Error bars represent standard error 
(n=12). 
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7.2.12 Reactive Oxygen Species (ROS) Generation 
A549 human lung carcinoma cells were seeded at 40,000 cells/mL and 100 µL/well in black walled 
96 well plates. After 24 hours of growth, the cells were exposed to various iron oxide nanoparticle 
systems (uncoated Fe3O4, Fe3O4+Dx-ECH, Fe3O4+ Dx-ECH-Amine, or Fe3O4 + TAT) at 
concentrations of 100 μg/mL or 500 μg/mL iron oxide for 24 hours. After 24 hours of exposure, 
the nanoparticle solutions were removed and cells were washed 2 times with media, and 100 μL of 
50 μM carboxy-DCF solution was added to each well followed by 20 minutes of incubation to 
facilitate internalization of the dye. Half of the samples were then irradiated with 5 Gy radiation. 
Carboxy-DCF fluorescence was measured using a plate reader (ex/em: 485/528 nm) followed by 
staining with HOESCHT 33342 nuclear stain to normalize data back to the number of cells present.  
7.2.13 Viability studies 
A549 human lung carcinoma cells were seeded at 5,000 cells/mL and 100 µL/well in black walled 
96 well plates. After 24 hours of growth, the cells were exposed to various nanoparticle systems 
(uncoated, Fe3O4 + Dx-ECH, Fe3O4 + Dx-ECH-Amine, or Fe3O4 + TAT) at a concentration of 500 
μg/mL iron oxide for 24 hours. After 24 hours of exposure, the nanoparticle solutions were removed 
and cells were washed 2 times with media and half of the samples were then irradiated with 5 Gy 
radiation. Cell viability was analyzed 3, 5, and 7 days after treatment using a calcein AM assay. 
Calcein AM fluorescence was measured on a plate reader and the fluorescence of each treatment 
was normalized to the fluorescence of the control on that day.   
7.3 Results and Discussion 
Iron oxide nanoparticle systems were previously synthesized and characterized for 
physicochemical properties (see Chapter 6). TEM images of A549 lung carcinoma after exposure 
to uncoated Fe3O4 or Fe3O4 + TAT with and without 5 Gy radiation treatment are shown in Figure 
7.3. Uncoated Fe3O4 nanoparticles with and without radiation are localized within lysosomes. No 
uncoated Fe3O4 nanoparticles were found to be interacting with the mitochondria or to have 
 
139 
 
penetrated the nuclear membrane. Uncoated Fe3O4 nanoparticles are taken up via non-specific 
endocytosis and do not have the ability to sufficiently destabilize lysosome membranes and escape 
into the cytosol (Terman, Kurz et al. 2006). Similarly, Könczöl et al. found that uncoated iron oxide 
nanoparticles were encapsulated in vesicles of A549 lung carcinoma after 24 hours of incubation 
(Koenczoel, Weiss et al. 2013). There was significantly greater uptake of the Fe3O4 + TAT 
nanoparticles into A549 cells as the TAT peptide facilitates cell penetration and escapes receptor 
mediated endocytosis. Fe3O4 + TAT nanoparticles could be found both in lysosomes as well as in 
the cytosol. The nanoparticles appeared to surround the nuclear membrane, but they did not 
penetrate it due to size restraints of the nuclear pore complex (Pan, He et al. 2012). When combined 
with radiation, the Fe3O4 + TAT nanoparticles appeared to destabilize the lysosomal membranes 
even more and greater interaction with surrounding mitochondria was observed. Similar lysosomal 
escape into the cytosol by nanoparticles conjugated with a cell penetrating peptide or nuclear 
localizing signal, such as TAT, has been previously observed (Xu, Xie et al. 2008, Austin, Kang et 
al. 2011).  
 
Figure 7.3 Internalization of Uncoated or TAT-conjugated iron oxide nanoparticles by A549 lung 
carcinoma, with and without radiation treatment. Scale bars represent 200 nm.   
Lysosomal membrane permeabilization is an upstream event in many apoptosis pathways as 
destabilization of the lysosomal membranes releases lysosomal contents such as proteolytic 
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enzymes (cathepsins, etc.) into the cytosol, which then induce mitochondrial damage by enhancing 
the production of superoxide radicals and hydrogen peroxide, further increasing lysosome 
permeability, resulting in an amplifying feedback loop (Zhao, Antunes et al. 2003). Acridine 
Orange (AO) is a metachromatic fluorophore which gives a distinct red fluorescence at high 
lysosomal concentrations and a weakly green fluorescence at low cytosolic concentrations and can 
therefore be used to measure lysosomal membrane permeability, with a decrease in the red 
fluorescence channel corresponding to an increase in lysosome permeability (Terman, Kurz et al. 
2006). This method was used by Domenech et al. to prove that targeted iron oxide nanoparticles 
have the ability to disrupt lysosomal membranes via mechanical forces actuated by an alternating 
magnetic field (Domenech, Marrero-Berrios et al. 2013). Therefore, AO was used to quantify 
lysosomal permeabilization by the Fe3O4 nanoparticle systems with and without radiation. As 
shown in Figure 7.4, uncoated Fe3O4 and Fe3O4 + TAT nanoparticles significantly decreased AO 
fluorescence compared to the control, but no further decrease was observed with the addition of 
radiation. Hydrogen peroxide was used as a positive control and there was no difference between 
hydrogen peroxide treatment and Fe3O4 + TAT nanoparticles indicating lysosomal membrane 
permeabilization. As previously shown, the TAT peptide on the nanoparticle surface destabilizes 
lysosomal membranes due to its highly positive charge (Kornhuber, Henkel et al. 2010). Uncoated 
Fe3O4 nanoparticles can catalyze the formation of the hydroxyl radical inside the lysosomes leading 
to lysosome membrane destabilization (Guicciardi, Leist et al. 2004, Kirkegaard and Jaattela 2009, 
Koenczoel, Weiss et al. 2013). Both Fe3O4 + Dx-ECH and Fe3O4 + Dx-ECH-Amine nanoparticles 
have protective coatings on their surfaces preventing the formation of ROS by surface reaction, 
which explains why these systems do not result in lysosomal membrane permeabilization.  
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Figure 7.4 Normalized acridine orange (AO) fluorescence of A549 lung carcinoma after 2 hour 
treatment with Fe3O4 nanoparticle systems with and without radiation. Error bars represent standard 
error (n=3) and ** indicates a significant difference from the control (p<0.01) via a two-way 
ANOVA. 
As previously mentioned, lysosomal permeability and toxicity of iron oxide nanoparticles can 
lead to toxic mitochondrial effects. The effects of the combined Fe3O4 nanoparticle treatments with 
radiation on mitochondrial function were analyzed using a XF96 Seahorse instrument, which 
measures oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) over time. 
Figure 7.5 represents the basal respiration associated with A549 lung carcinoma cells following 
Fe3O4 nanoparticle treatment with and without 5 Gy radiation treatment. Control A549 cells, which 
had not been exposed to Fe3O4 nanoparticles, had significantly increased basal respiration rates 
after radiation treatment, which is consistent with previous studies (Yamamori, Yasui et al. 2012). 
Uncoated Fe3O4 and Fe3O4 + TAT nanoparticles significantly decreased basal respiration rates 
when combined with radiation compared to radiation alone and no increase in respiration was 
observed following radiation treatment, indicating that mitochondrial integrity was compromised 
by the presence of the nanoparticles. Figure 7.6 represents the maximal respiration levels associated 
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with A549 lung carcinoma cells following Fe3O4 nanoparticle treatment with and without radiation. 
At the maximal respiration levels, there was a significant interaction between the nanoparticle 
system and radiation, indicating that the effects of the nanoparticle system were dependent on 
radiation expoure. An increase in respiration rate after radiation treatment was observed in both the 
control and Fe3O4+Dx-ECH-Amine nanoparticles. Additionally, the nanoparticle systems 
decreased the maximal respiration of the cells compared to the control, both with and without 
radiation treatment, indicating that the nanoparticles compromised the integrity of the 
mitochondria.  Mitochondrial DNA is highly susceptible to damage by ROS and other agents 
because it is not as well protected by histones as is nuclear DNA (Hervouet, Simonnet et al. 2007). 
Therefore, additional ROS stress by the uncoated Fe3O4 nanoparticles, or ROS stress induced by 
release of lysosomal contents, can lead to significant toxicities to the mitochondria.  
The overall metabolism of the cells can be depicted by plotting OCR versus ECAR. Figure 7.7 
represents the metabolic energy associated with A549 lung carcinoma cells after treatment with 
Fe3O4 nanoparticle systems with and without radiation and after FCCP stimulation so the cells were 
operating at their total maximal respiration levels. All cells treated with the Fe3O4 nanoparticle 
systems only were operating at approximately the same ECAR levels but decreased OCR compared 
to the control. The initial decrease in OCR associated with Fe3O4 + TAT nanoparticle treatment 
suggests that these nanoparticles can sensitize the cells to subsequent radiation therapy.  The cells 
treated with both the Fe3O4 + TAT nanoparticles and radiation operated at a significantly lower 
energy level than cells treated with nanoparticles alone. This is an indication that cells treated with 
Fe3O4 + TAT nanoparticles and radiation do not have the ability to respond to external stimuli, such 
as FCCP, indicating a decrease in substrate availability or that mitochondrial mass or integrity has 
been compromised (Hill, Benavides et al. 2012, Chacko, Kramer et al. 2014). Previous studies have 
shown that various iron oxide nanoparticle systems can adversely affect mitochondrial integrity. 
Khan et al. evaluated the effects of iron oxide nanoparticle concentration on the mitochondrial 
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membrane potential (MMP) of HeLa cells and found that, with increasing nanoparticle 
concentration, the percentage of cells with loss of MMP increased as well (Khan, Mohammad et 
al. 2012).  
 
Figure 7.5 Basal oxygen consumption rates of A549 lung carcinoma cells after Fe3O4 nanoparticle 
treatment with and without radiation. Error bars represent standard error (n=12). * indicates a 
significant difference between the no radiation and radiation treatments within a nanoparticle 
system (p<0.05), † indicates a significant difference compared to the control without radiation 
(p<0.05) and ‡ indicates a significant difference from the control with radiation (p<0.05), via a 
two-way ANOVA with an interaction term. 
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Figure 7.6 Maximal oxygen consumption rates of A549 lung carcinoma cells after Fe3O4 
nanoparticle treatment with and without radiation. Error bars represent standard error (n=12). * 
indicates a significant difference between the no radiation and radiation treatments within a 
nanoparticle system (p<0.05), † indicates a significant difference compared to the control without 
radiation (p<0.05) and ‡ indicates a significant difference from the control with radiation (p<0.05), 
via a two-way ANOVA with an interaction term. 
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Figure 7.7 Oxygen consumption rate vs. extracellular acidification rate of A549 lung carcinoma 
after exposure to Fe3O4 nanoparticle systems with and without radiation and FCCP stimulation. 
Error bars represent standard error (n=12) and ** indicates a significant difference in both OCR 
and ECAR from no-radiation Fe3O4 nanoparticle. 
Cancer cells are highly sensitive to exogenous ROS inducing agents due to increased inherent 
ROS production being associated with oncogenic transformation making the cells highly dependent 
upon their antioxidant systems (Huang, Chen et al. 2013, Luo, Li et al. 2015). Therefore, the ROS 
production associated with the nanoparticle systems with and without radiation was analyzed. As 
shown in Figure 7.8, ionizing radiation treatment alone significantly increased ROS production in 
A549 lung carcinoma, and this was further increased by pre-treatment with uncoated Fe3O4, Fe3O4  
+ Dx-ECH-Amine and Fe3O4  + TAT at a concentration of 500 µg/mL. Additionally, the Fe3O4 + 
TAT increased ROS generation to a significantly greater extent than the other systems. It is 
hypothesized that uncoated Fe3O4 nanoparticles increase ROS by surface catalysis of the hydroxyl 
radical which is the main form of ROS measured by carboxy-DCF (Cohn, Simon et al. 2008, 
Koenczoel, Weiss et al. 2013). Significant work has been completed to link oxidative stress induced 
by uncoated iron oxide nanoparticles to nanoparticle toxicity (Ahamed, Alhadlaq et al. 2013, 
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Cochran, Wattamwar et al. 2013, Alarifi, Ali et al. 2014, Park, Umh et al. 2014, Luo, Li et al. 2015). 
Ahamed et al. and Khan et al. both showed that uncoated iron oxide nanoparticles induced oxidative 
stress in A549 lung carcinoma, which increased with increasing concentration and increasing 
exposure time (Khan, Mohammad et al. 2012, Ahamed, Alhadlaq et al. 2013). The positive charge 
associated with primary amines functionalized to the nanoparticle surface could slightly increase 
lysosomal permeability, although this was not observed in the AO studies, resulting in the release 
of some lysosomal contents and inducing ROS associated toxicities. Fe3O4 + TAT nanoparticles 
destabilized lysosomal membranes and facilitated release of toxic components, as well as the 
nanoparticles, which compromised mitochondrial integrity and increased ROS production. 
Therefore, ROS generation was significantly increased when radiation was combined with the 
Fe3O4 + TAT nanoparticles.  
 
Figure 7.8 Relative carboxy-DCF fluorescence in A549 lung carcinoma following 24 hour 
treatment with Fe3O4 nanoparticle systems with and without 5 Gy radiation treatment. Error bars 
represent standard error (n=12) and * indicates a significant difference compared to radiation alone 
and † indicates a significant difference compared to 500 µg/mL uncoated and 500 µg/mL amine 
functionalized Fe3O4 nanoparticles. 
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To determine whether the nanoparticle systems combined with radiation treatment had an effect 
on cell viability, a long term viability study was completed. A549 cells were treated for 24 hours 
with the nanoparticle systems to facilitate uptake, followed by treatment with 5 Gy radiation. Cells 
were then re-seeded and allowed to grow for 3, 5 or 7 days post treatment. Figure 7.9 displays the 
relative viability of A549 lung carcinoma 3, 5 and 7 days post treatment with Fe3O4 nanoparticles 
alone, radiation alone, and the combined treatment. When combined with radiation, uncoated Fe3O4 
nanoparticles resulted in a delayed effect, as only at day 7 was the combined treatment significantly 
different from radiation alone. The uncoated Fe3O4 nanoparticles increased lysosomal permeability 
and increased intracellular ROS production, but the toxic effects were delayed. The Fe3O4 + Dx-
ECH nanoparticles did not significantly enhance the efficacy of radiation treatment. This was 
expected as this nanoparticle system did not induce lysosomal permeabilization, decrease 
mitochondrial integrity, nor increase ROS generation. The Fe3O4 + Dx-ECH-Amine nanoparticles 
did increase the efficacy of radiation treatment in the short term, but the effects did not continue 
through the analysis times. This could be due to the Fe3O4 + Dx-ECH-Amine nanoparticles having 
the ability to increase ROS generation upon exposure to radiation, but the nanoparticles did not 
cause other cellular effects. Therefore, the slight increase in ROS when combined with radiation 
by the Fe3O4 + Dx-ECH-Amine nanoparticles was enough to induce increased toxicities in short 
time frames, but as the cells continued to grow for the longer time points, they were able to 
overcome the toxicities induced by the slight increases in exogenous ROS. Fe3O4 + TAT 
nanoparticles significantly enhanced the effect of radiation when cell viability was analyzed 3, 5 
and 7 days post treatment, indicating that the Fe3O4 + TAT nanoparticles successfully sensitized 
A549 lung carcinoma cells to radiation therapy. Fe3O4 + TAT nanoparticles increased lysosomal 
membrane permeabilization, releasing toxic contents into the cytosol, which then compromised 
mitochondrial integrity and sensitized the cells to radiation treatment. The efficacy of the combined 
treatment was analyzed using a set of equations established by Babincova et al. (Babincova, 
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Altanerova et al. 2008). These equations are displayed in Table 7.1, and the calculations for the 
Fe3O4 + TAT nanoparticles are shown in Table 7.2.  On each day of analysis following treatment, 
the combined treatment of Fe3O4 + TAT nanoparticles and radiation therapy on A549 lung 
carcinoma was significantly greater than the expected outcome of combining the two treatments, 
indicating that it was a synergistic treatment.   
 
Figure 7.9 Relative viability of A549 lung carcinoma 3, 5 or 7 days following a) uncoated b) Dx-
ECH c) amine functionalized or d) TAT-conjugated Fe3O4 nanoparticle treatment with and 
without 5 Gy radiation. Error bars represent standard error (n=12) and * indicates a significant 
difference (p<0.05) via a one-way ANOVA. 
Table 7.1 Equations developed by Babincova et al. for analysis of combinational treatments. 
Synergistic: [Fe3O4 + Radiation] < [Fe3O4] x [Radiation]/100 
Additive: [Fe3O4 + Radiation] = [Fe3O4] x [Radiation]/100 
Sub-additive: [Fe3O4] x [Radiation]/100 < [Fe3O4 + Radiation] < [Fe3O4]; if [Fe3O4] < 
[Radiation] 
Interference: [Fe3O4] < [Fe3O4+ Radiation] < [Radiation], if [Fe3O4] < [Radiation] 
Antagonistic: [Radiation] < [Fe3O4 + Radiation], if [Fe3O4] < [Radiation] 
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Table 7.2 Calculations to analyze the effects of combined Fe3O4 + TAT nanoparticles and radiation 
treatments. Values represent viability average ± standard error (n=12) on days 3, 5 and 7 post 
treatment. * (p<0.05) and ** (p<0.01) indicate a significant difference from the [Fe3O4 + 
TAT]x[Radiation]/100 group on the same day. 
 Fe3O4 + TAT Radiation [Fe3O4 + TAT]x[Radiation]/100 [Radiation + Fe3O4 + TAT] 
Day 3 105.4 ± 4.5 86.4 ± 6.1 92.5 ± 9.2 68.7 ± 3.6 * 
Day 5 95.6 ± 3.2 86.4 ± 4.6 81.8 ± 3.8 66.2 ± 3.4 ** 
Day 7 90.4 ± 2.0 72.6 ± 2.6 65.5 ± 2.4 48.0 ± 2.6 ** 
 
7.4 Conclusions 
The cell penetrating peptide, TAT, was successfully conjugated to dextran-coated iron oxide 
nanoparticles. Electron microscopy of A549 lung carcinoma after uptake of Fe3O4 + TAT 
nanoparticles showed the nanoparticles interacting with mitochondria and membrane 
destabilization of lysosomes containing Fe3O4 + TAT nanoparticles. Lysosomal permeability was 
confirmed and quantified using the AO assay. Both the uncoated Fe3O4 and Fe3O4 + TAT 
nanoparticles had the ability to permeabilize lysosomal membranes after cellular uptake due to 
ROS generation and the positive charge of the TAT peptide, respectively. Fe3O4 + TAT 
nanoparticles combined with radiation also affected mitochondrial integrity of the cells. When 
mitochondria were uncoupled with FCCP, cells that had been previously treated with Fe3O4 + TAT 
nanoparticles combined with radiation showed significantly lower capability to meet ATP demands 
than the nanoparticle only treatment, indicating a loss of metabolic potential. ROS generation was 
also predicted to play a role in the additional toxicities associated with radiation when the cells 
were pre-treated with the nanoparticle systems. When combined with radiation, uncoated Fe3O4, 
Fe3O4 + Dx-ECH-Amine, and Fe3O4 + TAT nanoparticles significantly increased ROS production 
compared to radiation alone in A549 lung carcinoma. Due to this increase in ROS generation, in 
lysosomal permeability, and the loss of mitochondrial integrity and function, the combined 
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treatment of Fe3O4 + TAT nanoparticles and radiation resulted in a synergistic decrease in cell 
viability. 
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Chapter 8 Conclusions 
 
In this dissertation, peptide-conjugated iron oxide magnetic nanoparticles were synthesized, 
characterized, and evaluated for their cancer therapy applications via magnetically mediated 
hyperthermia, intra-cellular localized energy delivery, and catalysis of reactive oxygen species. 
Both magnetically mediated hyperthermia and intra-cellular localized energy delivery rely upon 
the ability of the magnetic nanoparticles to respond to an alternating magnetic field, while catalysis 
of reactive oxygen species generation utilizes the capability of the nanoparticles to catalyze the 
Haber-Weiss reaction via Fenton chemistry. First, an iron oxide nanoparticle system conjugated 
with a tumor-homing peptide, CREKA, was developed for magnetically mediated hyperthermia 
treatment of A549 lung carcinoma. The physicochemical properties of the nanoparticle system were 
fully characterized and revealed their ability to target tumor extracellular matrix components and 
generate sufficient heat to induce hyperthermia conditions. Additionally, in a proof-of-concept 
study, magnetically mediated hyperthermia was combined with a chemotherapeutic, cisplatin, and 
the combined treatment resulted in an additive toxic effect.  
Although the heating properties of the previously developed magnetic nanoparticles were 
sufficient to induce hyperthermia conditions, their specific absorption rate was significantly lower 
than other magnetic nanoparticle systems reported in literature. Therefore, the method of 
synthesizing dextran-coated iron oxide magnetic nanoparticles was altered, as it was determined 
that the time of dextran addition into the synthesis reaction dramatically changed the 
physicochemical properties of the magnetic nanoparticles. By manipulating the synthesis 
conditions, it was demonstrated that nanoparticles could be formed with various size, stability, and 
crystallinity properties for biological applications.  
After improving the synthesis method of dextran-coated iron oxide nanoparticles, the magnetic 
nanoparticles were functionalized with a cell penetrating peptide, TAT, to increase the intracellular 
concentration of the magnetic nanoparticles. This magnetic nanoparticle system was used to locally 
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deliver energy upon activation by a magnetic field. It was demonstrated that TAT-functionalization 
to the magnetic nanoparticles increased cell uptake by A549 and H358 lung cancer cell lines and 
permeabilized lysosomal membranes, sensitizing the cells to the damaging effects of localized 
energy delivery upon exposure to an alternating magnetic field. Although not statistically 
significant, there was an observable trend illustrating increasing apoptosis when lung cancer cells 
were treated with the TAT-functionalized magnetic nanoparticles and an alternating magnetic field 
compared to the nanoparticles alone.  
The last portion of this dissertation evaluated the intracellular effects of TAT-functionalized 
iron oxide nanoparticles combined with radiation on lung cancer cells. Studies indicated that the 
TAT-functionalized nanoparticles sensitized the cells to further treatment with radiation by 
permeabilizing lysosomal membranes, damaging mitochondrial integrity, and catalyzing 
production of the highly reactive hydroxyl radical. While the TAT peptide can also serve as a 
nuclear localizing signal, electron microscopy images indicated that the targeted magnetic 
nanoparticles were located within destabilized lysosomes or in the cytoplasm, but at significantly 
greater concentrations than uncoated nanoparticles.  Future work in this area should focus on 
targeting the magnetic nanoparticles to specific organelles such as the mitochondria or the nucleus 
in an effort to enhance nanoparticle effects and associated therapy.  
8.1 Significant Findings 
There are several findings in this work that contribute to the scientific community’s 
understanding of peptide-functionalized iron oxide nanoparticles for cancer therapy applications. 
Research in magnetically mediated hyperthermia for cancer therapy has grown significantly over 
the past decade with minimal clinical translation. Magnetically mediated energy delivery is a 
growing alternative to magnetically mediated hyperthermia, so this research directly impacts an 
important aspect of magnetic nanoparticle research. Although this work was specific to cancer 
therapy, there are a wide variety of other biological and environmental remediation applications.  
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 Dextran-coated iron oxide magnetic nanoparticles can be synthesized by a one-pot co-
precipitation method and have properties consistent with those required for tumor targeting 
in vivo.  
 CREKA-conjugated magnetic nanoparticles can be used for magnetically mediated 
hyperthermia treatment of lung cancer and combination with cisplatin results in an additive 
effect. 
 Timing of dextran addition to the synthesis reaction of dextran-coated iron oxide 
nanoparticles significantly effects the physical and chemical properties of the material 
likely due to the viscosity of the dextran solution retarding crystal growth.  
 Functionalization of the cell penetrating TAT peptide to iron oxide nanoparticles increases 
the intracellular iron concentration within lung cancer cells.  
 Internalized, TAT-functionalized iron oxide nanoparticles increases reactive oxygen 
species production within lung cancer cells upon exposure to an alternating magnetic field 
and increased lysosomal permeability.  
 Although not statistically significant, trends were observed that suggest an increase in cell 
apoptosis when the TAT-functionalized iron oxide nanoparticle system is combined with 
alternating magnetic field treatment.  
 When combined with radiation, TAT-functionalized iron oxide nanoparticles significantly 
increase reactive oxygen species production compared to radiation alone in A549 lung 
carcinoma.  
 Treatment with TAT-functionalized iron oxide nanoparticles and radiation significantly 
reduces the metabolic energy of lung cancer cells indicating compromise of mitochondrial 
integrity or a decrease in substrate availability.  
 Dual treatment with TAT-functionalized iron oxide nanoparticles and radiation results in a 
synergistic therapy for A549 lung carcinoma.  
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Appendix A Combination treatment of multi-cellular tumor spheroids 
In this study, multicellular tumor spheroids were fabricated and used to analyze the effects of 
anti-cancer treatments as three-dimensional models more accurately represent avascular tumors in 
vivo compared to traditional monolayer cell cultures. The main limitation of using multicellular 
tumor spheroids as a screen for treatment efficacy is the difficulty in analyzing spheroid viability 
via a high throughput assay. Therefore, in this study, three viability assays were screened for 
accuracy in determining spheroid viability. A single assay was then selected to evaluate the efficacy 
of radiation and chemotherapy combined with hyperthermia treatment. This work was completed 
in conjunction with Kendall Huddleston Murphy, Jonathan Colburn, and Sarah Patterson as a part 
of the NSF Research Experience for Undergraduates at the University of Kentucky. 
A.1 Introduction 
Monolayer cell cultures have been the traditional form of in vitro screening for drugs and novel 
therapies. However, 2-dimensional (2D) cultures lack many of the physiological properties of cells 
in vivo. In vivo, cells reside in a 3-dimentional (3D) matrix complete with an extracellular matrix 
(ECM) made up of various macromolecules (collagens, proteoglycans, and laminin). 2D cell 
cultures grown on slides coated with substrata do not form an extra-cellular matrix, leading to 
several drawbacks of monolayer cultures: 1. lack of molecular gradients which play a vital role in 
cell differentiation, determination of cell fate, and signal transduction, 2. alterations in gene 
expression patterns and metabolism, and 3. morphological and phenotypic changes due to altering 
production of their own ECM proteins (Hutmacher, Horch et al. 2009). 3D cell cultures can be used 
to better mimic tumor cell growth and responses to drugs and therapies to in vivo tumors. 
Multicellular tumor spheroids (MCTS) 200-500 µm in diameter mimic avascular tumors in that 
they have diffusion limitations of oxygen and other nutrients resulting in a proliferation gradient: a 
necrotic core surrounded by a layer of quiescent cells, followed by a viable outer rim (Mueller-
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Klieser, Vaupel et al. 1987).  Diffusion limitations out of the spheroid result in waste accumulation 
within the core of the spheroid and contribute to the necrotic core.  
Physical properties of MCTS also hinder drug penetration. Nirmalanandhan et al. reported cell-
line dependent differences in response to multiple drugs between spheroid and monolayer cell 
cultures (Nirmalanandhan, Duren et al. 2010).  The proximity of cells as well as the presence of an 
extracellular matrix in MCTS is thought to effect MCTS response to various treatments as well 
(Minchinton and Tannock 2006).  Due to these characteristics and suitability for high throughput 
studies, MCTS have been applied in various cancer therapy studies.  Khoei et al. reported superior 
hyperthermic resistance of spheroids compared to cell monolayers in DU 145 human prostate 
carcinoma cells (Khoei, Goliaei et al. 2004) and interestingly enough, Yamauchi et al. demonstrated 
the opposite result in HT29 colon adenocarcinoma cells with different experimental methods 
(Yamauchi, Asao et al. 2011).  Senavirathna et al. successfully applied a MCTS model to study the 
effects of proton beam radiotherapy and doxorubicin-loaded temperature-sensitive liposomes 
(Senavirathna, Fernando et al. 2013). 
Coinciding with the increased complexity of MCTS culture, is increased difficulty of analysis.  
For example, many traditional analysis techniques used in monolayer cell culture studies cannot be 
applied for MCTS analysis due to assay penetration limitations. Variability in spheroid 
compactness and shape can also affect results. A popular method of analyzing MCTS is to measure 
volume over time (Friedrich, Ebner et al. 2007). Other studies dissociate the spheroids and either 
analyze the dissociated cells directly (Ivascu and Kubbies 2006, Mattix, Olsen et al. 2014), or apply 
a colony formation assay to analyze the ability of the cells to replicate (Khoei, Goliaei et al. 2004, 
Yamauchi, Asao et al. 2011). However, the dissociation process is labor-intensive and can cause 
damage or a decrease in the cell population (Friedrich, Ebner et al. 2007).  Neither of these methods 
provides a basis for determining the viability of intact MCTS. Thus, viability assays appropriate to 
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MCTS culture must be further developed and validated to increase MCTS use as a translational 
research method. 
Hyperthermia, the heating of tissue to 41 - 45 ˚C, induces cell apoptosis, or controlled cell 
death, primarily by denaturing nucleolic, cytoplasmatic, or membrane proteins.  In vitro tumor cells 
do no exhibit hyperthermia sensitivity compared to healthy cells however, in vivo, tumor tissue is 
particularly sensitive to hyperthermia treatment due to properties such as hypoxia and low pH levels 
(Issels 2008).  At temperatures above the hyperthermia range, cell death occurs through necrosis 
with lower selectivity between healthy and tumor tissues (Hildebrandt, Wust et al. 2002). However, 
high temperatures are difficult to achieve in vivo and are generally avoided in clinical application 
due to the negative effects of necrosis.  
Hyperthermia has been previously demonstrated to interact synergistically with radiation and 
chemotherapy but hyperthermia treatment alone has proved insufficient to result in major effects 
(Wust, Hildebrandt et al. 2002, Issels 2008).  In combination with chemotherapy, hyperthermia is 
generally most effective when administered simultaneously with drug administration.  Mechanisms 
involved in the interaction between hyperthermia and drugs include increase of blood flow, 
vascular permeability, and cellular membrane fluidity, all of which enable increased tumor and 
cellular uptake of drug (Issels 2008).  Hyperthermia can also increase the reaction rate of the drug 
with the cellular target (Halamikova, Vrana et al. 2007) and has been used to overcome drug 
resistance in some cell lines (Hildebrandt, Wust et al. 2002).   
When combined with radiation therapy, hyperthermia has been shown to decrease the repair 
rate of sub-lethal DNA strand break, and therefore increase the efficacy of radiation. In vivo, mild 
hyperthermia treatment increases tumor oxygenation by increasing blood perfusion to the tumor 
and therefore increasing reactive oxygen species production upon radiation treatment. On the 
contrary, studies have indicated that physical clamping or the use of physiological modifiers to 
reduce blood flow to the tumor can enhance the efficacy of hyperthermia by reducing the 
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convective cooling effects (Overgaard and Nielsen 1980). The results of radiation combined with 
hyperthermia studies vary greatly and are also highly dependent on cell line, order of treatment, 
and tumor size. A study completed by Sapareto et al. showed that timing of irradiation and thermal 
therapy has dramatic effects on the efficacy of the combined treatment and is also cell line 
dependent. Irradiating HA-1 cells immediately prior to thermal therapy had the greatest toxic effect, 
while the opposite was true for EMT6 cells. Therefore, the consensus is that thermal therapy during 
radiation treatment is most effective (Sapareto, Raaphorst et al. 1979). Larger tumors have been 
shown to be more sensitive to the combined therapy compared to smaller tumors due to having a 
higher cell population of radio resistant, yet heat sensitive cells (Vaupel, Kallinowski et al. 1989). 
Despite some success in clinical application, hyperthermia therapy faces several key 
challenges.  Due to lack of heat perfusion and the deep location of metastatic tumors, conventional 
hyperthermia methods such as water baths, microwaves, radiotherapy, and limb perfusion make it 
difficult to target to tumor tissue without harming healthy tissue. Additionally, hyperthermia 
temperatures may be difficult to reach and maintain for sufficient time periods (Wust, Hildebrandt 
et al. 2002). A relatively new hyperthermia treatment, magnetically-mediated hyperthermia 
(MMH), also known as magnetic fluid hyperthermia, utilizes magnetic nanoparticles in the 
presence of an alternating magnetic field (AMF) to locally generate heat.  Upon activation by an 
AMF, magnetic nanoparticles convert the field energy into heat through Brownian rotation and 
Néel paramagnetic switching.  Because an AMF can be applied with minimal effect on bodily 
tissue, MMH is a promising alternative to current hyperthermia treatments (Laurent, Dutz et al. 
2011).  A clinical trial by Maier-Hauff et al. demonstrated the feasibility of intracranial MMH using 
aminosilane coated iron oxide nanoparticles and a sophisticated dosing software (Maier-Hauff, 
Rothe et al. 2007). 
There has been significant progress in MMH research (see Chapter 3), but with limited clinical 
translation due to the lack of consistency between in vitro studies, preliminary in vivo studies, and 
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clinical trials. By applying the MCTS model to MMH studies at the in vitro screening stage, it 
should enable a more thorough screening of MMH techniques compared to cell monolayers. First, 
however, a standard protocol for analysis must be developed in order to use MCTS to try to bridge 
the gap between in vitro and in vivo studies. Specifically, an assay is needed that will accurately 
report spheroid viability in a high throughput manner.  
The first objective of this study was to evaluate the efficacy and consistency of selected 
viability assays on A549 lung carcinoma MCTS.  Three viability assays were selected: resazurin, 
acid phosphatase (APH), and calcein AM/ethidium homodimer-1.  Based on experiments by 
Friedrich et al., it was expected that the APH assay would provide an accurate and consistent 
method for assaying the A549 lung carcinoma MCTS (Friedrich, Eder et al. 2007).  Assays were 
investigated for accuracy and consistency by varying the number of MCTS analyzed as well as the 
seeding density of spheroids assayed. The effect of spheroid dissociation was also analyzed for 
each assay. Secondly, a feasible assay was chosen for a proof of concept study to demonstrate the 
interaction between cisplatin (CDDP), a common chemotherapeutic, and hyperthermia in the 
MCTS model. The third objective combined radiation therapy with hyperthermia treatment on 
MCTS in a proof of concept study.  
A.2 Materials and Methods 
A.2.1 Materials 
Fetal bovine serum (FBS) and Type 1 rat tail collagen were obtained from Fisher Scientific 
(Florence, KY), and Dulbecco’s Modified Eagle Medium (DMEM), pen-strep, L-glutamine, 
Fungizone®, sodium pyruvate, calcein AM, and ethidium homodimer-1 were obtained from 
Invitrogen (Grand Island, NY).  Trypsin (0.25% trypsin/0.53 mM EDTA) and A549 lung cancer 
cells were purchased from American Type Culture Collection (Manassas, VA).  Nunc Sphera 96-
well plates and p-nitrophenyl phosphate (pNPP), disodium salt, were obtained from Thermo 
Scientific (Rochester, NY).  Sodium acetate trihydrate, resazurin, and cisplatin were purchased 
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from Sigma Aldrich (St. Louis, MO).  Phosphate buffered saline solution (PBS) was obtained from 
EMD Millipore (Billerica, MA).   
A.2.2 Cell culture 
Cell culture media was prepared by adding 10% FBS, 1 mM sodium pyruvate, 4 mM L-glutamine, 
pen-strep (100 U/mL penicillin and 100 µg/mL streptomycin), and 10 μg/ml Fungizone® to 500 
mL DMEM. The media mixture was sterile filtered.  A549 lung carcinoma cells were cultured 
between passages 4 and 24. 
A.2.3 MCTS formation 
A549 cells were seeded at 50,000 cells/mL (unless otherwise specified) at 100 µL/well into Nunc 
Sphera 96-well plates and collagen was added to the cell solution at a concentration of 20 µg/mL 
to aid spheroid formation.  The round bottom 96-well plates were centrifuged at 1250 rpm for 15 
min to aggregate the cells. Cells were incubated to allow spheroid compaction and growth at 37 ˚C 
and 5% CO2 for 48 hours. Figure A.1 depicts the MCTS formation process over time. 
 
Figure A.1 Chronological images of three different A549 MCTS during formation. 
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A.2.4 MCTS dissociation 
Plates were centrifuged for 5 min at 1250 rpm, and 140 µL per well of supernatant was carefully 
removed.  0.25% trypsin-EDTA was diluted with PBS to obtain 0.1% trypsin and 160 µL was 
added per well. Plates were again centrifuged and 160 µL of supernatant was replaced with 0.1% 
trypsin.  Spheroids were disassociated in wells by rapid pipetting and immediately returned to 
incubator.  Disassociation via shear stress was repeated five times (every 20 min) and if spheroids 
were not yet dissociated, further shear stress was applied with a 20-guage needle.  Cell suspensions 
were transferred to a well plate coated for regular cell culture to avoid re-aggregation and the trypsin 
was neutralized with cell culture media. 
A.2.5 Acid phosphatase assay 
Plates were centrifuged and supernatant was replaced with PBS due to potential interference of cell 
culture media with APH signal (amount of supernatant replaced was adjusted based on 
corresponding volumes and wells).  Plates were centrifuged again, and supernatant was removed 
to obtain half the desired volume.  The desired volume was obtained by adding APH buffer (0.1 M 
sodium acetate, 0.1% (v/v) Triton X-100, and 8 mg/mL pNPP in deionized water before dilution; 
use 2 mg/mL pNPP for dissociated cells). Spheroids were incubated with APH buffer (final 
concentrations of 4 mg/mL and 1 mg/mL for MCTS and dissociated MCTS, respectively) for 6 h 
and dissociated cells for 90 min.  Plates were placed on an incubator shaker for the initial and final 
15 min of incubation.  After the incubation period, the absorbance of the wells was read at 405 nm 
by a Biotek SynergyMx microplate reader. 
A.2.6 Resazurin assay 
Resazurin (10 mM) was added to each well for a 10% (v/v) solution.  Plates were incubated for 6 
h at 37 ˚C to allow resazurin to be metabolized. The plates were placed on an incubator shaker for 
the initial and final 15 min of this period.  The fluorescence of each well was read by a Biotek 
SynergyMx microplate reader at an excitation of 530 nm and an emission of 590 nm. 
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A.2.7 Calcein AM/Ethidium homodimer-1 (live/dead) assay 
Two spheroids per treatment group were transferred with 200 µL media per spheroid to a 12-well 
plate.  One row was filled with 400 µL of media to obtain background fluorescence.  PBS was 
supplemented with 2 µM calcein AM and 4 µg/mL ethidium homodimer-1 before addition at 400 
µL/well.  Plates were incubated for 1 h.  Following incubation, one live and one dead image per 
spheroid were obtained and combined using a Nikon Eclipse LV 100 microscope.  The first control 
spheroid was used to focus the microscope and to set auto-exposure times, which remained 
consistent throughout the imaging process.  This first spheroid was not included in the data, and all 
other images were obtained within 5 s to prevent bleaching of fluorescence.  Mean intensity values 
of images were exported for data analysis. 
Dissociated spheroids were transferred to a 96-dark-well plate as described in the dissociation 
procedure; each dissociated spheroid was transferred to a different well.  Cells were allowed to 
attach and to grow for 48 h, at which point media was removed from wells.  PBS supplemented 
with 2 µM calcein was added at 100 µL. After 25 min incubation, mean relative fluorescence values 
were obtained by a Biotek SynergyMx microplate reader using an area scan (ex: 495/em: 515 nm).  
After reading fluorescence values, qualitative images were also obtained as described above. 
A.2.8 Assay validation studies 
The APH and resazurin assays were tested for response to varying numbers of spheroids.  Between 
one and five spheroids were transferred to each well of a 48-well plate and excess media was 
removed to a final volume of 200 µL/well.  The remainder of the APH assay was completed as 
described above, with the exception that the spheroids were only incubated for 90 min.  For the 
resazurin assay, between one and five spheroids were transferred to a 48-well plate with 100 µL 
media/spheroid; additional media was added as necessary to reach a final volume of 500 µL in all 
wells.  Then the resazurin assay was carried out as described above.  For all viability assays, the 
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appropriate background samples were prepared to correct for background absorption and 
fluorescence. 
The APH and resazurin assays were also tested for response to varying seeding density of 
spheroids.  MCTS were seeded at concentrations between 2,500 and 15,000 cells per spheroid and 
were allowed to grow for 24 h before performing APH and resazurin assays. 
All assays were applied to MCTS treated with 0, 20, and 2000 µM CDDP dissolved in media for 
72 h.  These concentrations were chosen because they represent a concentration near and a 
concentration far greater than the IC50.  Following 72 h of incubation, some spheroids were 
dissociated, and APH, resazurin, and live/dead assays were performed on intact and dissociated 
spheroids.  All values were normalized to the average value of the controls not treated with CDDP. 
And for ethidium staining, reported values are one less than the normalized values to give the 
controls a relative cell death of zero. 
A.2.9 Incubator-induced hyperthermia with CDDP 
After 48 h of growth, MCTS were treated with CDDP in media at concentrations between 0 and 
2000 µM.  Immediately following the addition of CDDP, half of the spheroids in each treatment 
group were returned to an incubator at 37 ˚C while the remaining spheroids were placed in an 
incubator set to 43 ˚C.  In order to efficiently raise well temperature, the well plate was placed on 
a hot pad resting on a hot plate set to 60 ˚C.  When the well temperature reached 43 ˚C, the well 
plate was removed from the hot pad and maintained between 42.5 and 43 ˚C.  The well plate 
remained in the incubator for 30 min after reaching 41.5 ˚C, which was deemed the effective 
starting point of hyperthermia treatment.  The temperature was continuously monitored through the 
use of a fiber optic temperature sensor (Luxtron FOT Lab Kit from LumaSense) inserted into a 
central well through a small hole drilled through a well plate lid.  After hyperthermia treatment, the 
well plate was returned to an incubator at 37 ˚C.  IC50 values and regression curves were obtained 
using SigmaPlot to fit the data to a four parameter logistic curve. 
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A.2.10 Incubator induced hyperthermia with radiation 
Following the 48-hour growth period, MCTS were subjected to gamma irradiation. A cesium-137 
irradiator was used to administer doses of 0, 2, 4, and 6 Gy at room temperature. Immediately 
following radiation, a subset of the irradiated spheroids were exposed to hyperthermia. The time 
delay between treatments could not be reduced to less than 15 minutes due to differing treatment 
locations. In order to efficiently raise well temperature, the well plate was placed on a hot pad 
resting on a hot plate set to 60 ˚C.  When the well temperature reached 43 ˚C, the well plate was 
removed from the hot pad and maintained between 42.5 and 43 ˚C.  The well plate remained in the 
incubator for 60 min after reaching 41.5 ˚C, which was deemed the effective starting point of 
hyperthermia treatment.  The temperature was continuously monitored through the use of a fiber 
optic temperature sensor (Luxtron FOT Lab Kit from LumaSense) which was inserted into a central 
well through a small hole drilled through a well plate lid.  After hyperthermia treatment, the well 
plate was returned to an incubator at 37 ˚C.  Viability was analyzed 5 and 7 days post-treatment 
using the APH assay and live/dead assay as previously described.  
A.3 Results and discussion 
A.3.1 MCTS assay validation 
Spheroids were analyzed by the APH and resazurin assays and the number of spheroids per 
well varied from one to five. The response of the assay to this setup can indicate the consistency in 
signal generation of the assay for a single spheroid as well as its ability to handle increasingly large 
quantities of cells.  Results are portrayed in Figure A.2 and R2 values are given for each assay based 
on linear regression of the data. The live/dead assay was not applied in this study due to the 
difficulty of obtaining images that encompass all the spheroids in a given well.  Although neither 
assay responded linearly, the APH assay displayed a clearer trend compared to the resazurin assay.  
It could be suggested that the APH assay responded in an exponential manner to increasing number 
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of spheroids however, this was deemed unlikely as the signal is expected to follow a logarithmic 
rather than exponential increase in signal at sufficiently high numbers of spheroids. 
 
Figure A.2 Results of APH and resazurin assays of wells containing one to five MCTS after 24 
hours of formation.  Bars represent standard error (n≥3). 
The APH and resazurin assays were further validated by varying MCTS seeding density in 
order to conclude whether the assay effectively penetrated spheroids and to determine how spheroid 
size affected assay results.  In the case of perfect penetration of an entirely viable spheroid, the 
assay would respond linearly to an increase in seeding density.  If the assay does not penetrate 
beyond the spheroid surface, the assay response would be expected to resemble a fractional power 
curve.  In reality, the response is likely to lie somewhere in between due to the growth of the 
spheroids after seeding, death of innermost cells and imperfect penetration of the assay.  As 
demonstrated in Figure A.3, no substantial difference in trend was observed between the APH and 
resazurin assays.  Wells seeded with 2,500 cells per well did not form spheroids but remained 
largely dispersed throughout the wells.  Interestingly, the average fluorescence returned by the 
resazurin assay of these wells far exceeded all the values for formed spheroids, whereas the average 
absorbance returned by the APH assay fell below the linear trend.  This indicates a much stronger 
response of resazurin than pNPP to dissociated cells.  If this is the case, minor imperfections in 
spheroid formation could affect the resazurin assay more strongly than the APH assay. 
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Figure A.3 Results of APH and resazurin assays of spheroids seeded at various densities and grown 
for 24 hours. Bars represent standard error (n≥4). 
In validation studies with CDDP, there was no accurate standard for determining the response 
of A549 MCTS to varying concentrations of CDDP.  Instead, simply a reasonable decrease in 
viability due to CDDP treatment was expected.  Spheroid dissociation was used to compare 
response of the assay to tightly packed and dispersed cells, since each assay used is generally 
accepted as accurate in cell monolayers.  Each treatment was normalized to the control to give the 
relative viability.  Results are given in Figure A.4.  The APH assay returned consistent relative 
viability results between intact and dissociated spheroids after exposure to 20 or 2000 µM CDDP. 
The resazurin assay presented large discrepancies between intact and dissociated spheroids at the 
same CDDP concentration suggesting that its use for MCTS analysis is limited.  
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Figure A.4 APH and resazurin assays of intact and dissociated spheroids, and calcein assay of 
dissociated spheroids.  Dissociation and assay were performed following 72 hours of treatment 
with CDDP. Each group was separately normalized to its own control.  Bars represent standard 
error (n≥5). 
The live/dead assay of intact spheroids was displayed separately in Figure A.5.  The calcein 
AM stain of intact spheroids indicated no trend in viability in response to CDDP, suggesting that it 
is a poor indicator of spheroid viability.  The ethidium stain of intact spheroids demonstrated a 
reasonable trend however, relative cell death cannot be directly compared with relative viability.  
As demonstrated by the upper row of Figure A.6, the images associated with the live/dead assay 
provide a useful means of qualitative analysis of spheroid response to treatment.  Besides a general 
trend in viability, these images suggested that 20 µM CDDP inhibits growth of the spheroid and 
2000 µM CDDP was strong enough to begin to disperse cells, causing the spheroid to appear larger 
than after 20 µM CDDP treatment. 
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Figure A.5 Live/dead assay of intact spheroids, performed following 72 hours of treatment with 
CDDP.  Each group was separately normalized to its own control.  Bars represent standard error 
(n≥5). 
 
Figure A.6 Representative images of intact spheroids stained with calcein AM and ethidium 
homodimer-1 (upper), and of dissociated spheroids stained with calcein AM (lower).  Staining was 
performed after 72 hours of treatment with CDDP for intact spheroids and an additional attachment 
period of 48 hours preceded stain of dissociated spheroids.  Scale bars represent 200 µm.  
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A.3.2 Cisplatin combined with hyperthermia on MCTS 
Based on the consistency of the APH assay and on its ease of application, this assay was chosen 
for a proof of feasibility study investigating the interaction between incubator-induced 
hyperthermia and CDDP (Figure A.7).  CDDP has been previously shown to be more effective 
when administered at elevated temperatures (Urano, Kuroda et al. 1999) and a sigmoidal response 
with increasing concentration of CDDP has been previously observed on monolayer cell cultures. 
This same trend was observed for MCTS treated with CDDP with and without 30 minutes of 
hyperthermia. The IC50 value, the concentration of CDDP that results in 50% cell death, was 
compared to CDDP alone with the combined treatment. A decrease in the IC50 value from 54 to 
34 µM was observed upon application of hyperthermia with CDDP on A549 MCTS. Live/dead 
images obtained in parallel with this experiment confirm qualitatively that a sharp decrease in 
viability was observed at about 40 µM CDDP. However, this study was completed as a single trial 
(n≥5) and should be repeated to assess consistency of the treatment. 
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Figure A.7 Relative viabilities of MCTS treated with varying concentrations of CDDP for 72 hours 
with and without hyperthermia for 30 minutes at 43 ˚C immediately following CDDP exposure.  
Error bars represent standard error (n≥5). Corresponding live/dead images and IC50 values are 
included. 
A.3.3 Radiation combined with hyperthermia on MCTS 
The third objective of this study was to analyze the effects of radiation combined with 
hyperthermia treatment on A549 MCTS. Various radiation treatments of 0, 2, 4, and 6 Gy were 
dosed to MCTS, and following radiation exposure half of the MCTS were treated with 60 minutes 
of incubator-induced hyperthermia. Normalized viability was determined by the APH assay and 
live/dead staining 5 and 7 days following treatment. Both 5 and 7 days post treatment, radiation 
treatment alone effected the relative viability of A549 MCTS however, hyperthermia treatment did 
not further decrease the relative viability of the MCTS (Figures A.8 and A.11). Additionally, upon 
analysis of the reported dead fluorescence values, there was a greater increase in dead fluorescence 
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as radiation treatment increased, but no additional enhancement was observed by hyperthermia 
treatment (Figures A.9 and A.12). 
Analyzing MCTS viability as well as the relative dead fluorescence, there was no difference 
between the control and hyperthermia treatment alone. This is consistent with previous studies 
suggesting that hyperthermia is not powerful enough by itself to effectively treat cancer. Traditional 
monolayer studies suggest that hyperthermia combined with radiation does often result in a 
synergistic effect (Horsman and Murata 2002) however, this was not observed when treating 
MCTS. Radiation was combined with hyperthermia to treat MCTS because MCTS work to bridge 
the gap between traditional monolayer cell culture and in vivo animal studies. Most traditional 
monolayer cell culture used with hyperthermia in literature administer a single treatment of 
hyperthermia. Since the MCTS are more representative of in vivo studies, the protocols may need 
to be altered to better represent treatments which would be administered in vivo, such as 
fractionated radiation. By fractionating the radiation dosage and exposing the MCTS to cyclic 
hyperthermia treatments, a synergistic therapy may result however, significant optimization needs 
to occur.  
 
Figure A.8 Relative viability of A549 lung carcinoma 5 days after radiation treatment (0, 2, 4, 6 
Gy) with and without 60 minutes incubator induced hyperthermia, measured using APH assay. 
Error bars represent standard error (n=9). 
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Figure A.9 Relative dead fluorescence of A549 lung carcinoma MCTS 5 days after radiation 
treatment (0, 2, 4, 6 Gy) with and without 60 minutes incubator induced hyperthermia. Error bars 
represent standard error (n=6). 
 
Figure A.10 Live/Dead images of A549 MCTS 5 days following radiation treatment with and 
without hyperthermia exposure. 
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Figure A.11 Relative viability of A549 lung carcinoma 7 days after radiation treatment (0, 2, 4, 6 
Gy) with and without 60 minutes incubator induced hyperthermia, measured using APH assay. 
Error bars represent standard error (n=9). 
 
Figure A.12 Relative dead fluorescence of A549 lung carcinoma MCTS 7 days after radiation 
treatment (0, 2, 4, 6 Gy) with and without 60 minutes incubator induced hyperthermia. Error bars 
represent standard error (n=6). 
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Figure A.13 Live/Dead images of A549 MCTS 7 days following radiation treatment with and 
without hyperthermia exposure. 
A.4 Conclusions 
Cancer therapy research using MCTS poses significant challenges due to difficulty in analyzing 
the MCTS post treatment. However, there are significant benefits to utilizing MCTS for analysis 
prior to expensive in vivo studies as MCTS more accurately represent physiological conditions 
compared to monolayer cell cultures. In this work, three assays were analyzed to determine the 
most consistent and accurate analysis method of MCTS viability. The APH assay appeared to be 
more consistent and accurate at determining the relative viability of MCTS compared to the 
resazurin assay.  Although the live/dead assay was not studied as extensively as the APH and 
resazurin assays, it was determined that due to the associated costs, time sensitivity, and labor 
intensity, the live/dead assay is not suitable for use in high throughput studies but rather provides 
images as a verification of results obtained by other assays.  Although several previous studies 
involving MCTS perform a viability assay after dissociation of spheroids, this option is impractical 
for high throughput due the level of associated labor.  Additionally, the dissociation process 
provides significant opportunity for inconsistency in working volumes and may cause damage or 
loss of cells. 
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After determining the appropriate viability assay, two proof of concept studies were completed 
to analyze the effects of hyperthermia combined with chemotherapy or radiation on A549 lung 
carcinoma MCTS. When cisplatin was combined with 30 minutes of incubator-induced 
hyperthermia, the IC50 value decreased, suggesting that the combined treatment was more effective 
than the CDDP alone. When radiation was combined with 60 minutes of incubator hyperthermia 
on MCTS, there was no enhancement of radiation therapy. This could be due to a variety of reasons 
including the cell line, hyperthermia time and temperature, delay between radiation and 
hyperthermia treatment, order of the treatments, etc. Previous work has indicated the variability in 
treatment efficacy by combining hyperthermia and radiation and this study further confirms these 
results. Future work with MCTS and hyperthermia should address magnetically mediated 
hyperthermia in combination with a chemotherapeutic. MCTS would allow for evaluation of 
nanoparticle uptake and penetration into the spheroid as well as analysis of the effects of 
magnetically mediated hyperthermia on an in vitro three-dimensional model.  
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